University of New Mexico UNM Digital Repository

Pharmaceutical Sciences ETDs

Electronic Theses and Dissertations

Fall 11-21-2018

ASSESSING THE IMPACT OF PRESCRIPTION OPIOID USE VERSUS NO USE ON ADHERENCE TO CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MAINTENANCE MEDICATIONS, COPD EXACERBATIONS AND TOTAL HEALTHCARE COSTS

Akshay Kharat The University of New Mexico

Follow this and additional works at: https://digitalrepository.unm.edu/phrm_etds Part of the <u>Pharmacy and Pharmaceutical Sciences Commons</u>

Recommended Citation

Kharat, Akshay. "ASSESSING THE IMPACT OF PRESCRIPTION OPIOID USE VERSUS NO USE ON ADHERENCE TO CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MAINTENANCE MEDICATIONS, COPD EXACERBATIONS AND TOTAL HEALTHCARE COSTS." (2018). https://digitalrepository.unm.edu/phrm_etds/20

This Dissertation is brought to you for free and open access by the Electronic Theses and Dissertations at UNM Digital Repository. It has been accepted for inclusion in Pharmaceutical Sciences ETDs by an authorized administrator of UNM Digital Repository. For more information, please contact disc@unm.edu.

Akshay Kharat Candidate

College of Pharmacy, Pharmaceutical Sciences

This dissertation is approved, and it is acceptable in quality and form for publication:

Approved by the Dissertation Committee:

Matthew Borrego, PhD Chairperson

Melissa Roberts, PhD

Patricia Marshik, PharmD

Vishvas Garg, PhD

ASSESSING THE IMPACT OF PRESCRIPTION OPIOID USE VERSUS NO USE ON ADHERENCE TO CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MAINTENANCE MEDICATIONS, COPD EXACERBATIONS AND TOTAL HEALTHCARE COSTS

ΒY

AKSHAY A. KHARAT

B.S., Pharmacy, University of Mumbai, 2009 M.S., Pharmacoeconomics, Epidemiology, Pharmaceutical Policy, and Outcomes Research, The University of New Mexico, 2012

DISSERTATION

Submitted in Partial Fulfillment of the Requirements for the Degree of

Doctor of Philosophy Pharmaceutical Sciences

The University of New Mexico Albuquerque, New Mexico

December 2018

DEDICATION

To my parents, Ajinath and Ratnamala Kharat for always believing in me.

ACKNOWLEDGEMENTS

This dissertation would not be possible without the support of many individuals. I would like to wholeheartedly thank my dissertation committee members Dr. Matthew Borrego, Dr. Vishvas Garg, Dr. Melissa Roberts and Dr. Patricia Marshik for their precious time and efforts. My committee members have provided thought provoking input to develop this study into a dissertation quality research. This dissertation would also not be possible without the support of Truven Health Analytics for providing the MarketScan database.

Most importantly, I would like to thank my mentor, Dr. Matthew Borrego for his valuable teachings. I have learnt many valuable lessons from Dr. Borrego which have made me into a researcher that I am today. Dr. Borrego has constantly encouraged and challenged me to think of innovative solutions to answer complex research problems. I highly appreciate Dr. Borrego's patience with me. Today, as I look back at my journey through a masters and a PhD degree, I cannot think of anyone else who has had such a powerful role in developing me as a respectful researcher than Dr. Matthew Borrego. Because of Dr. Borrego's efforts, I will always strive to maintain integrity and be ethical as I continue my professional career. I hope my actions in the future will continue to make Dr. Borrego proud.

My education would never be possible without my pillars of strength, my parents Drs. Ajinath and Ratnamala Kharat, my sister Aditi, and my beloved wife Kaitlin. I have successfully completed my graduate education because of my incredible family. I am grateful to have you all in my life. I am forever in your debt!

iv

ASSESSING THE IMPACT OF PRESCRIPTION OPIOID USE VERSUS NO USE ON ADHERENCE TO CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MAINTENANCE MEDICATIONS, COPD EXACERBATIONS AND TOTAL

HEALTHCARE COSTS

by

AKSHAY A. KHARAT

B.S., Pharmacy, University of Mumbai, 2009

M.S., Pharmacoeconomics, Epidemiology, Pharmaceutical Policy, and Outcomes Research, The University of New Mexico, 2012

Doctor of Philosophy, Pharmaceutical Sciences, The University of New Mexico, 2018

ABSTRACT

OBJECTIVES: COPD contributes significant morbidity and mortality worldwide and is currently the third leading cause of mortality in the United States. Chronic pain prevalence is high among COPD patients leading to a high rate of prescription opioid use. The potential impact of concurrent prescription opioid use on COPD maintenance medication adherence, COPD exacerbations, and total healthcare costs is not well understood. The study objectives were i) to assess the impact of prescription opioid use compared to no prescription opioid use on COPD maintenance medication adherence in 90, 180, 270, and 365-day follow-up periods, and ii) to assess the impact of long-term prescription opioid use (≥ 90 day prescription opioid supply in a one-year period)

compared to no prescription opioid use on COPD maintenance medication adherence, COPD exacerbations and total healthcare costs in one-year follow-up period.

METHODS: Patients with COPD diagnosis were identified using ICD9-CM diagnosis codes and COPD maintenance medication prescription claims from the Truven Health MarketScan[®] Commercial Claims and Encounters Database from July 1, 2008 to December 31, 2009. COPD patients with prescription opioid claims were matched 1:1 to non-opioid users on baseline characteristics: age (±3 years), sex, severe and moderate COPD exacerbations, oxygen therapy use, short-acting beta₂-agonist use, COPD maintenance medication adherence, and asthma status. Conditional multiple logistic regression, multiple negative binomial regression and generalized linear model with a gamma distribution and log-link function were used to identify the impact of long-term prescription opioid use versus no opioid use on COPD maintenance medication adherence (PDC) \geq 0.8], COPD exacerbations, total healthcare costs in a one-year period, respectively.

RESULTS: A total of 5,541 matched pairs of prescription opioid versus nonopioid users were identified. After adjusting for confounders, prescription opioid use was associated with statistically significantly lower odds of being adherent to COPD maintenance medications compared to no use of prescription opioids in all the four follow-up periods. Long-term prescription opioid users (n=566) had significantly higher mean Deyo-Charlson comorbidity scores (2.4±1.8 vs 1.7±1.2, p<0.0001), presence of comorbid chronic conditions (86.6% vs 76.3%, p<0.0001) and comorbid pain conditions (93.5% vs 70.7%, p<0.0001). After adjusting for confounders, long-term prescription opioid use was associated with 0.63 times (95% CI 0.46-0.88, p<0.01) lower odds of

vi

being adherent to COPD maintenance medications; and long-term prescription opioid users had higher adjusted mean all-cause total healthcare costs \$23,996 (\pm \$1,106.22) vs \$13,947 (\pm \$512.67), p<0.0001], compared to non-users of prescription opioids. Long-term prescription opioid use was not statistically significantly associated with severe or total (moderate + severe) COPD exacerbations.

CONCLUSIONS: Concurrent long-term use of prescription opioids may significantly lower COPD maintenance medication adherence which may translate into higher total all-cause healthcare costs and requires additional investigation.

Table of contents

СН	APTER 1 INTRODUCTION	1
C	Chronic Obstructive Pulmonary Disease burden	1
F	Prescription opioid therapy	2
Å	Adverse events associated with the use of opioids	2
N	Nedication adherence among patients with COPD	4
ι	Jse of prescription opioids among patients with COPD	6
C	Saps in the literature and need for the study	8
٦	Theoretical framework	10
S	Significance of the study	11
	Study objective	12
S	Study hypotheses and specific aims	12
	Specific aim 1	12
	Null hypothesis 1A	12
	Null hypothesis 1A (sub-analysis):	12
	Null hypothesis 1B	13
	Null hypothesis 1B (sub-analysis):	13
	Null hypothesis 1C	13
	Null hypothesis 1C (sub-analysis):	13
	Null hypothesis 1D	14
	Null hypothesis 1D (sub-analysis):	14
	Specific aim 2	14
	Specific aim 3	15
	Null hypothesis 3A	15
	Null hypothesis 3B	15

Specific aim 4	15
Null hypothesis 4	
CHAPTER 2 LITERATURE REVIEW	17
Overview of Chronic Obstructive Pulmonary Disease (COPD)	
COPD burden	
Diagnosis of COPD	
COPD exacerbations and assessing the risks for future exacerbations	
Management of COPD	
Overview of prescription opioid therapy	
Opioid epidemic	
Prescription opioid therapy in the treatment of chronic non-cancer pain	
Risks of developing long-term use from an acute use of prescription opioid	
Guidelines for prescription opioid therapy for chronic non-cancer pain	
Initiating and continuing prescription opioids in CNCP:	32
Selection of prescription opioids, duration, dosage, follow-up and discontinuation:	
Assessing the risks and harms of opioid prescribing:	33
Aberrant Drug Related Behavior	
Tolerance	34
Physical Dependence	35
Addiction	35
Diversion	
Misuse	
Abuse	37
Side effects associated with the use of opioids	
Hormonal effects	
Hyperalgesia	

Opioid-induced sedation and sleep disturbances	38
Opioid-induced constipation	38
Opioid-induced respiratory depression	39
Overview of medication adherence	40
Proportion of days covered (PDC)	42
Significance of medication adherence in COPD treatment	43
Use of prescription opioids among COPD patients	47
Prevalence and the effects of prescription opioid use in COPD patients and healthc	are
outcomes	48
Theoretical Framework	54
Significance and need for the study	59
CHAPTER 3 METHODS	61
Research Design	61
Study population	62
Study dataset timeline	63
Index period	63
Index date	63
Post-index period	66
Inclusion and exclusion criteria	67
Criteria for the identification of COPD	67
Study inclusion criteria	68
Study exclusion criteria	68
Study variables	69
Independent Variables	69
Dependent Variables	78
Operational definition of study outcome for Specific Aims 1 and 2	78

Operational definition of study outcome for Specific Aim 3	
Operational definition of study outcome for Specific Aim 4	85
Data Analysis	86
Matching the exposed and the unexposed groups	
Statistical analyses for Specific Aim 1	
Statistical analyses for Specific Aim 2	
Statistical analyses for specific aim 3	
Statistical analyses for specific aim 4	
Sample size estimation	
IRB approval	
CHAPTER 4 RESULTS	
Sample Selection	
Baseline characteristics of prescription opioid users and non-users	pre-matching: 98
Baseline characteristics of prescription opioid user and non-users p	oost matching: 98
Baseline characteristics of prescription opioid user and non-users p Results for Specific Aim 1	-
Results for Specific Aim 1	107 107
Results for Specific Aim 1	107 107
Results for Specific Aim 1 Results for Specific Aim 1A Baseline characteristics as per specific aim 1A:	107
Results for Specific Aim 1 Results for Specific Aim 1A Baseline characteristics as per specific aim 1A: Unadjusted logistic regression analyses:	107 107 107 112 115
Results for Specific Aim 1 Results for Specific Aim 1A Baseline characteristics as per specific aim 1A: Unadjusted logistic regression analyses: Multiple logistic regression analyses:	107 107 107 112 115 118
Results for Specific Aim 1 Results for Specific Aim 1A Baseline characteristics as per specific aim 1A: Unadjusted logistic regression analyses: Multiple logistic regression analyses; Multiple logistic regression analyses;	107 107 107 107 112 112 115 118 118 121
Results for Specific Aim 1 Results for Specific Aim 1A Baseline characteristics as per specific aim 1A: Unadjusted logistic regression analyses: Multiple logistic regression analyses: Multiple logistic regression analyses, sub-group analysis: Results for Specific Aim 1B	107
Results for Specific Aim 1 Results for Specific Aim 1A Baseline characteristics as per specific aim 1A: Unadjusted logistic regression analyses: Multiple logistic regression analyses: Multiple logistic regression analyses, sub-group analysis: Results for Specific Aim 1B Baseline characteristics as per specific aim 1B:	107 107 107 107 107 112 115 118 118 121 121 126
Results for Specific Aim 1 Results for Specific Aim 1A Baseline characteristics as per specific aim 1A: Unadjusted logistic regression analyses: Multiple logistic regression analyses; Multiple logistic regression analyses, sub-group analysis: Results for Specific Aim 1B Baseline characteristics as per specific aim 1B: Unadjusted logistic regression analyses;	107 107 107 107 107 112 115 118 121 121 126 129

Baseline characteristics as per Specific Aim 1C:	133
Unadjusted logistic regression analyses:	138
Multiple logistic regression analyses:	141
Multiple logistic regression analyses, sub-group analysis:	143
Results for Specific Aim 1D	146
Baseline characteristics as per Specific Aim 1D:	146
Unadjusted logistic regression analyses:	151
Multiple logistic regression analyses:	154
Multiple logistic regression analyses, sub-group analysis:	154
Sample for Specific Aims 2, 3 and 4	159
Results for Specific Aim 2	164
Baseline characteristics as per Specific Aim 2:	
Unadjusted logistic regression analyses:	169
Multiple logistic regression analyses:	169
Results for Specific Aim 3	173
Results for Specific Aim 3 A	173
Baseline characteristics as per Specific Aim 3A:	173
Negative binomial regression: Number of severe COPD exacerbation in one-year	follow-up:180
Results for Specific Aim 3B	183
Baseline characteristics as per Specific Aim 3B:	183
Negative binomial regression: Number of moderate and severe COPD exacerbat	ions in one-year
follow-up	189
Results for Specific Aim 4	193
CHAPTER 5 DISCUSSION	199
Discussion for Specific Aim 1	199
Discussion for Specific Aim 2	207

Discussion for Specific Aim 3	212
Discussion for Specific Aim 4	216
Study limitations	219
Future research	222
Study implications and conclusions	223
References	225
Appendix A: UNM Human Research Review Committee approval	248

List of tables

Table 1. Classification of airflow limitation in patients with COPD	22
Table 2. Medications in the treatment of COPD	25
Table 3. ABCD assessment tool by GOLD	27
Table 4. COPD treatment algorithm	28
Table 5. Sample data elements collected in the MarketScan Commercial Claims	
database	64
Table 6. Conditions satisfying the inclusion and exclusion criteria and their	
corresponding ICD-9CM diagnosis codes	70
Table 7. Study independent variables	71
Table 8. ICD-9CM codes for medical conditions included in the Deyo-Charlson	
comorbidity index and their corresponding weights	77
Table 9. Outcomes assessed in the study (dependent variables)	79
Table 10. Variables for matching the exposed and unexposed groups	87
Table 11. Specific Aims and corresponding statistical tests	89
Table 12. Sample size calculation for logistic regression	95
Table 13: Baseline characteristics of the unmatched study sample	99
Table 14: Baseline characteristics of the matched study sample	103
Table 15: Baseline characteristics for Specific Aim 1A	108
Table 16: Unadjusted logistic regression predicting the odds of being adherent to COPD	
maintenance medications in 90 days follow-up	113
Table 17: Multiple logistic regression predicting the odds of being adherent to COPD)
maintenance medications in 90 days follow-up	. 116

Table 18: Multiple logistic regression predicting the odds of being adherent to COPD
maintenance medications in 90 days follow-up (sub-group analysis) 119
Table 19: Baseline characteristics for Specific Aim 1B 122
Table 20: Unadjusted logistic regression predicting the odds of being adherent to COPD
maintenance medications in 180 days follow-up
Table 21: Multiple logistic regression predicting the odds of being adherent to COPD
maintenance medications in 180 days follow-up 130
Table 22: Multiple logistic regression predicting the odds of being adherent to COPD
maintenance medications in 180 days follow-up (sub-group analysis) 131
Table 23: Baseline characteristics for Specific Aim 1C
Table 24: Unadjusted logistic regression predicting the odds of being adherent to COPD
maintenance medications in 270 days follow-up 139
Table 25: Multiple logistic regression predicting the odds of being adherent to COPD
maintenance medications in 270 days follow-up 142
Table 26: Multiple logistic regression predicting the odds of being adherent to COPD
maintenance medications in 270 days follow-up (sub-group analysis) 144
Table 27: Baseline characteristics for Specific Aim 1D
Table 28: Unadjusted logistic regression predicting the odds of being adherent to COPD
maintenance medications in 365 days follow-up 152
Table 29: Multiple logistic regression predicting the odds of being adherent to COPD
maintenance medications in 365 days follow-up
Table 30: Multiple logistic regression predicting the odds of being adherent to COPD
maintenance medications in 365 days follow-up (sub-group analysis) 157

Table 31: Baseline characteristics of long-term and non-users of prescription opioids in
one-year follow-up period for Specific Aims 2, 3, and 4 160
Table 32: Baseline characteristics for specific aim 2 165
Table 33: Unadjusted logistic regression predicting the odds of being adherent to COPD
maintenance medications in one-year follow-up 170
Table 34: Multiple logistic regression predicting the odds of being adherent to COPD
maintenance medications in one-year follow-up 172
Table 35: Baseline characteristics for Specific Aim 3A 174
Table 36: Adjusted negative binomial regression: Number of severe COPD
exacerbation in one-year follow-up181
Table 37: Baseline characteristics for specific aim 3B 184
Table 38: Adjusted negative binomial regression: Number of moderate and severe
COPD exacerbation in one-year follow-up191
Table 39: Unadjusted all-cause total healthcare costs for long-term prescription opioid
users and non-opioid users194
Table 40: Adjusted all-cause total healthcare costs using generalized linear model with
a gamma distribution and log-link function
Table 41: Adherence to COPD maintenance medications among prescription opioid
users and non-opioid users among COPD patients in the four different follow-up
periods
Table 42: Adherence to COPD maintenance medications among prescription opioid
users and non-opioid users among COPD patients in the four different follow-up
periods as per Specific Aim 1 sub group analyses

Table 43: Summary of the logistic regression results of the odds of being adherent to
COPD maintenance medications among prescription opioid users and non-opioid
users among COPD patients in the four different follow-up periods
Table 44: Summary of the logistic regression results of the odds of being adherent to
COPD maintenance medications among prescription opioid users and non-opioid
users among COPD patients in the four different follow-up periods as per Specific
Aim 1 sub group analyses 206

List of figures

Figure 1. Important indicators for considering diagnosis of COPD ¹	0
Figure 2. Andersen's Behavioral Model of Health Services Use	6
Figure 3. The impact of prescription opioid use on COPD maintenance medication	
adherence, COPD exacerbations and COPD-related total healthcare costs using	
Andersen's Behavioral Model of Health Services Use	8
Figure 4. Study dataset timeline 65	5
Figure 5. Measuring medication adherence to individual medication classes using the	
interval-based approach for PDC87	1
Figure 6. Using PDC to measure concurrent medication adherence to multiple classes	
of COPD maintenance medications82	2
Figure 7: Study sample selection flowchart	7

CHAPTER 1 INTRODUCTION

Chronic Obstructive Pulmonary Disease burden

Chronic Obstructive Pulmonary Disease (COPD) is defined as "a common, preventable and treatable disease that is characterized by persistent respiratory symptoms and airflow limitation that is due to airway and/or alveolar abnormalities usually caused by significant exposure to noxious particles or gases"¹. COPD is chronic and progressive in nature and is currently treatable but irreversible¹. COPD contributes to a significant healthcare burden around the world and the United States (US). An estimated 384 million people in 2010 had COPD representing 11.7% of the world population and the prevalence is expected to rise^{1–4}. Many people may have COPD but may go undiagnosed and most may get diagnosed only at advanced stages. COPD is one of the leading causes of mortality across the world with about 6% of all deaths (3 million deaths) worldwide in 2012 being attributed to it⁵. COPD is the fourth leading cause of mortality worldwide and the third leading cause of mortality in the US¹. Along with mortality, COPD patients also contribute significantly to the utilization of healthcare resources such as emergency room visits, hospitalization, and physician office visits¹. According to the American Lung Association, the US spent about \$49.9 billion for the management of COPD in 2010 with about \$29.5 billion in direct healthcare costs⁶. According to the Centers for Disease Control and Prevention (CDC) the direct healthcare expenditures for COPD are expected to rise to US \$49 billion by 2020⁷. Patients with COPD commonly experience other chronic comorbidities such as diabetes, musculoskeletal pain, and cardiovascular conditions. The presence of these

conditions may make the management of COPD difficult and may contribute significantly to the utilization of healthcare services by COPD patients⁸.

Prescription opioid therapy

Prescription opioids are commonly used to alleviate acute pain, chronic pain in terminal patients with cancer and in patients with chronic non-cancer pain (CNCP). The prevalence of CNCP among the US adult population is high (11% to 15% of the adult population), and prescription opioids are used on a wide scale for treating CNCP^{9,10}. About 20% of patients with CNCP receive prescription opioids either acutely or on a long-term basis¹¹. Although there is established validity for the use of prescription opioids acutely in CNCP, there is little evidence for their use on a long-term basis for CNCP^{12–15}. Furthermore, the effect of either acute or long-term use of prescription opioids for CNCP on adherence to treatment for concurrent conditions, health-related quality of life, and pain-relief is still not very well understood¹⁶. Despite lacking evidence for effectiveness, the use of prescription opioids on a long-term basis is highly prevalent in the US population. Overall, about 11 million people in 2005 were prescribed long-term prescription opioid therapy¹⁷.

Adverse events associated with the use of opioids

Prescription opioids have the potential to induce psychological addiction and have been abused on a wide scale. With the significant increase in the use of prescription opioids over the past decade the problems of opioid abuse and misuse have increased significantly, becoming a major public health concern. Prescription opioid abuse and misuse contributes to a significant healthcare and economic burden in the US. In 2009, about 1.2 million emergency room visits were associated with

prescription drugs, mostly prescription opioids, compared to 1 million visits for cocaine and heroin combined^{18,19}. Annually, about \$20.4 billion are spent in direct and indirect costs for the treatment of opioid poisoning^{20,21}. About \$800 million and \$1.3 billion are spent annually for emergency room visits and inpatient visits for the treatment of opioid poisoning in the US, respectively^{20,21}. Opioid use is also associated with high mortality rates, and 2014 was recorded as the year with the highest number of deaths due to drug overdoses, with about 6 out of 10 deaths due to overdoses attributed to opioid abuse^{20,22}. Deaths due to opioid overdoses, both prescription and illicit, have increased by four times since 1999¹⁸. About 30,000 deaths in 2014 were due to overdose of prescription opioids and heroin²³. The number of deaths attributed to prescription opioids alone exceed the number of deaths due to heroin and cocaine combined^{18,20}.

About 8% of the US population suffers from substance abuse disorder and this rate is much higher among patients with $CNCP^{24-26}$. Use of prescription opioids either on a long-term or short-term basis may result in patients exhibiting aberrant drug related behavior (ADRB) such as misuse, diversion, physical dependence, abuse, addiction and tolerance. The likelihood of developing ADRB among long-term opioid users is high, even short-term use (acute use) of prescription opioids significantly increases the of odds of developing ADRB²⁷. Patients with CNCP using low-dose acute opioids (defined as \leq 36 mg of morphine equivalent dosage) had 3.03 times (OR=3.03; 95% CI: 2.32-3.95) significantly higher odds of developing ADRB compared to non-opioid users²⁷. However, among long-term, high dose prescription opioid users (defined as \geq 120 mg of morphine equivalent dosage) the odds increased by 122 fold (OR=122.45; 95% CI: 72.79-205.99)²⁷.

Along with ADRB, the use of prescription opioids has also been reported to be associated with a range of adverse events. Use of prescription opioids on a long-term basis may have effect on a variety of hormones in both men and women. Depression has been reported as result of prescription opioid use²⁸. Long-term use of prescription opioids has been associated with hyperalgesia, a condition in which use of prescription opioids leads to an increased sensitivity to pain^{26,29}. Opioid induced sedation is also a common side effect of prescription opioid use³⁰. One of the most commonly observed side effects associated with the use of prescription opioids is constipation. It occurs in as many as 95% of patients taking prescription opioids³¹. Although constipation may not be regarded as a serious adverse event, it may lead to morbidity, lowered health related quality of life and even mortality has been reported among some patients²⁶. Respiratory depression is a serious adverse effect associated with the use of prescription opioids. One of the most common causes of deaths among illicit opioid users is respiratory depression³².

Medication adherence among patients with COPD

Medication adherence is the degree to which patients follow the recommendations by their healthcare providers with regards to the timing of medication use, in the prescribed dose, and with the recommended frequency. It is defined as compliance of patients with the recommended medication dosage³³. Medication non-adherence leads to sub-optimal control of medical conditions, increases the risks of mortality, and leads to a significant increase in healthcare costs^{34–38}. About 33% to 69% of all medication-related hospitalizations have been attributed to non-adherence to medications, costing the US approximately \$100 billion a year^{34,36,39,40}. Good medication

adherence is therefore helpful in achieving optimal clinical outcomes and in-turn lowering healthcare costs in the management of health conditions^{41–43}.

Patients with COPD commonly suffer from problems of poor medication adherence. Poor medication adherence to maintenance medications among COPD patients can be attributed to a number of reasons. Maintenance medications for COPD are prescribed in inhaled form using devices which may require education on proper techniques of use of inhalers. These inhaled, maintenance medications may require to be taken in multiple doses on a daily basis. Patients with COPD also commonly suffer from comorbid conditions such as diabetes, depression, cardiovascular diseases and hypertension which may add to the medication burden and lead to poor medication adherence^{44,45}. In general, patients with COPD exhibit low adherence to their maintenance medications even when compared to their asthmatic counterparts⁴⁶. About 60% of COPD patients exhibit poor adherence to COPD treatment and even more do not use their inhalers correctly^{46–48}.

Although COPD is a chronic progressive disorder without a cure, proper management of COPD with medication therapy helps to control the symptoms of COPD and may prolong the advancement of the disease^{1,49}. Adherence to maintenance medications in patients with COPD have proven benefits in terms of economic, clinical, and humanistic outcomes. It has been shown that adherence to COPD maintenance medications helps to reduce mortality risks and the risk of severe respiratory exacerbations, leading to reduction in the number of inpatient and emergency room visits and their associated costs⁵⁰. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) treatment guidelines for managing COPD symptoms acknowledge the

importance of medication adherence to maintenance medications for controlling COPD symptoms and exacerbations¹.

Many studies have been published previously that examine the clinical and economic significance of medication adherence to COPD-related maintenance medications^{51–55}. There is established evidence in support of medication adherence to maintenance medications in COPD treatment^{51–55}. Adherence to maintenance medications helps to control COPD symptoms and helps reduce COPD exacerbations, reduces healthcare resource utilization and costs and also reduces the risk for mortality^{51–55}.

Use of prescription opioids among patients with COPD

Prescription opioids are commonly used among patients with COPD and are proven to be effective in providing analgesia⁵⁶. Patients with COPD commonly experience dyspnea, a feeling of shortness of breath and labored breathing associated with pain. The use of prescription opioids in the treatment of dyspnea among COPD patients is widely accepted^{56,57}. Along with dyspnea, the presence of chronic pain is also widely prevalent among COPD patients. The prevalence of chronic pain is significantly higher among COPD patients compared to patients with other chronic conditions (59.8% vs 51.7%)⁵⁸. With the high prevalence of chronic pain, the use of prescription opioids for treating pain is also highly prevalent among COPD patients⁵⁸. When compared to patients without COPD but with another chronic illness in multivariate analyses, COPD patients had statistically significant higher odds of chronic use of prescription opioids (OR: 1.74; 95% CI: 1.57 - 1.92)⁵⁸.

With the wide use, adverse events associated with prescription opioids may also be common among patients with COPD. Respiratory depression is a major concern in patients with COPD. COPD patients who abuse or misuse prescription opioids may be at increased likelihood of respiratory depression than those without COPD. Due to the fear of respiratory depression, physicians may feel hesitant to provide prescription opioids for patients with COPD⁵⁹. Despite the likelihood of respiratory depression, previously published controlled trials have reported prescription opioids to be safe for use in patients with COPD^{56,57,60–63}. These studies however, suffered from many limitations such as small sample sizes, and systematic exclusion of patients experiencing no benefits and those who died⁶⁴. The importance of assessing the effect of concomitant prescription opioid use on adherence to other chronic medications has been acknowledged in the past⁶⁵. A study among type 2 diabetes patients using a large US administrative database reported that type 2 diabetes patients using prescription opioids on a long-term basis (≥90 days) had statistically significantly poorer compliance to oral antihyperglycemic agents in comparison to type 2 diabetes patients not taking long-term prescription opioids⁶⁵. It is therefore important to understand if the use of prescription opioids has an impact on medication adherence, healthcare resource utilization and costs among COPD patients.

Vozoris N et al, 2016 conducted a study to identify the occurrence of adverse respiratory outcomes within 30 days of incident prescription opioid use among older COPD patients⁶⁴. The study found that incident prescription opioid users were associated with a significantly higher risk for COPD and pneumonia-related emergency room visits and mortality compared to non-opioid users. Similarly, Ekstrom M and

colleagues conducted a study to identify the effects of prescription opioid and benzodiazepine use on hospital admission rates and mortality rates among COPD patients from Sweden⁶⁶. The use of prescription opioids in COPD patients had no effect on the rate of hospital admission compared to COPD patients without prescription opioids. The use of low dose prescription opioids (≤30mg of morphine equivalent dose per day) had no statistically significant effect on mortality rate, however using high dose prescription opioids (>30mg of morphine equivalent dose per day) significantly increased the mortality rate of COPD patients (hazard ratio: 1.21; 95% CI: 1.02 -1.44)⁶⁶. Vozoris N et al, 2017 conducted a retrospective cohort study to identify the impact of incident prescription opioid use on adverse cardiac events, among a geriatric sample of COPD patients identified using an administrative claims⁶⁷. Incident use of prescription opioids was associated with statistically significant increased rates of ischemic heart disease-related mortality and morbidity. When stratified by the type of prescription opioid agents used, prescription opioid-only users had significantly higher hazard rates for ischemic heart disease-related emergency room visits and hospitalizations (hazard ratio 1.38; 95% Cl 1.08–1.77) and mortality (hazard ratio 1.83; 95% CI 1.32–2.53) compared to users of combination prescription opioids⁶⁷.

Gaps in the literature and need for the study

Previously published studies about the prevalence of prescription opioid use among patients with COPD suggests that there is a high prevalence of prescription opioid use among COPD patients⁵⁸. COPD patients may have higher prevalence of chronic pain compared to patients without COPD but with other chronic conditions and subsequently display a higher use of prescription opioids⁵⁸. Despite physicians' fear of

respiratory depression due to opioid use, COPD patients still exhibit a high prevalence of both long-term and short-term use of prescription opioids⁵⁸. Only three studies assessed and reported the impact of prescription opioid use and adverse health outcomes among COPD patients^{64,66,67}. Although these studies classified prescription opioids according to high or low doses they did not assess the effect of long-term use compared to short-term use of prescription opioids on COPD-related health outcomes. These studies also found contrasting results on the effects of opioids on adverse health outcomes. Vozoris et al found prescription opioid use to be associated with increased all-cause and COPD related mortality and COPD and pneumonia-related emergency room visits⁶⁴. The dose of prescription opioids, either low-dose or high-dose, had the same effect on the outcomes. However, Ekstorm M et al reported that only high dose prescription opioids were associated with increased mortality and low dose prescription opioids did not increase the risks of mortality among COPD patients⁶⁶. The use of prescription opioids did not have any effect on COPD-related hospital admissions. Vozoris N et al, 2017 found that prescription opioid-only users compared to users of prescription opioids combined with non-opioid agents had significantly higher hazard rates for ischemic heart disease-related emergency room visits, hospitalizations and mortality⁶⁷.

Although the prevalence of prescription opioid use is high among COPD patients, the effects of prescription opioids in this population is not very well studied. Medication adherence is an important aspect of maintenance medication therapy among COPD patents and has been associated with significant clinical effects. None of the previously reported studies have assessed the impact of prescription opioid use on adherence to

maintenance medications for COPD. Managing and controlling COPD exacerbations is an important aspect of controlling COPD symptoms. None of the previously published studies have assessed the impact of prescription opioids on COPD exacerbations. Furthermore, long-term use of prescription opioids may lead to aberrant drug related behavior among COPD patients and may have severe consequences on COPD-related medication adherence, and healthcare costs. However, no previous study has reported the impact of long-term prescription opioid use in COPD patients.

Theoretical framework

Healthcare behavior theories have been utilized by research studies in the past to understand and explain why individuals or a group of individuals undertake certain health behaviors⁶⁸. For the purpose of this study, Andersen's Behavioral Model of Health Services Use was used as a theoretical framework to facilitate the analysis of the study objectives. The model was originally developed by Ronald M Andersen and has been modified since the original publication in 1968^{69,70}.

The model has been extensively used by previous studies to assess healthcare service utilization patterns in a multitude of disease areas and patient populations^{71–75}. The model is based on the theory that factors such as predisposing factors which predispose individuals to seek care, need factors which necessitate individuals and health professionals to assess their health status, and enabling factors which provide the means to or act as barriers to access to care together contribute towards patient health behaviors and outcomes.

As per the Andersen's Behavioral Model of Health Services Use, prescription opioid use along with additional factors may affect adherence to maintenance

medications for COPD and healthcare outcomes (COPD exacerbations and total healthcare costs). These predisposing, need and enabling factors comprise sociodemographic characteristics, clinical characteristics, physician characteristics, and prior utilization characteristics.

Significance of the study

If a significant negative association is identified between the use of prescription opioids and medication adherence to COPD-related maintenance medications and COPD exacerbations, it would suggest the need for improving the management of COPD patients concurrently taking prescription opioids to address non-adherence to maintenance therapy. Also, if our study results indicate higher healthcare costs for the management of COPD patients concurrently taking prescription opioids then proper identification and management of prescription opioid therapy along with efforts to improve COPD-related medication adherence may decrease the total healthcare costs of management of COPD. Heightened attempts to identify comorbid prescription opioid use and manage poor medication adherence to maintenance medications for COPD may lead to improved COPD outcomes such as lower rate of COPD exacerbations and healthcare costs. For COPD patients taking maintenance medications, identification of concurrent prescription opioid use might be an effective gauge of potential poor medication adherence in the future and may advocate the need for improved surveillance and management to attain optimum medication adherence.

The results from our study could facilitate designing effective interventions that may help reduce non-adherence to maintenance medications for COPD and further improving COPD-related exacerbations and healthcare costs. The healthcare resources

and costs saved from these interventions could further help better allocation of limited healthcare resources among COPD patients. If the concurrent use of prescription opioids has a significant effect on adherence to maintenance medication for COPD and COPD exacerbations and total healthcare costs, then the results of the study may encourage future research to identify the impact of concurrent prescription opioid use on adherence to medications for other chronic conditions.

Study objective:

The objective of the study was to assess the impact of prescription opioid use compared to no prescription opioid use on COPD maintenance medication adherence, COPD exacerbations and total all-cause healthcare costs among a real-world sample of COPD patients.

Study hypotheses and specific aims

Specific aim 1:

To examine the impact of prescription opioid use compared to no prescription opioid use on adherence to COPD maintenance medications, over four different time periods, among a real-world, large sample of COPD patients after adjusting for other confounders.

Null hypothesis 1A:

There is no difference in adherence to COPD maintenance medications between prescription opioid users and non-users, within the first 90 days of initiating a prescription opioid, among a real-world, large sample of COPD patients after adjusting for other confounders.

Null hypothesis 1A (sub-analysis):

There is no difference in adherence to COPD maintenance medications between prescription opioid users (classified as having \geq 30-day supply of prescription opioids and <30-day supply of prescription opioids) and non-users, within the first 90 days of initiating a prescription opioid, among a real-world, large sample of COPD patients after adjusting for other confounders.

Null hypothesis 1B:

There is no difference in adherence to COPD maintenance medications between prescription opioid users and non-users, within the first 180 days of initiating a prescription opioid, among a real-world, large sample of COPD patients after adjusting for other confounders.

Null hypothesis 1B (sub-analysis):

There is no difference in adherence to COPD maintenance medications between prescription opioid users (classified as having \geq 30-day supply of prescription opioids and <30-day supply of prescription opioids) and non-users, within the first 180 days of initiating a prescription opioid, among a real-world, large sample of COPD patients after adjusting for other confounders.

Null hypothesis 1C:

There is no difference in adherence to COPD maintenance medications between prescription opioid users and non-users, within the first 270 days of initiating a prescription opioid, among a real-world, large sample of COPD patients after adjusting for other confounders.

Null hypothesis 1C (sub-analysis):

There is no difference in adherence to COPD maintenance medications between prescription opioid users (classified as having \geq 30-day supply of prescription opioids and <30-day supply of prescription opioids) and non-users, within the first 270 days of initiating a prescription opioid, among a real-world, large sample of COPD patients after adjusting for other confounders.

Null hypothesis 1D:

There is no difference in adherence to COPD maintenance medications between prescription opioid users and non-users, within the first 365 days of initiating a prescription opioid, among a real-world, large sample of COPD patients after adjusting for other confounders.

Null hypothesis 1D (sub-analysis):

There is no difference in adherence to COPD maintenance medications between prescription opioid users (classified as having \geq 30-day supply of prescription opioids and <30-day supply of prescription opioids) and non-users, within the first 365 days of initiating a prescription opioid, among a real-world, large sample of COPD patients after adjusting for other confounders.

Specific aim 2:

To examine the impact of long-term prescription opioid use (≥90-day supply in a one-year period) compared to no prescription opioid use on adherence to COPD maintenance medications among a real-world, large sample of COPD patients after adjusting for other confounders.

Null hypothesis 2:

There is no difference in adherence to COPD maintenance medications between long-term prescription opioid users (≥90-day supply in a one-year period) and non-users among a real-world, large sample of COPD patients after adjusting for other confounders.

Specific aim 3:

To examine the impact of long-term prescription opioid use (≥90-day supply in a one-year period) compared to no prescription opioid use on COPD exacerbations among a real-world, large sample of COPD patients after adjusting for other confounders.

Null hypothesis 3A:

There is no difference in the number of severe COPD exacerbations between long-term prescription opioid users (≥90-day supply in a one-year period) and non-users among a real-world, large sample of COPD patients after adjusting for other confounders.

Null hypothesis 3B:

There is no difference in the number of moderate and severe COPD exacerbations between long-term prescription opioid users (≥90-day supply in a oneyear period) and non-users among a real-world, large sample of COPD patients after adjusting for other confounders.

Specific aim 4:

To examine the impact of long-term prescription opioid use (≥90-day supply in a one-year period) compared to no prescription opioid use on all-cause total healthcare

costs (prescription medication and medical costs) among a real-world, large sample of COPD patients after adjusting for other confounders.

Null hypothesis 4:

There is no difference in all-cause total healthcare costs (prescription medication and medical costs) between long-term prescription opioid users (≥90-day supply in a one-year period) and non-users among a real-world, large sample of COPD patients after adjusting for other confounders.

CHAPTER 2 LITERATURE REVIEW

This chapter provides a review of the literature associated with the various concepts of the study and is divided into numerous major sections: overview of chronic obstructive pulmonary disease (COPD), overview of prescription opioid therapy, overview of medication adherence, overview of COPD exacerbations, use of prescription opioid therapy among patients with COPD, and a comprehensive literature review of the impact of prescription opioid therapy on adherence and healthcare resource utilization among patients with COPD.

The chapter begins by providing a description of COPD along with its prevalence, healthcare and economic burden associated with COPD, methods for the diagnosis of COPD, overview of COPD exacerbations, and guidelines for the pharmacological management of patients with COPD. An overview of prescription opioid therapy in noncancer patients and its prevalence is then presented. A discussion of the problems of opioids and prescription opioid epidemic and the economic and healthcare burden associated with the problems of prescription opioid use along with adverse effects associated with the use of prescription opioids is provided. Next, a description of medication adherence, the methods for measuring medication adherence, barriers to medication adherence, followed by a detailed description of the proportion of days covered (PDC) method for the measurement of medication adherence is presented. Further a description of the clinical significance of measuring medication adherence in general, and among patients with COPD is provided.

A detailed literature review of the impact of prescription opioid therapy on adherence to COPD maintenance medications, and the impact of prescription opioid

therapy on healthcare resource utilization and costs is provided. The gaps in the literature of the impact of prescription opioid therapy on adherence to COPD maintenance medications and healthcare resource utilization and costs and drawbacks of the studies identified from the literature review is provided.

Overview of Chronic Obstructive Pulmonary Disease (COPD)

COPD burden

Chronic Obstructive Pulmonary Disease (COPD) is a common condition of the respiratory system and is one of the prominent contributors of mortality across the world. COPD is defined as "a common, preventable and treatable disease that is characterized by persistent respiratory symptoms and airflow limitation that is due to airway and/or alveolar abnormalities usually caused by significant exposure to noxious particles or gases"¹. Emphysema and chronic bronchitis are conditions that have been used to define COPD, however they are not used in the latest updated versions of the treatment guidelines provided by Global Initiative by Chronic Obstructive Lung Disease (GOLD)¹. COPD is characterized by chronic airflow limitation which is caused by a combination of obstructive bronchiolitis and emphysema¹. The chronic inflammation in COPD leads to narrowing of small airways, combined with a reduction in the recoil ability of lungs which together have a negative effect on airways to remain open¹. There are many different factors which increase the risks of developing COPD. These factors include tobacco smoking, exposure to noxious gases and particles, genetic factors, airway hyper-responsiveness, and improper development of lungs during adolescence. COPD is chronic and progressive in nature and is currently treatable but irreversible¹.

COPD contributes to a significant healthcare burden in the world and the US. It is

estimated that about 384 million people in 2010 had COPD representing 11.7% of the world population^{1,2}. With the increasing life expectancy of the population in the developed countries, and the rising number of smokers in the developing countries the prevalence of COPD is expected to rise^{1,3,4}. About 6% (3 million deaths) of all deaths worldwide in 2012 were attributed to COPD⁵. COPD is the fourth leading cause of mortality worldwide and the third leading cause of mortality in the US¹. Along with mortality, COPD patients also contribute significantly to the utilization of healthcare resources such as emergency room visits, hospitalization, and physician office visits. According to the American Lung Association, the US spent about \$49.9 billion for the management of COPD in 2010 with about \$29.5 billion in direct healthcare costs⁶. According to the Centers for Disease Control and Prevention (CDC), the direct healthcare expenditures for COPD are expected to rise to US \$49 billion by 2020⁷. Patients with COPD commonly experience other chronic comorbidities such as diabetes, musculoskeletal pain, and cardiovascular conditions. The presence of these conditions may make the management of COPD difficult and may contribute significantly to the utilization of healthcare services by COPD patients⁸.

Diagnosis of COPD

GOLD recommends the consideration for diagnosis of COPD in individuals who are greater than 40 years of age and possess any of the symptoms of COPD coupled with the risk factors such as tobacco smoking, exposure to noxious gases and particles, genetic factors, airway hyper-responsiveness, and improper development of lungs during adolescence (Figure 1.)¹.

Figure 1. Important indicators for considering diagnosis of COPD¹

SYMPTOMS

Presence of Dyspnea: persistent; is progressive over time; and becomes characteristically worse over time.

Presence of chronic cough: May be recurrent and may be unproductive; but subsequently is present every day, often throught the day; recurrent wheeze.

Chronic sputum production: intermittent

with periods of flare-ups, or any patterns of chronic sputum production. Spirometry for diagnosis of COPD

RISK FACTORS

History of risk factors: host factors such as genetic factors, developmental abnormalities etc.; tobacco smoking (including popular local preparations); smoke fromhome cooking and heating fuels; occupational dusts, vapors, fumes, gases and other chemicals.

Family history of COPDand/or childhood factors: childhood respiratory infections, low birthweight etc. Spirometry testing is regarded as a reliable and most reproducible form of test for the diagnosis of COPD¹. Although a reliable method for diagnosis of COPD, spirometry testing is not recommended as a screening tool for individuals who do not exhibit the symptoms and risk factors for COPD but rather for active case finding among individuals with the symptoms and risk factors for COPD¹.

Spirometry is a non-invasive and objective measurement of airway obstruction with a high sensitivity and a moderate specificity⁷⁶. It is commonly performed using a device called spirometer. A spirometer helps clinicians measure the volume of air an individual can inhale and exhale. There are two measures important for the diagnosis of COPD which are calculated using a spirometer, forced vital capacity (FVC) and forced expiratory volume in one second (FEV₁). The FVC is a measure of the volume of air that can be forcibly exhaled from a maximum inspiration¹. Whereas FEV_1 is the volume of air that is exhaled during the first second of the calculation of FVC¹. The ratio of these measures (FEV₁ / FVC) is used to diagnose COPD and is indicative of the amount of airflow limitation in an individual. Generally, the FEV₁ / FVC is calculated after inhalation of a short-acting bronchodilator. A FEV₁ / FVC value of <0.7, after administration of a short-acting bronchodilator, along with presence of COPD-related symptoms and risk factors constitutes a diagnosis of COPD in an individual¹. The severity of airflow limitation is defined by various cut-off points in the FEV1 values (Table 1). It is important to note however, that severity of airflow limitation based on the FEV1 values alone are not predictive of future COPD exacerbations or the severity of COPD exacerbations or mortality.

GOLD Stage	Airflow limitation severity	Definition
GOLD stage 1	Mild	FEV1 ≥ 80% predicted
GOLD stage 2	Moderate	$50\% \leq \text{FEV}_1 < 80\%$ predicted
GOLD stage 3	Severe	$30\% \leq FEV_1 < 50\%$ predicted
GOLD stage 4	Very Severe	FEV ₁ < 30% predicted

Table 1. Classification of airflow li	imitation in patients with COPD
---------------------------------------	---------------------------------

 $FEV_1 = forced expiratory volume in one second$ Source: GOLD¹

COPD exacerbations and assessing the risks for future exacerbations

COPD patients may periodically experience sudden flare-up of their COPD symptoms which may necessitate hospitalizations¹. These are known as COPD exacerbations and are defined as "acute worsening of respiratory symptoms that result in additional therapy"¹. Patients with COPD may experience various symptoms during exacerbations such as, dyspnea, wheezing, irregular breathing, anxiety, cough, changes in skin or nail color, difficulty in sleeping and eating, headaches in the mornings, inflammation of legs or ankles, and inability to speak^{77,78}. Assessment of COPD exacerbations is very important as it has been regarded as a strong predictor of future exacerbations⁷⁹.

COPD exacerbations may be classified as mild, moderate or severe¹. Mild COPD exacerbation may likely be controlled using only short-acting bronchodilators¹. A moderate COPD exacerbation may require treatment using a short-acting bronchodilator with a combination of antibiotics and may even require an oral corticosteroid¹. A severe COPD exacerbation on the other hand may require an emergency room visit or an inpatient hospitalization and may sometimes be associated with acute respiratory failure¹.

Management of COPD

Treatment for stable COPD is based on an assessment of patient's symptoms and their likelihood of experiencing future exacerbations. Although COPD cannot be reversed the objectives of COPD treatment are twofold, decrease COPD symptoms, and lessen the risks for future exacerbations. For optimal management of COPD, a combination of both pharmacological and non-pharmacological strategies are

undertaken. Patients with COPD need to be provided proper education on optimal management of their symptoms and reducing their risk factors which include lifestyle modification along with a healthy diet and physical exercise. Patients with COPD need to be regularly monitored for their symptoms, exacerbations, medication adherence and presence of adverse events which need to be managed as well.

One of the most common problems with COPD patients is cigarette smoking. It is important that patients with COPD quit smoking, and therefore patients should be provided counseling to encourage them to quit. If necessary, medications and smoking cessation interventions should be delivered. Patients should also be encouraged to take necessary steps to reduce the risks from indoor and outdoor pollutants. COPD patients are also recommended by the Centers for Disease Control and Prevention (CDC) to receive pneumococcal vaccination, although meta-analysis studies among COPD patients have found no benefit from pneumococcal vaccination in terms of reduction of inpatient and emergency room visits or reduction in the rates of pneumonia⁸⁰. COPD patients are recommended to have an annual influenza vaccination, which unlike pneumococcal vaccination has found to be associated with reduction in COPD exacerbation rates⁸¹. Pulmonary rehabilitation among severe COPD stages may also prove beneficial in improving exercise tolerance, and reducing dyspnea⁸².

Along with lifestyle modification, patients with COPD are prescribed pharmacological therapy which is crucial in the management of COPD. The various agents used in the treatment of COPD are listed in Table 2.

Drug class	Drugs in the class
Beta ₂ -agonist	Short-acting
	Fenoterol
	Levalbuterol
	Salbutamol (albuterol)
	Terbutaline
	Long-acting
	Arformoterol
	Formoterol
	Indacaterol
	Olodaterol
	Salmeterol
Anticholinergics	Short-acting
5	Ipratropium bromide
	Öxitropium bromide
	Long-acting
	Aclidinium bromide
	Glycopyrronium bromide
	Tiotropium
	Umeclidinium
Combination of short-acting	Fenoterol/Ipratropium
beta ₂ -agonist and	
anticholinergic in one device	
	Salbutamol/Ipratropium
Combination of long-acting	Formoterol/Aclidinium
beta ₂ -agonist and	
anticholinergic in one device	
	Formoterol/Glycopyrronium
	Indacaterol/Glycopyrronium
	Vilanterol/Umeclidinium
	Olodaterol/Tiotropium
Methylxanthines	Aminophylline
	Theophylline
Combination of long-acting	Formoterol/Beclomethasone
beta ₂ -agonist and	
corticosteroids in one	
device	
	Formoterol/Budesonide
	Salmeterol/Fluticasone
	Vilanterol/Fluticasone
	furoate
Phosphodiesterase-4	Roflumilast
inhibitors	Konurmast

Table 2. Medications in the treatment of COPD

GOLD recommends that the choice of medications in the management of COPD should rely on patients' symptoms and risk of future exacerbations. They have created an ABCD assessment tool to simplify healthcare providers in choosing the various medications (Table 3)¹. Based on the ABCD assessment tool, GOLD provides an algorithm for treatment of COPD patients as described in Table 4¹.

In summary, COPD is a common respiratory condition and is the fourth leading cause of mortality worldwide¹. It is associated with a significant health care burden with about 12% of the world population suffering from COPD and leading to about US \$50 billion in healthcare spending, annually^{1,2,6}. It is generally diagnosed using spirometry in people above 40 years of age and possessing symptoms of COPD coupled with risk factors for COPD such as exposure to smoke, particulate matter, or having a family history of COPD. Patients with COPD commonly experience exacerbations which may require an emergency room visit or inpatient hospitalization. Having a COPD exacerbation is regarded as the strongest predictor of future exacerbations⁷⁹. Patients with COPD are commonly prescribed inhaled bronchodilators which help in controlling the symptoms of COPD and reduce the likelihood of future exacerbations¹.

Overview of prescription opioid therapy

Opioid epidemic

The use of prescription opioids has increased drastically in the past few years with nearly three-fold increase in sales of prescription opioids in the US in 2015 compared to 1999 and nearly four times the amount sold in Europe in 2015^{18,83,84}. Prescription opioids are commonly used to alleviate acute pain, chronic pain in terminal patients with cancer and in patients with chronic non-cancer pain (CNCP). Although the

ABCD classification	Spirometric evaluation	Exacerbation history	mMRC	САТ
A Contraction of the second seco	GOLD stage 1	≤1 exacerbation not leading to hospital admission	0 – 1	<10
В	GOLD stage 2	•	≥2	≥10
С	GOLD stage 3	≥2 exacerbations or ≥1 exacerbation leading to hospital admission	0 – 1	<10
D	GOLD stage 4	≥2 exacerbations or ≥1 exacerbation leading to hospital admission	≥2	≥10

Table 3. ABCD assessment tool by GOLD

Source: GOLD¹

Group	GOLD recommendation for pharmacological therapy
A	Patients should be prescribed either a short-acting or long-acting
	bronchodilator.
	Symptoms should be evaluated and therapy should be continued if
	adequate symptoms relief is achieved.
	If symptomatic benefits not achieved, therapy should be stopped and
	alternative class of bronchodilator should be prescribed.
В	Long-acting bronchodilators are preferred over short-acting.
	Choice of long-acting bronchodilator is based on symptom relief of
	individual patients.
	If patients have persistent breathless on monotherapy with long-acting
	bronchodilator, dual-therapy with bronchodilators is recommended.
	• If severe breathlessness if present, patients can be directly initiated with
	dual-therapy with bronchodilators.
С	 Initial therapy with long-acting bronchodilator.
	LAMA preferred over LABA for initial therapy.
	If patients experience persistent exacerbations, then LABA/LAMA or
	LABA/ICS combination therapy is recommended.
	LABA/LAMA combination is preferred over LABA/ICS.
D	 Initiate combination therapy with LABA/LAMA or LABA/ICS.
	LABA/LAMA combination is preferred over LABA/ICS.
	• If patients continue to experience exacerbations, then choose either:
	LABA/LAMA/ICS, or LABA/ICS.
	If patients with LABA/LAMA/ICS still continue to experience
	exacerbations then choose either: add roflumilast, add macrolide, or
	stop ICS.
LAMA = I	ong-acting muscarinic agent

Table 4. COPD treatment algorithm

LAMA = long-acting muscarinic agent LABA = long-acting beta₂ agonist ICS = inhaled corticosteroid Source: GOLD¹ use of prescription opioids in cancer and short-term use in acute pain and CNCP is effective, their use however on a long-term basis for CNCP is widely debated^{12–15}. Opioids in general have the potential to induce psychological addiction and have been abused on a wide scale. Opioid abuse and misuse contributes to a significant healthcare and economic burden in the US. Prescription opioid abuse has become a major public health concern in the past years.

With the rising rates of prescribing of prescription opioids, comes the rise in mortality due to prescription opioid abuse and overdoses. Prescription opioid abuse is considered an epidemic, and 2014 was recorded as the year with the highest number of deaths due to drug overdoses with about 6 out of 10 deaths due to overdoses attributed to opioid abuse^{20,22}. Deaths due to opioid overdoses, both prescription and illicit, have increased by four times since 1999¹⁸. About 30,000 deaths in 2014 were due to overdose of prescription opioids and heroin²³. About 78 deaths daily are due to opioid overdoses in the US⁸⁵. The number of deaths attributed to prescription opioids alone exceed those due to heroin and cocaine combined^{18,20}.

According to Birnbaum H et al, prescription opioid abuse contributes to a significant economic burden, not just on the US healthcare system (\$25 billion) but also the US justice system (\$5.1 billion) including correctional facilities and police costs, workplace burden (\$25.6 billion) including lost employment and lost earnings from premature death, and society (\$55.7)⁸⁶. In 2009, about 1.2 million emergency room visits were associated with prescription drugs, mostly prescription opioids, compared to 1 million visits for cocaine and heroin combined^{18,19}. About \$20.4 billion are spent in direct and indirect costs attributed annually in the treatment of opioid poisoning^{20,21}.

About \$800 million and \$1.3 billion are spent annually for emergency room visits and inpatient visits for the treatment of opioid poisoning in the US, respectively^{20,21}. Average treatment costs per event for prescription opioid poisoning is higher compared to heroin poisoning which may be attributed to the longer half-life of prescription opioids (varies by drug) compared to heroin (15 to 30 minutes) requiring longer monitoring time²¹.

Prescription opioid therapy in the treatment of chronic non-cancer pain

It is estimated that about 11% to 15% of the adult US population has chronic pain on a daily basis^{9,10}. Prescription opioids are commonly used for the treatment of CNCP. CNCP is defined as pain typically lasting more than 3 months which may result from an injury, inflammation or an underlying condition or an unknown cause^{87,88}. About 20% of patients with CNCP receive prescription opioids, either acutely or on a long-term basis¹¹.

There is established validity for the use of prescription opioids acutely in CNCP^{14,15}. However, there is little evidence for their use on a long-term basis for CNCP^{12,13}. The effect of long-term use of prescription opioids for CNCP on adherence to treatment for comorbid conditions, health-related quality of life, and pain-relief is still not very well understood¹⁶. A Cochrane literature review of studies assessing safety, efficacy and effectiveness of long-term prescription opioid use in CNCP patients reported that there was very limited evidence for clinically meaningful amount of alleviation of pain associated with long-term use of prescription opioids for CNCP¹³. The study found that prescription opioid use was only effective in a small group of patients with no history of substance abuse¹³. Many of the participants from previously published studies discontinued their prescription opioid treatment due to opioid-related side effects

or inadequate pain relief¹³. The review also reported that long-term use of prescription opioids for CNCP had inconclusive evidence for improvement on functioning or quality of life. Despite lacking evidence for effectiveness, the use of prescription opioids among CNCP patients on a long-term basis is highly prevalent in the US population. About 11 million people in 2005 were prescribed long-term prescription opioid therapy for CNCP¹⁷.

Risks of developing long-term use from an acute use of prescription opioid

Previously published evidence suggests that as low as 8 days of acute use of prescription opioids has the likelihood of developing long-term use when measured over 1 to 3 years. Shah and colleagues used a 10% random sample from the 2006 – 2015 IMS Lifelink + database to identify commercially insured adult patients who had used a prescription opioid⁸⁹. Included patients were required to be prescription opioid-naïve with a 6-month pre-period of no evidence of prescription opioid use. Patients with cancer and evidence of opioid abuse diagnosis were excluded. They measured the time to discontinuation of prescription opioids. The study found that the number of days of doses in the first prescription fill is a significant predictor of long-term use of prescription opioids. Patients who had just 8 days of supply of the first prescription opioid fill had a rate of long-term use (1 year of use) of 13.5% compared to 6% among people having only 1-day supply. This rate increased considerably to 29.9% when the first fill of prescription opioid was for 31 days. About 1 in 7 patients who had a refill of a prescription opioid (or a second fill) were using prescription opioid one year later. Results from the study suggest that a transition from acute use to a long-term use may happen in just 3 days of prescription opioid use. Similarly, a study conducted by Deyo

RA and colleagues in 2017 among prescription opioid-naïve patients residing in Oregon reported that patients refilling their opioid prescription had 2.25 (95% CI, 2.17-2.33) times higher likelihood of developing chronic long-term use compared to patients having only one fill of prescription opioids⁹⁰.

Guidelines for prescription opioid therapy for chronic non-cancer pain

Although prescription opioid use is highly prevalent in the US population, there seems no uniform consensus among clinicians in prescribing opioid therapy⁹¹. The Centers for Disease Control and Prevention (CDC) in 2016 published evidence based guidelines in order to assist clinicians to appropriately prescribe opioids for patients with CNCP⁹². It is important to note that the CDC acknowledges the lack of evidence for long-term prescription opioid use in CNCP, "In summary, evidence on long-term opioid therapy for chronic pain outside of end-of-life care remains limited, with insufficient evidence to determine long-term benefits versus no opioid therapy, though evidence suggests risk for serious harms that appears to be dose-dependent^{"92}. The CDC guideline provides recommendations in three different areas of opioid prescribing: when to initiate and continue opioids in CNCP; selection of opioids, duration, dosage, follow-up and discontinuation; and assessing the risks and harms of opioid prescribing⁹².

Initiating and continuing prescription opioids in CNCP:

CDC recommends the use of non-pharmacological therapy (such as exercise therapy, cognitive behavior therapy, etc.) and non-opioid pharmacological therapy (such nonsteroidal anti-inflammatory drugs, acetaminophen) in patients with CNCP⁹². Prescription opioid therapy should only be considered if the anticipated benefits (for both pain and functioning) of prescription opioid therapy outweigh the risks⁹².

Prescription opioids when initiated should be used in conjunction with nonpharmacological and non-opioid pharmacological therapy⁹². Clinicians should discuss treatment goals along with the risks and benefits of treatment with patients before starting prescription opioid therapy⁹².

Selection of prescription opioids, duration, dosage, follow-up and discontinuation:

Patients should generally start with immediate-release prescription opioids instead of long-acting prescription opioids⁹². Prescription opioid therapy should be initiated with the lowest effective dose and generally patients should not be prescribed doses \geq 90 mg of morphine equivalent dose per day⁹². Patients should be prescribed only required doses, no additional doses should be prescribed⁹². After initiating a prescription opioid therapy, patients should be monitored within 1 to 4 weeks to assess the effectiveness of the therapy and increase the dosage as needed. Clinicians should regularly monitor dosage (every 3 months) to assess the benefits and harms of the therapy⁹². If the clinicians decide that the risk of the prescription opioid therapy outweighs the benefits than they should taper the therapy and lower the dosage or taper the therapy and discontinue the therapy⁹².

Assessing the risks and harms of opioid prescribing:

Clinicians should regularly monitor patients on prescription opioid therapy for CNCP. Factors such as previous history of overdose and substance abuse, concurrent benzodiazepine administration, and prescription opioid doses \geq 50 mg of morphine equivalent dose per day may increase the patients' likelihood of having an opioid overdose⁹². When such factors are present, clinicians should consider offering naloxone

to patients. Before prescribing an opioid, clinicians should consider a patients' history of substance abuse and concurrent receipt of opioids from other sources and receipt of other medications which could lead to serious adverse events⁹². Clinicians should also regularly monitor such data every 3 months along with the use of other drugs and use of illicit drugs by urine testing while the patient is on prescription opioid therapy⁹². If possible, benzodiazepines should not be prescribed concurrently with prescription opioids⁹².

Aberrant Drug Related Behavior

About 8% of the US population suffers from substance abuse disorder, and this rate is much higher among patients with $CNCP^{24-26}$. Use of prescription opioids may result in patients exhibiting aberrant drug related behavior (ADRB) such as misuse, diversion, physical dependence, abuse, addiction and tolerance. The likelihood of developing ADRB among long-term prescription opioid users is high, even the use of acute prescription opioids significantly increases of odds of developing ADRB²⁷. Patients with CNCP using low-dose acute prescription opioids (defined as \leq 36 mg of morphine equivalent dosage) had 3.03 times (OR=3.03; 95% CI: 2.32-3.95) significantly higher odds of developing ADRB (abuse and dependence) compared to non-opioid users²⁷. However, among long-term, high dose prescription opioid users (defined as \geq 120 mg of morphine equivalent dosage) the odds of developing ADRB increased significantly by 122 folds (OR=122.45; 95% CI: 72.79-205.99)²⁷.

Tolerance

Use of prescription opioids may lead to development of tolerance to opioid medications. A tolerance to an opioid prescription is developed when increasing doses

of prescription opioids are required over time to generate the original degree of therapeutic effect⁹³. For example, a patient may be prescribed a short-acting prescription opioid and later during the treatment may require increasing dosage of the short-acting prescription opioid to achieve the same therapeutic effect of the initial dosage of the short-acting prescription opioid. Subsequently, the same patient might even be prescribed a long-acting prescription opioid to achieve the therapeutic effect of the initial dosage of the short-acting prescription opioid.

Tolerance to prescription opioids is not necessarily misuse, or addiction to prescription opioids. Patients who are tolerant may still be adherent to their physician's prescribing guideline. In short, tolerance occurs when opioids are prescribed over a long-term basis. As patients who develop tolerance for opioids are prescribed higher doses of opioids, their odds for accidental overdoses are increased.

Physical Dependence

Like tolerance, use of prescription opioids may lead to physical dependence on opioid medications. Physical dependence is a manifestation of withdrawal symptoms and is revealed when a specific drug class like opioids are reduced in dosage, abruptly stopped, or when an antagonist if prescribed. Patients who are physically dependent are not necessarily addicted or abusing the drug.

Addiction

Addiction occurs when use of prescription opioids leads to a "chronic, relapsing brain disease that is characterized by compulsive drug seeking and use, despite harmful consequences"⁹⁴. When addicted, a person displays an inability to refrain from using opioids, or control cravings leading to a compulsive drug seeking behavior⁹⁵. A person

with addiction may display the following characteristics: inability to abstain from opioid use; cravings for opioid medications; impaired behavioral control; diminished ability to recognize problems with behavior and interpersonal relationships; and lack of or poor emotional response⁹⁶.

If opioid addiction in not treated a person can progress to illegally obtaining and using heroin⁹⁷. According to Jones M et al, about 4 out of every 5 heroin users progressed to heroin after use of prescription opioids⁹⁷. In a 2014 survey of heroin users by Cicero J and colleagues over 90% of respondents reported switching to heroin because it was cheaper and more readily available than prescription opioids⁹⁸. If not managed, addiction to prescription opioids can progress to greater cravings and may lead to premature death or disability⁹⁵.

Diversion

Section 309 of the Uniform Controlled Substances Act of 1994 defines diversion as "the transfer of a controlled substance from a lawful to an unlawful channel of distribution or use"⁹⁹. For example, a patient receiving a prescription opioid may share, or sell their medications with their family members or friends. Patients may also purchase prescription opioids from non-medical sources such as friends, family members, or through internet websites which do not require a prescription for purchase. Diversion may also involve theft from hospitals, pharmacies or from patients.

Misuse

Misuse of prescription opioids is their use that is not as directed or instructed by physicians or health care providers¹⁰⁰. Misuse may or may not necessarily be intentional or may not necessarily result in harm. For example, a patient may misuse opioid

prescription by increasing the dosage of the medication either forgetfully or intentionally due to physical dependence or tolerance to achieve a higher therapeutic effect. Patients may also hoard their opioid prescriptions during periods of reduced symptoms for use as and when needed¹⁰⁰.

Abuse

Abuse is the intentional use of an opioid medication for non-medical reasons such a recreational use, or altering one's state of consciousness such as achieving a state of "high"¹⁰¹.

Side effects associated with the use of opioids

Along with aberrant drug related behavior, the use of prescription opioids has also been reported to be associated with certain side effects such as hyperalgesia, sedation, constipation, respiratory depression, depression etc.

Hormonal effects

Use of prescription opioids on a long-term basis may have effect on a variety of hormones in both men and women. Men and women who take prescription opioids on a long term-basis may show reduced levels of testosterone leading to problems with sexual dysfunction, and decreased physical energy^{26,28,102–104}. Depression has also been reported as a result of prescription opioid use²⁸. In women, taking prescription opioids on a long-term basis has also been associated with reduced estrogen levels which may have an impact on osteoporosis in geriatric patients^{28,104}. Non-spinal fractures were reported by Ensrud K et al among a sample of older women taking prescription opioids¹⁰⁴.

Hyperalgesia

Long-term use of prescription opioids has also been associated with hyperalgesia, a condition in which use of prescription opioids leads to an increased sensitivity to pain^{26,29}. Patients taking prescription opioids to manage chronic pain may find themselves unexpectedly having a higher sensitivity to pain with an increasing use of prescription opioids^{26,105}. A study by Chu L et al reported that patients treated for chronic back pain reported developing hyperalgesia within just a month of using morphine¹⁰⁶.

Opioid-induced sedation and sleep disturbances

Opioid induced sedation is also a common side effect of opioid use³⁰. Although patients can eventually develop tolerance for sedation, increasing the dosage of prescription opioids may lead to sedation which in turn has been proposed to affect medication adherence and reduce patients' quality of life²⁶. Conversely, studies have also shown that patients taking prescription opioids may also experience reduced sleep and increased sleep disturbances¹⁰⁷.

Opioid-induced constipation

One of the most common side effects associated with the use of prescription opioids is constipation. It occurs in as many as 95% of patients taking prescription opioids³¹. Although constipation may not be regarded as a serious adverse event associated with prescription opioids the chronic nature of constipation in opioid users makes it difficult to develop tolerance towards it²⁶. Constipation may lead to dose lowering of prescription opioids which may in turn lead to decreased analgesic effects of opioids, and may sometimes lead to complete cessation of therapy²⁶. Constipation may

also lead to morbidity and mortality and lowered health related quality of life among patients²⁶. Opioid-induced constipation may not improve on its own and requires adequate treatment and monitoring¹⁰⁸.

Opioid-induced respiratory depression

Respiratory depression is a serious adverse effect associated with the use of opioids. One of the most common causes of deaths among illicit opioid users is respiratory depression³². Although the proportion of patients who die due to respiratory depression among prescription drug users is low, the large number of patients using opioid prescriptions makes it an important healthcare concern¹⁰⁹. Concerns for respiratory depression may lead to under-treatment of pain¹⁰⁹.

Respiratory depression is a major concern in patients with respiratory conditions such as COPD. Patients with COPD commonly experience dyspnea, a feeling of shortness of breath and labored breathing associated with pain. The use of prescription opioids in the treatment of dyspnea among COPD patients is widely accepted^{56,57}. However, COPD patients prescribed opioids need to be appropriately monitored. COPD patients who abuse or misuse opioids may be at increased likelihood of respiratory depression than those without COPD.

In summary, prescription opioids are commonly used for the treatment of CNCP. Although prescription opioids are recommended for acute use in patients with CNCP, their use on a long-term basis is widely debated with a systematic literature review study reporting little to no improvement in pain-relief or health-related quality of life among long-term users of prescription opioids with CNCP^{12–15}. Even the CDC

acknowledges the lack of evidence for long-term prescription opioid use in CNCP. Patients using prescription opioids even on acute basis may lead to using them on a long-term basis^{89, 90}. For example, evidence from a previously published study suggests that as low as 8 days of acute use of prescription opioids has the likelihood of developing long-term use of 1 to 3 years⁸⁹. Use of prescription opioids may result in patients exhibiting ADRB²⁷. The use of prescription opioids has also been reported to be associated with side effects such as hyperalgesia, sedation, constipation, respiratory depression, depression etc²⁶.

Overview of medication adherence

Medication adherence is the ability of patients to follow the recommendations by their healthcare providers with regards to the timing of medication use, in the prescribed dose, and with the recommended frequency. It is defined as compliance of patients with the recommended medication dosage³³.

Adherence is commonly reported in the form of a "percentage of prescribed doses actually taken by the patient over a specified period"¹¹⁰. Generally, patients with acute condition are more likely to be adherent to their medication regimen than patients diagnosed with chronic conditions¹¹¹

As compared to real world settings, the average medication adherence rates in randomized controlled trials (RCTs) is significantly higher due to selection of patients and attention received by the patients. In spite of this, medication adherence rates of only 40% to 80% are achieved by RCT participants with severe medical conditions^{112–114}. There is however, no set standard for an optimum medication adherence rate. A medication adherence rate of 80% is commonly observed in published RCTs and

observational studies, whereas other RCTs consider rates of 95% to be necessary for optimum adherence (RCTs with patients diagnosed with human immunodeficiency virus).

Medication non-adherence may lead to sub-optimal control of medical conditions, increase the risks of mortality, and may lead to a significant increase in healthcare costs^{34–38}. About 33% to 69% of all medication-related hospitalizations have been attributed to non-adherence to medications, costing the US approximately \$100 billion a year^{34,36,39,40}. Good medication adherence is therefore helpful in leading to better clinical and economic outcomes in the management of health conditions^{41–43}. With the increasing importance of proper management of patients and improving medication adherence, the World Health Organization has compiled guidelines for healthcare professionals and policymakers to enhance medication adherence strategies and interventions¹¹¹.

Several previous studies have tried to understand the reasons that contribute to non-adherence to medications among patients. The following are some of the common barriers to medication non-adherence among patients: presence of comorbid conditions, severity of the disease, presence of depression, low perceived health status, high number of medications, complexity of medication regimen, low health literacy, high cost of medications, side effects of medications, poor patient-provider relationship, and polypharmacy^{115–119}. To improve medication adherence of patients, all the potential barriers to medication adherence need to be addressed.

There are several different methods of measuring medication adherence which can be classified into two categories: direct and indirect methods of measurement.

Medication adherence can be measured either directly through addition of biological markers to drug formulations, measurement of amount of drug or metabolite in urine or blood, or directly observed therapy. Indirect methods of measurement include patient interviews, patient diaries, prescription refill rate, electronic monitoring, assessing clinical outcomes, and assessing physiological indictors such as heart rates.^{33,110,114}.

The International Society of Pharmacoeconomics and Outcomes Research (ISPOR) formed the ISPOR Medication Compliance and Persistence Special Interests group (SIG) with the goal to stimulate research in issues related to medication adherence, persistence, and implications of health outcomes¹²⁰. Accordingly, the ISPOR SIG group developed a checklist for appropriately conducting medication adherence studies.

Proportion of days covered (PDC)

Proportion of days covered (PDC) is a validated method of measuring medication adherence that is used in studies involving pharmacy refill data, and is a recommended technique for assessing medication adherence by the ISPOR SIG^{33,120}. Use of PDC for the measurement of medication adherence is also consistent with recommendations of the Pharmacy Quality Alliance (PQA) and the National Quality Forum (NQF), which support the use of PDC as the preferred method to assess medication adherence¹²¹. The Centers for Medicaid and Medicare Services (CMS) uses medication adherence to using PDC as one of the measures for assessing quality and performance and assigning star ratings for Medicare Part C and D plans¹²². Recent studies on adherence to COPD maintenance medications have also used PDC as the primary measure of medication adherence^{51,52}.

PDC is an indirect measure to assess medication adherence that has been used with increasing frequency^{123–126}. "The PDC is calculated as the number of days with drug on hand divided by the number of day in the specified time interval"¹²⁰. The PDC is generally represented in the form of a percentage.

PDC = total number of days with drug on hand x 100 total number of days in the time interval

Similar to PDC, medication possession ratio (MPR) is also an indirect method commonly utilized to assess medication adherence¹²⁷. The MPR is the ratio of the dispensed "days' supply divided by the number of days before the patient discontinues the medication"¹²⁷. The MPR however, calculates medication adherence only when the patient has the drug on hand, PDC on the other hand assess adherence over an entire specified time period. The PDC also has an advantage over the use of MPR when patients are prescribed multiple medications at a time. Patients with COPD prescribed maintenance medications may undergo different patterns of maintenance medication use. When multiple maintenance medication use patterns are present, MPR may cause double counting and overestimate the actual medication adherence. Contrarily, while assessing medication adherence using PDC, filled prescriptions are assessed such as to avoid double-counting in the numerator.

Significance of medication adherence in COPD treatment

Patients who have chronic conditions and require therapy on a long-term basis have lower adherence than patients with acute conditions¹¹¹. Patients with COPD may

also suffer from problems of poor medication adherence because of the number of medications concurrently prescribed for controlling the symptoms. Maintenance medications for COPD are usually prescribed in inhaled form using devices which may require education on proper techniques of use of inhalers. These inhaled, maintenance medications may be taken in multiple doses on a daily basis. Patients with COPD may also commonly suffer from comorbid conditions such as diabetes, depression, cardiovascular diseases and hypertension which may add to the medication burden and lead to poor medication adherence^{44,45}. In general, patients with COPD are poorly adherent to their maintenance medications even when compared to their asthmatic counterparts⁴⁶. About 60% of COPD patients exhibit poor adherence to COPD treatment and even more do not use their inhalers correctly^{46–48}.

COPD is a progressive disorder without a cure, however proper management of COPD with medication therapy helps to control the symptoms of COPD and may prolong the advancement of the disease^{1,49}. Adherence to maintenance medications in patients with COPD have proven benefits in terms of economic, clinical, and humanistic outcomes. It has been shown that adherence to COPD maintenance medications helps to reduce mortality risk and the risk of severe respiratory exacerbations, which may in turn lead to reduction in the number of inpatient and emergency room visits and their associated costs⁵⁰. Invariably, the GOLD guidelines emphasize adherence to COPD-related maintenance medications for achieving control of COPD symptoms and exacerbations¹.

Many studies have been published previously that examined the clinical and economic significance of medication adherence to COPD-related maintenance

medications. Eaddy and colleagues conducted a literature review of studies published from 1974 to 2008, to assess the impact of medication adherence in chronic conditions and its impact on clinical and economic outcomes⁵³. In the review, studies conducted in patients with COPD and asthma were grouped together. They reported that past studies have sufficiently shown that medication adherence among COPD and asthma patients has a significant positive impact on clinical outcomes. Furthermore, they found that medication adherence was significantly associated with lower healthcare resource utilization and costs among patients with COPD or asthma.

Simoni-Wastila L et al, 2012 assessed a sample of Medicare beneficiaries diagnosed with COPD using the 2006-2007, 5% random sample of Medicare beneficiaries⁵¹. They calculated medication adherence (using PDC) and persistence to maintenance medications for COPD for 18 months among 33,816 COPD patients satisfying the study inclusion criteria. They found that both high medication adherence (PDC \geq 80%) and persistence (greater than 280 days on maintenance medications) were statistically significantly associated with lower all-cause hospitalization and allcause Medicare costs.

Toy E and colleagues assessed the impact of medication adherence (using PDC) to COPD-related maintenance medications on all-cause healthcare resource utilization⁵². They followed a sample of 55,076 COPD patients for 12 months after index date (date of first fill of a COPD-related maintenance medication) using a large administrative dataset from 1999 to 2006. They found that medication adherence to maintenance medications was significantly associated with healthcare resource utilization and costs. Every 5% increase in medication adherence on the PDC scale was

associated with a 2.5%, 1.8% and \$300,00 decrease in all-cause inpatient visits, emergency room visits, and annual costs, respectively.

Halpern et al conducted a study using a large administrative database among 4,537 COPD patients initiating maintenance medications tiotropium or fluticasone and salmeterol combination between December 2004 and December 2005⁵⁴. They reported that patients who were adherent (MPR \geq 80%), had lower respiratory-related medical and inpatient costs by 37.1% (95% CI 0.43-0.91) and 53.4% (95% CI 0.30-0.72), respectively.

Vestbo J et al, 2009 analyzed data for 6,112 patients with COPD who participated in the Towards a Revolution in COPD Health (TORCH) study, a doubleblind randomized controlled trial⁵⁵. They assessed medication adherence for patients prescribed either fluticasone propionate and salmeterol combination or each drug individually. They found that patients who had "good adherence" (defined as adherence of greater than 80% to study medications) had statistically significantly lower odds of 3year mortality compared to patients who had poor adherence to study medications. Patients with good adherence, as compared to patients with poor adherence, also had significantly lower hospital admissions after controlling for other factors.

In summary, previously published studies have provided evidence highlighting the importance of medication adherence to maintenance medications in COPD treatment. Good medication adherence helps to control COPD symptoms and helps reduce COPD exacerbations, reduce healthcare resource utilization and costs, and reduces the risk for mortality.

Use of prescription opioids among COPD patients

A significantly higher number of patients with COPD experience chronic pain compared to patients with other chronic health conditions⁵⁸. With the high prevalence of chronic pain, the use of prescription opioids for treating pain is also highly prevalent (55.8%) among COPD patients⁵⁸. Prescription opioids are commonly used in treating pain in COPD patients and are proven to be effective in providing analgesia⁵⁶.

Patients with COPD may experience dyspnea, a feeling of shortness of breath and labored breathing associated with pain. The use of prescription opioids in the treatment of dyspnea among COPD patients is widely accepted^{56,57}. Along with dyspnea, prescription opioids are also used in COPD patients for other frequently occurring conditions such as insomnia and musculoskeletal pain^{128,129}. The GOLD guidelines also support cautious use of prescription opioids among COPD patients¹.

With their wide use, adverse events associated with prescription opioids may also be common in COPD patients. Respiratory depression is a major concern in patients with COPD. COPD patients who abuse or misuse opioids may be at increased likelihood of respiratory depression than those without COPD. Due to the fear of respiratory depression, physicians may feel hesitant to provide prescription opioids for patients with COPD⁵⁹. Despite the likelihood of respiratory depression, previous published controlled trials have reported prescription opioids to be safe for use in patients with COPD^{56,57,60–63}. These studies however, suffered from many limitations such as small sample sizes, and systematic exclusion of patients experiencing no benefits and those who died⁶⁴. With the high prevalence of prescription opioid use, it is important to understand how prescription opioids affect COPD patients' healthcare

resource utilization and costs and medication adherence to maintenance medications. **Prevalence and the effects of prescription opioid use in COPD patients and healthcare outcomes**

Roberts M and colleagues used 2006 to 2010 data from a managed care plan from southwest region in the US to assess the prevalence of chronic pain among COPD patients⁵⁸. COPD patients (n=7,952) above 40 years of age were matched in a 1:2 ratio to a similar sample of patients without COPD (n=15,904) but having a diagnosis of another chronic health condition. The prevalence of chronic pain was higher in COPD patients compared to the matched group of non-COPD patients (59.8% vs 51.7%). When compared to patients without COPD but with another chronic illness in multivariate analyses, COPD patients had higher odds of having chronic pain, and overall use of chronic pain-related medication, and statistically significant higher odds of chronic use of short and long acting prescription opioids (OR: 1.74; 95% CI: 1.57 – 1.92). The findings from the study suggest that COPD patients have a high prevalence of chronic pain and consequently have a high prevalence of opioid medications compared to patients with other chronic conditions.

Vozoris N et al, 2015 conducted a study using an administrative claims database from Ontario, Canada to estimate the prevalence of prescription opioid use among older COPD patients¹³⁰. They identified physician-diagnosed COPD patients from 04/01/2003 to 03/31/2012 using a validated algorithm. Only incident prescription opioid users were included in study, defined as patients without a receipt of prescription opioid use for 12months before the first prescription opioid fill. Included patients were followed for 12 months from the first prescription opioid fill to assess patterns of opioid use. The study

included a total of 123,316 COPD patients of which about 60% received an opioid prescription during the study period, representing a high prevalence of incident prescription opioid use among older COPD patients. Among COPD patients enrolled in long-term care, about 20% received a greater than 30-day supply of prescription opioids, 35 to 43% had second dispensing of prescription opioids, 24.2% had early refills, and about 9% had concurrently received multiple prescription opioids.

Cicero T and colleagues conducted a study using a sample of privately insured patients from a large administrative claims database from the Midwest region¹³¹. Their objective was to describe the prevalence of chronic and acute prescription opioid use among pain patients and to identify the presence of comorbid conditions among prescription opioid users. They identified a total of 3,726 chronic prescription opioid users (defined as having >180 days of supply for opioids in a year) and 37,108 acute prescription opioid users (defined as having <10 days of supply for opioids a year), and 337,366 non-opioid users. About 4.5% of the entire study sample had a diagnosis of COPD however COPD patients represented over 6% of all prescription opioid users. The prevalence of prescription opioid use among COPD patients was high, about 15% of all COPD patients in the study were prescription opioid users with about 3% of all COPD patients being chronic prescription opioid users. Of all the chronic prescription opioid users in the study, 12.7% had a diagnosis of COPD. Cicero T et al reported that although chronic prescription opioid users represented only 0.65% of the entire study population they had significantly higher all-cause healthcare resource utilization, compared to acute and non-users, and filed over 5% of all medical claims. Chronic prescription opioid users, compared to acute and non-opioid users, had significantly

higher number of emergency room and outpatient visits, longer inpatients hospital visits, visited higher number of physicians, and had higher comorbid health condition diagnoses, including COPD.

Vozoris N et al, 2016 conducted a study to identify the effects of prescription opioid use on adverse respiratory outcomes among older COPD patients⁶⁴. They used a validated algorithm to identify physician-diagnosed COPD patients from 04/01/2007 to 03/31/2012, using an administrative claims database from Ontario, Canada. A cohort of COPD patients with incident prescription opioid use (n=89,224), with evidence of no prescription opioid use in 12-months pre-period, was matched to a controlled group of COPD patients having an incident fill for any medication (n=41,930), with no fill for the same medication in the 12-months pre-period using inverse probability of treatment weighting using propensity score technique. Their objectives were to identify the occurrence of adverse respiratory outcomes within 30 days of incident prescription opioid use. Adverse respiratory outcomes were defined as COPD or pneumonia-related outpatient respiratory exacerbation, hospitalization, or an intensive care unit (ICU) admission during a hospitalization for COPD or pneumonia, and COPD and all-cause mortality. The authors reported that incident prescription opioid users, regardless of opioid dose, were associated with a significantly higher risk for COPD and pneumoniarelated emergency room visits (hazard ratio (HR) 1.14, 95% CI: 1.00–1.29) and mortality (HR 2.16, 95% CI: 1.61–2.88) and all-cause mortality (HR 1.76, 95% CI 1.57– 1.98). The significant results persisted even after adjusting for the use of low dose (≤ 30 mg morphine equivalent dose per day) and high dose prescription opioids (>30 mg morphine equivalent dose per day). No differences were found for hospitalizations and

ICU admissions between the two groups. The objectives of the study were to only assess the risk of incident prescription opioid use, and the authors therefore did not assess the effect of long-term prescription opioid use. It is possible that long-term prescription opioid use may be associated with higher adverse events than incident use, however this was beyond the scope of the study.

Ekstrom M and colleagues conducted a study to identify the effects of prescription opioid and benzodiazepine use on hospital admission rates and mortality rates among COPD patients⁶⁶. They used a Swedish national registry to identify severe COPD patients, above 45 years of age and starting long-term oxygen therapy between 2005 and 2009. Patients were classified based on their baseline prescription opioid use, irrespective of whether the dose changed in the follow-up period, as low dose prescription opioids (≤30 mg morphine equivalent dose per day) and high dose prescription opioids (>30 mg morphine equivalent dose per day). In the adjusted analysis, the use of prescription opioids in COPD patients had no effect on the rate of hospital admission compared to COPD patients without prescription opioids, this effect persisted even when accounted for the use of low dose or high dose of prescription opioids. For mortality rates, use of low dose prescription opioids had no statistically significant effect on mortality rate, however using high dose prescription opioids significantly increased the mortality rate of COPD patients (hazard ratio: 1.21; 95% CI: 1.02 – 1.44). There was a linear dose response relationship with increased mortality for increased opioids doses (increments of 0.1 mg morphine equivalent dose per day). The finding of lack of association between low-dose prescription opioids and mortality among COPD patients in the Ekstrom M et al study contradicts the findings from the

Vozoris N et al, that use of even low-dose prescription opioids were associated with increased COPD-related and all-cause mortality⁶⁴.

Vozoris N et al, 2017 conducted a retrospective cohort study to identify the impact of incident prescription opioid use on adverse cardiac events⁶⁷. The study was conducted among a geriatric sample of COPD patients identified using an administrative claims database from Ontario, Canada between April 2008 to April 2013. The COPD patients were either residents of long-term care facilities or non-institutionalized community dwellers. The study cohort included COPD patients with incident prescription opioid use and the control group were COPD patients without evidence of a prescription opioid fill. Study objectives were to identify the occurrence of adverse cardiac events, defined as mortality, emergency room visits, and inpatient hospitalization associated with ischemic heart disease and cardiac failure, within 30 days of incident prescription opioid use⁶⁷. Incident use of prescription opioid was associated with statistically significant increased rates of ischemic heart disease-related mortality and morbidity among COPD patients residing in long-term care facilities. Contrarily, among community dwelling COPD patients, incident prescription opioid use was not significantly associated with adverse cardiac events. This insignificant association could be attributed to the fact that about 90% of COPD patients used a combination of an opioid agent (combined with non-opioid agents such as non-steroidal anti-inflammatory agents) compared to just 10% using potent opioid-only agents such as fentanyl and hydromorphone. Hence, when stratified by the type of prescription opioid agents used, prescription opioid-only user had significantly higher hazard rates for ischemic heart disease-related emergency room visits and hospitalizations (hazard ratio 1.38; 95% CI

1.08–1.77) and mortality (hazard ratio 1.83; 95% Cl 1.32–2.53) compared to users of combination prescription opioids.

In summary, previously published studies about the prevalence of prescription opioid use among patients with COPD suggests a high prevalence of prescription opioid use among COPD patients^{58,131}. COPD patients may have higher prevalence of chronic pain compared to patients without COPD but with other chronic conditions and subsequently display a higher use of prescription opioids⁵⁸. Despite physicians' fear of respiratory depression due to prescription opioid use, COPD patients still exhibit a high prevalence of both long-term and short-term use of prescription opioids. Only three studies assessed the effect of prescription opioid use on adverse health outcomes among COPD patients^{64,66,67}. Although these studies classified prescription opioids according to high or low doses they did not assess the impact of length of prescription opioid use either long-term use or short-term use of prescription opioids on COPDrelated health outcomes. These studies also found contrasting results on the effects of prescription opioids on adverse health outcomes. Vozoris et al found opioid use to be associated with increased all-cause and COPD related mortality and COPD and pneumonia-related emergency room visits⁶⁴. The dose of prescription opioids, either low-dose or high-dose, had the same effect on the outcomes. Contrarily, Ekstorm M et al reported that increased mortality was associated with only high dose prescription opioids, whereas low dose prescription opioids did not increase the risks of mortality among COPD patients⁶⁶. Vozoris N et al, 2017 found that prescription opioid-only users compared to users of prescription opioids combined with non-opioid agents had

significantly higher hazard rates for ischemic heart disease-related emergency room visits, hospitalizations and mortality⁶⁷.

Although the prevalence of prescription opioid use is high among COPD patients, the effects of prescription opioids on COPD outcomes in this population is not very well studied. Medication adherence is an important aspect of maintenance medication therapy among COPD patents and has been associated with significant clinical and economic outcomes. None of the previous studies have assessed the impact of prescription opioid use on adherence to maintenance medications for COPD. Managing and controlling COPD exacerbations is an important aspect of controlling COPD symptoms. None of the previously published studies have assessed the impact of prescription opioids on COPD exacerbations. Furthermore, long-term prescription opioids may lead to aberrant drug related behavior among COPD patients and may have severe consequences on COPD-related medication adherence and COPD-related healthcare resource utilization and costs. However, no study in the past has the assessed the effect of long-term prescription opioid use in COPD patients.


Theoretical Framework

The Andersen's Behavioral Model of Health Services Use was used as a theoretical framework to facilitate the analyses of the study objectives. The model was originally developed by Ronald M Andersen and has been modified since the original publication in 1968^{69,70}. The model has been extensively used by previous studies to assess healthcare service utilization patterns in a multitude of disease areas and patient populations^{71–75}. The model is based on the theory that factors such as predisposing factors which predispose individuals to seek care, need factors which necessitate

individuals and health professionals to assess their health status, and enabling factors which provide the means to or act as barriers to access to care together contribute towards patient health behaviors outcomes. The model, as depicted in Figure 2, predicts the influence of different factors on individual's predisposition or predisposing factors, ability or enabling factors and need to access the available resources that eventually result in patients' health behavior and eventually outcome such as healthcare service utilization^{69,70}.

Predisposing factors already exist in individuals or group of individuals prior to them having the disease condition. These factors indicate the tendency of the individuals towards utilization of healthcare services and they include sociodemographic characteristics such patient age, gender, race, education level, and values towards health and illness.^{187,188}.





*Source: Andersen (1995)⁷⁰


Enabling factors are the means available to an individual to be able to utilize healthcare services. These factors include accessibility to services, access to care, insurance status, source of care and income level^{69,70}.

Need factors are comprised of factors that include self-perception of individuals about their health status and the evaluation of the individual's healthcare provider: perceived health status, severity of disease, number of physician visits, presence of comorbidities and quality of life^{69,70}.

Health behavior describes the behavior that individuals undertake due to the influence of predisposing, need and enabling factors. Outcomes are comprised of utilization of healthcare resources and the associated costs of the use.

Andersen's Behavioral Model of Health Services Use presents a complete theoretical framework of numerous factors influencing healthcare services utilization. The model serves as a guide for the choice of variables which may impact adherence to COPD-related maintenance medications and COPD exacerbations and healthcare costs among COPD patients. In the proposed study, predisposing, need, and enabling factors together affect a patient's health behavior, which is their ability to either adhere or not to adhere to their maintenance medication regimen for COPD. The impact of the factors on medication adherence eventually will affect the individual's outcome, which is COPD exacerbations and total healthcare costs. The health behavior variables in this study are COPD-related maintenance medication adherence that will influence COPDrelated exacerbations (both moderate and severe exacerbations) and total healthcare costs (prescription medication and medical costs) (Figure 3.).

Figure 3. The impact of prescription opioid use on COPD maintenance medication adherence, COPD exacerbations and COPD-related total healthcare costs using Andersen's Behavioral Model of Health Services Use



* CCI, Deyo-Charlson comorbidity index; IP, inpatient; ER, emergency room; OP, outpatient; MM, maintenance medication; SABA, short-acting beta agonist; MSA, metropolitan statistical area.

Prescription opioid use along with additional factors may affect adherence to maintenance medications for COPD and healthcare outcomes (COPD-related healthcare resource utilization and costs). Predisposing, need and enabling factors comprised of sociodemographic characteristics, clinical characteristics, physician characteristics, and prior utilization characteristics may also affect adherence. Although the model enlists a range of factors to consider to better explain healthcare utilization, some factors may not be measurable considering the retrospective claims nature of the data used to conduct the analyses.

A disparity in access to care between the prescription opioid user and non-user groups of COPD patients can be due to a stronger effect of enabling and predisposing factors on COPD-related medications, COPD exacerbations, and total costs compared to need factors¹³². On the other hand the stronger influence of need factors compared to enabling and predisposing factors on total healthcare costs can signify equal access to care¹³².

Andersen's Behavioral Model of Health Services Use is a widely used model to understand factors that have an influence on the utilization of healthcare services by individuals. The choice of the variables in the study was determined by the various components of the Andersen's Behavioral Model of Health Services Use. Controlling for the various predisposing, enabling, and need factors in the model helps us understand the impact prescription opioid use may have on adherence to maintenance medications for COPD and COPD exacerbations and total healthcare costs.

Significance and need for the study

If a significant negative association is identified between the use of prescription

opioids and medication adherence to COPD-related maintenance medications and COPD-exacerbations, it would suggest for improving the management of COPD patients to address non-adherence to maintenance therapy. Also, if our study results indicate higher healthcare costs for the management of COPD patients concurrently taking prescription opioids then proper identification and management of prescription opioid therapy along with efforts to improve COPD-related adherence may decrease the total healthcare costs of management of COPD.

Increased efforts to identify comorbid prescription opioid use and manage poor adherence to maintenance medications for COPD may lead to improved COPD outcomes such as lower rate of COPD exacerbations and lower total healthcare costs. For COPD patients taking maintenance medications, identification of concurrent prescription opioid use might be an effective gauge of potential poor medication adherence in the future and may advocate for improved surveillance and management to attain optimum medication adherence. The results from our study could facilitate designing effective interventions that would help reduce non-adherence to maintenance medications for COPD and thus improving COPD exacerbations and total healthcare costs and further lead to better allocation of limited healthcare resources among COPD patients. If concurrent use of prescription opioids has a significant association on adherence to maintenance medication for COPD and COPD exacerbations and total healthcare costs, then the results of the study may encourage future research to identify the effects of concurrent prescription opioid use on adherence to medications for other chronic conditions.

CHAPTER 3 METHODS

This chapter is a description of the methods utilized to execute the numerous specific aims of the study. The chapter starts with a detailed description of the study research design and the study population. Next, a description of the study database timeline is provided followed by a detailed description of the study inclusion and exclusion criteria. A description of the study's independent and dependent variables is provided followed by the statistical techniques used to analyze the study objective by specific aims. Finally, the chapter provides a section on estimation of the required sample size for the study, followed by the potential study limitations, institutional review board approval, and the timeline for conducting the study.

Research Design

A retrospective, cross-sectional study design was utilized to examine the impact of prescription opioid use on adherence to maintenance medications for COPD, COPD exacerbations and total healthcare costs among COPD patients. Patients using maintenance medications for COPD were identified from the 2008 to 2010, Truven MarketScan Commercial Claims and Encounters Database. Patients using maintenance medications for COPD were identified in the 12-month index period. A 6-month preindex period without an opioid prescription was used to determine inclusion of only prescription opioid naïve patients. Adherence to maintenance medications for COPD and COPD-related severe and moderate exacerbations and total, all-cause healthcare costs were assessed in the 12-month post-index period. Patients were required to be continuously enrolled in the dataset in both the pre- and post-index periods for a total of 24 months.

Study population

This study utilized the Truven Health MarketScan Commercial Claims and Encounters Database which is comprised of patients aged 40 to 64 years old. The National, Heart, Lung, and Blood Institute reports that COPD generally occurs in adults 40 years old and above⁷⁸. The Truven Health MarketScan Commercial Claims Database only includes patients below the age of 65. Therefore, our inclusion criteriion was restricted to ages 40 to 64.

The Truven Health MarketScan Commercial Claims and Encounters Databases is the largest administrative claims database in the US with 143 million unique patients in total since 1996. Nearly half of all US private healthcare insurance plans are represented in the MarketScan databases. The MarketScan Commercial Claims and Encounters Databases reflect patients' real-world treatment costs and patterns as they proceed through the healthcare system. The dataset includes information on active employees, early retirees, and their dependents insured by employer-sponsored plans¹³³. The MarketScan database contains information on outpatient and inpatient visits, prescription drugs, and costs of services¹³³.

In one full average data year, MarketScan database contains information on 50 million unique patients. The dataset has a large number of patients and can provide a US nationally representative sample with employer-provided health insurance¹³³. The MarketScan database offers information on healthcare provided in "all settings including, physician office visits, hospitalizations, and retail and mail-order and specialty pharmacies"¹³³. The MarketScan database allows for longitudinal information on patients for multiple years. As the database is sourced from large employers it allows for

tracking of patients across multiple health plans. This is useful as patients often change health plans and this allows for information on patients who have the potential to lack information due to this change. Sample elements collected in the MarketScan database are listed in Table 5.

Study dataset timeline

Data used in the study consisted of data available in the Truven Health MarketScan Commercial Claims and Encounters Data for the time period, January 1, 2008 to December 31, 2010. The study data was classified into three specific time periods: pre-index period, index period, and post-index period. The study dataset timeline is depicted in Figure 4. Study dataset timeline

Index period

The period from July 1, 2008 to December 31, 2009 was categorized as the index period. This period was used to identify COPD patients with a prescription fill for COPD-related maintenance medications and additionally a fill for prescription opioids for the exposed group.

Index date


The first fill of a prescription opioid and maintenance medication during the index period was identified for COPD patients. The date of the first fill of a prescription opioid was marked as the index date for the exposed group (prescription opioid users) and the first prescription fill of a maintenance medication as the index date for the control (nonopioid users).

Demographic characteristics Patient ID	Medical information	Health plan features	Financial information	Drug information	Enrollment information
Age	Admission date and type	Coordination of benefits amount	Total payments	Generic product ID	Date of enrollment
Gender	Principal diagnosis code	Deductible amount	Net payments	Average wholesale price	Member days
Employment status (hourly, etc)	Discharge status	Copayment amount	Payments to physician	Prescription drug payment	Date of disenrollment
Relationship of patient to beneficiary	Major diagnostic category	Plan type	Payments to hospital	Therapeutic class	
Geographic location (state, zip code)	Principal procedure code		Payments – total admission	Days supplied	
	Secondary diagnosis codes (up to 14)			National drug code	
	Secondary procedure codes (up to 14)			Refill number	
	DRG			Therapeutic group	
	Length of stay				
	Place of service				
	Provider ID		4 0 1 2 2		

Table 5. Sample data elements collected in the MarketScan Commercial Claims database

*Adapted from Hansen LG and Chang S, 2012¹³³

Figure 4. Study dataset timeline



Pre-index period

After the identification of the index date within the index period, a period of 6 months preceding the index date was categorized as the pre-index period. This 6-month per-index period is important for several reasons:

 The pre-index period was used to ensure continuous eligibility of patients with COPD in the dataset;

2. This pre-index period was used to ensure that patients with COPD do not have the presence of prescription opioid fill before the index date;

3. During the pre-index period, adherence to COPD maintenance medications before the start of a prescription opioid therapy was assessed;

4. The pre-index period was also the period during which COPD exacerbation were identified;

5. Presence of other comorbid chronic conditions was also assessed during the pre-index period.

Post-index period

Post-index period was classified as a period of 12 months following the index date among patients with COPD. It was used to ensure continuous eligibility of the patients in the dataset. A 12-month post-index period helps maintain uniform length of follow-up for each patient in the study. Healthcare outcomes for the study such as medication adherence to COPD maintenance medication, COPD exacerbations, and total, all-cause healthcare costs were assessed during this period. Use of prescription opioids either long-term or short-term were also be identified in the post-index period.

Inclusion and exclusion criteria

Criteria for the identification of COPD

The study population with COPD was identified from healthcare claims using the ICD-9-CM diagnoses codes. Patients with COPD were identified on the basis of ICD-9-CM diagnosis codes corresponding to COPD (Table 6.). The study population comprised patients diagnosed with COPD and having a minimum of two prescription claims for COPD maintenance medications. Evidence of maintenance medication use was identified using national drug codes (NDC). NDCs are 11-digit codes that are unique to each medication approved by the US FDA. The numbers in an NDC can be used to identify the drug manufacturer, the specific dosage and strength of the medication, and the package size and form. The specific NDC codes for inhaled, long-acting bronchodilators (maintenance medications) for COPD, approved during the study period, were used to identify patient's maintenance medication use status. The following criteria for the identification for COPD patients was used:

- At least one inpatient hospitalization claim for COPD in the primary or secondary diagnosis position and a minimum of two prescription claims for maintenance medications for COPD.
- At least two emergency room visit claim for COPD in the primary or secondary diagnosis position and a minimum of two prescription claims for maintenance medications for COPD.
- At least two outpatient provider visit claim for COPD in the primary or secondary diagnosis position and a minimum of two prescription claims for maintenance medications for COPD.

Study inclusion criteria

- Patients with a diagnosis of COPD were included in the study. The aforementioned criteria were employed to identify the presence of COPD. Only patients having evidence of COPD maintenance medication (as described above) use were included in the study.
- The identified patients with COPD were required to have continuous enrollment in the database in the pre-index and post-index periods (6 months before and 12 months after the index date).
- 3. Only patients aged 40 to 64 years old at the index date were included.
- 4. Prescription opioid users were also required to have a COPD maintenance medication on-hand when initiating a prescription opioid therapy.

Study exclusion criteria

- Patients who do not have continuous eligibility in the dataset 6 months before and 12 months after the index date were excluded from the study.
- 2. Patients with diagnosis of any cancer, HIV and AIDS (Table 6.) were excluded from the study as the use of prescription opioid therapy in these patients is markedly different than in patients without these conditions.
- 3. COPD maintenance medication use may differ among COPD patients with certain respiratory comorbidities compared to COPD patients without these comorbidities^{134,135}. Hence COPD patients with the following comorbid conditions were excluded: asbestosis, sarcoidosis, pulmonary tuberculosis, fibrosis due to tuberculosis, cystic fibrosis, pulmonary fibrosis, pneumoconiosis, bronchiectasis, and alpha-1 antitrypsin (Table 6.).

- 4. Only prescription opioid naïve patients were included. A 6-month pre-index period without an opioid prescription was used to ensure that only patients who are drug-naïve for prescription opioids are included.
- Patients who start prescription opioid therapy before starting COPD maintenance medications were excluded.
- **6.** COPD patients who have claims for prescription opioids specifically methadone and buprenorphine were excluded. Methadone and buprenorphine are used as opioid maintenance therapy for the treatment of opioid addiction and are therefore different than prescription opioid therapy for the treatment of CNCP.

Study variables

Independent Variables

Table 7. provides a list of all the independent variables that were used in the analyses of the specific aims. The independent variables are representative of sociodemographic characteristics, clinical characteristics, prior utilization characteristics, COPD severity, and physician characteristics.

The selection of variables is based on the proposed theoretical framework, the Andersen's Behavioral Model of Health Services Use. Variables were categorized into three groups: predisposing factors, enabling factors, and need factors. Predisposing factors include sociodemographic variables. Enabling factors include economic

Condition	Corresponding ICD-9CM diagnosis codes	
	Included condition	
COPD	491.x, 492.x, or 496	
	Excluded conditions	
Cancer conditions	140, 141, 142, 143, 144, 145, 146, 147,	
	148, 149, 150, 151, 152, 153, 154, 155,	
	156, 157, 158, 159, 160, 161, 162, 163,	
	164, 165, 170, 171, 172, 173, 174, 175,	
	176, 179, 180, 181, 182, 183, 184, 185,	
	186, 187, 188, 189, 190, 191, 192, 193,	
	194, 195, 196, 197, 198, 199, 200, 201,	
	202, 203, 204, 205, 206, 207, 208, 209,	
	230, 231, 232, 233, 234, 235, 236, 237,	
	238, 239	
HIV/AIDS	042.xx, 079.53, 279.10, 279.19, 795.71,	
	995.8x	
Asbestosis	501	
Sarcoidosis	135	
Pulmonary tuberculosis	011	
Fibrosis due to tuberculosis	011.40	
Cystic fibrosis	277.00	
Pulmonary fibrosis	513.31	
Pneumoconiosis	505	
Bronchieostasis	494.0, 494.1	
Alpha-1 antitrypsin	273.4	

Table 6. Conditions satisfying the inclusion and exclusion criteria and theircorresponding ICD-9CM diagnosis codes

Variable	Operational Definition	Factors as per Andersen's Behavioral Model
Sociodem	ographic characteristics	
Sex	Dichotomized as: Male Female	Predisposing factor
Age	Categorized as: 40 to 49 years 50 to 59 years ≥60 years	Predisposing factor
Metropolitan Statistical Area	Dichotomized as: Urban Rural	Predisposing factor
Region	Categorized as: Northeast North Central South West	Predisposing factor
Insurance Plan Type	Categorized as: Preferred provider organization (PPO) Health maintenance organization (HMO) Other	Enabling factor
Clini	cal characteristics	
Prescription opioid use (Specific Aim 1)	Characterized as: Non-user User	Need factor
Prescription opioid use (Specific aim 1 – sub-group analysis)	Characterized as:	Need factor
	<30-day supply in the follow-up period	

Table 7. Study independent variables

Variable	Operational Definition	Factors as per Andersen's Behavioral Model
	≥30-day supply in the follow-up period	
Prescription opioid user (Specific Aims 2 to 4)	Dichotomized as:	Need factor
	Non-user Long-term user	
Deyo-Charlson Comorbidity Index	Continuous variable indicating Deyo-Charlson Comorbidity score in the pre-index period	Need factor
Pain conditions	Categorized as: Back pain Neck pain Arthritis/Joint pain Headache/Migraine Dyspnea	Need factor
Number of pain conditions	Categorized as: 0 1 ≥2	Need factor
Type of index maintenance medication	Categorized as:	Need factor
medication	ICS+LABA LAMA+LABA or LAMA+ICS ICS+LABA+LAMA ICS or LABA or LAMA	
Mail-order index maintenance medication prescription	Dichotomized as:	Enabling factor
	Yes No	
Co-morbid conditions	Categorized as: Asthma	Need factor

Variable	Operational Definition	Factors as per Andersen's Behavioral Model
	Cardiovascular disease Chronic kidney disease Depression Diabetes Osteoporosis Anemia	
Number of comorbid conditions	Categorized as:	Need factor
	0 1	
	≥2	
Adherence to COPD- maintenance medications in the pre-index period	Dichotomized as:	Need factor
	Adherent if PDC ≥ 80% Non-adherent if PDC < 80%	
COPD	severity indicators	
Supplemental oxygen use in the pre-index period	Dichotomized as:	Need factor
	Yes No	
SABA use in the pre- index period	Dichotomized as:	Need factor
	Yes No	
COPD-related severe exacerbations in the pre-index period	Dichotomized as:	Need factor
F	0 ≥1	
COPD-related moderate	Dichotomized as:	Need factor

Variable	Operational Definition	Factors as per Andersen's Behavioral Model
exacerbations in the pre-index period		
	0	
	≥1	
Physic	cian characteristics	
Pulmonologist visit in the pre-index period	Categorized as:	Enabling factor
	Yes	
	No	
Prior util	ization characteristics	
Total all-cause	Continuous variable representing	Need factor
healthcare costs in	total all-cause healthcare costs	
the pre-index period	(medical costs + prescription	
•	costs) in the pre-index period	

* ICS denotes inhaled corticosteroid; LABA, long-acting beta agonist; LAMA, long-acting muscarinic agent; SABA, short-acting beta agonist; and PDC, proportion of days covered.

variables and variables related to access to healthcare. Need factors include variables related to the severity of the disease.

Predisposing factors:

Demographic variables in this study include patient's age, sex, and region of residence and metropolitan statistical area. Patient's age was calculated as the difference between year of birth and the year of the study index date.

Enabling factors:

The enabling variables in the study include type of insurance plan the patient is enrolled in, visit to a pulmonologist in the pre-index period, and whether the index maintenance medication is a mail-order prescription. The type of health insurance plan the patient was enrolled in was categorized as health maintenance organization (HMO), preferred provider organization (PPO) and other plan types which included point of service (POS), comprehensive, preferred of service (POS) with capitation, consumerdriven health plan (CDHP), high-deductible health plan (HDHP).

Need factors:

Severity of the disease constitute the need factors in the Andersen model. As the MarketScan Commercial Claims and Encounters Data doesn't record clinical variables for severity, the study includes proxy measures for severity such as having moderate and severe COPD exacerbations in the pre-index period, total all-cause healthcare expenditures in the pre-index period, presence of chronic comorbidities and pain conditions in the pre-index along with comorbidity index measured by the Deyo-Charlson comorbidity index, the type of index maintenance medication, the use of short-acting beta agonist in the pre-index, and also the use of supplemental oxygen.

Since outcomes in the post-index period may be influenced by several variables in the pre-index period, these variables were adjusted for while conducting data analyses. Patients with low or high medication adherence or higher or lower healthcare costs in the pre-index period could also lead to high or low medication adherence or higher or lower total healthcare costs in the post-index period, respectively. Having a history of COPD exacerbations has been considered as a strong predictor of having COPD exacerbations in the future⁷⁹. Hence, variables related to COPD severe and moderate exacerbations, medication adherence, total healthcare costs in the pre-index period were adjusted for in multiple regression analyses.

Charlson's comorbidity index identifies the comorbid conditions in patients and applies weights to those conditions depending on the disease severity. The weight assigned to a comorbid condition depends on its relationship with mortality. In 1987, Charlson developed a comorbidity index based on 17 comorbidities. The comorbid conditions included in the Charlson's index are reported in Table 8. The Charlson index assigns weights of 1, 2, 3 or 6 to these comorbid conditions based on their severity (Table 8.). The diseases that have a higher impact on mortality have higher weights as opposed to conditions that have a lower impact. All the weights for all the 17 comorbidities are totaled for each patient to calculate the index severity score. The Deyo modification of the Charlson index has been adapted for its use in administrative claims databases¹³⁶. This study uses the Deyo modification of the Charlson index.

 Table 8. ICD-9CM codes for medical conditions included in the Deyo-Charlson comorbidity index and their corresponding weights

Medical Condition	ICD-9 CM Code			
Conditions with a weight of 1				
Cerebrovascular disease	430-433, 435			
Congestive heart failure	398, 402, 428			
Dementia	290, 291, 294			
Mild liver disease	571, 573			
Myocardial infarction	410, 412			
Peripheral vascular disease	440-447			
Rheumatologic disease	710, 714, 725			
Ulcer disease	531-534			
Conditions with a we	ight of 2			
Hemiplegia	342, 434, 436, 437			
Moderate or severe renal disease	403, 404, 580-586			
Any tumor	140-195			
Diabetes	250			
Leukemia	204-208			
Lymphoma	200, 202, 203			
Conditions with a weight of 3				
Moderate or severe liver disease	070, 570, 572			
Conditions with a weight of 6				
Acquired immune deficiency syndrome (AIDS)	042-044			
Metastatic solid tumor	196-199			

Dependent Variables

Table 9 provides a list of all the dependent variables assessed in the study along with their operational definitions and are presented by each specific aim in the study.

Operational definition of study outcome for Specific Aims 1 and 2

Specific Aim 1 examines the impact of prescription opioid use compared to no opioid use on adherence to controller mediations for COPD among a real-world, large sample of COPD patients after adjusting for other confounders. The outcome measured in Specific Aim 1 was medication adherence.

For the calculation of medication adherence to COPD maintenance medications using proportion of days covered (PDC), a technique developed by Choudhry NK et al, 2009 and recommended by the Pharmacy Quality Alliance (PQA)^{121,137} was used. The interval-based technique using the proportion of days during which the patients had at least one of their medications available to them is useful when calculating medication adherence in a scenario where patients with chronic conditions such as COPD have multiple classes of maintenance medications being concurrently prescribed. Using medication possession ratio (MPR) in such a scenario may overestimate medication adherence to controller medications, and assessing adherence using PDC to only the index prescription as done by previous studies may underestimate the actual medication adherence¹²⁷. Therefore, the interval-based technique for calculation of PDC was utilized in the study.

Variable	Operational definition			
Specific Aim 1				
Medication adherence measured using proportion of days covered (PDC)	Dichotomized as:			
	Adherent if PDC ≥ 80%			
	Non-adherent if PDC < 80%			
Speci	fic Aim 2			
Medication adherence measured using	Dichotomized as:			
proportion of days covered (PDC)	Adherent if PDC ≥ 80%			
	Non-adherent if PDC < 80%			
Speci	fic Aim 3			
Severe COPD exacerbations	Count variable – number of post-index severe COPD exacerbations			
Moderate and severe COPD	Count variable – number of post-index			
exacerbations	severe and moderate COPD exacerbations			
Specific Aim 4				
Total medical costs	Continuous variable – post-index all- cause drug costs + medical costs (USD, 2010)			


Table 9. Outcomes assessed in the study (dependent variables)

The following steps adapted from Naik R et al, 2011¹³⁸ were utilized in the calculation of PDC as a measure of medication adherence:

For the numerator in the PDC equation, the number of days during which patients had at least one of their prescribed COPD long-acting maintenance medications available to them starting from the index date until the latest prescription date in the follow-up period for any of the maintenance medications they were using was calculated (Figure 5.)¹³⁷. New variables accounting for the number of follow-up days in the post-index period were created to represent each day in the follow-up period. Each variable records whether the person did or did not have a fill for a COPD maintenance medication. If an included person has a COPD maintenance medication from a particular class on a particular day, he/she is given a value of 1. Whereas, a value of 0 represents no fill. The numerator then is the sum of all the days in the postindex period during which the person had a COPD maintenance medication. For example, for a patient being treated with an inhaled corticosteroid and long-acting beta agonist, the numerator of the adherence measure is the number of days during which he/she had either an inhaled corticosteroid or long-acting beta agonist (Figure 6.)¹³⁷. Similarly, for the calculation of PDC in the pre-index period the numerator was considered to be the number of the days the person had a COPD maintenance medication from the first fill of a maintenance medication in the pre-index period, until the index-date.

Accounting for oversupply when a patient refills a maintenance medication prescription early: When a patient refills a COPD maintenance medication before the last day of the previous dispensing of the same maintenance medication, the new


Figure 5. Measuring medication adherence to individual medication classes using the interval-based approach for PDC



*Adapted from Choudhry NK et al, 2009¹³⁷

The numerator in the PDC calculation is the total number of days of medication supplied from all prescriptions in a particular medication class (i.e. x+y days). The denominator in the PDC calculation is the total number of days in the specified time interval (i.e. t=365 days).

Figure 6. Using PDC to measure concurrent medication adherence to multiple classes of COPD maintenance medications



A, represents the index date or the day the prescription for the first COPD maintenance medication belonging to class 1 was filled

B, represents the last refill date of the first COPD maintenance medication belonging to class 1

C, represents the last day of supply of the first COPD maintenance medication belonging to class 1

D, represents the day the first prescription of a COPD maintenance medication belonging to class 2 was filled

E, represents the last refill date of the second COPD maintenance medication belonging to class 2

F, represents the last day of supply of the second COPD maintenance medication belonging to class 2

B to C, represents the time when the patients has prescriptions for both the first and second COPD maintenance medication belonging to the 2 classes *Adapted from Choudhry NK et al, 2009¹³⁷ prescription refill is adjusted to begin the day after the last day of the previous prescription refill.

Accounting for oversupply when a patient switches to a different maintenance medication: Unlike oversupply due to early refills, when a patient switches to another COPD maintenance medication the switch is automatically accounted for in the calculation of the PDC. As per PDC, medication adherence for each class of COPD maintenance medication is not calculated rather each day a patient has a controller medication irrespective of the class of the controller medication is calculated. So, oversupply when switching to a different class of COPD controller medications is accounted for in the numerator of the PDC ratio. The length of stay in a hospital, in an event of a hospitalization, is added to the numerator of the PDC calculation. The denominator in the calculation of PDC is capped to the number of days in the follow-up period. For specific aims 1A, 1B, 1C, 1D and 2 the denominators in the PDC calculation are 90 days, 180 days, 270 days, 365 days, and 365 days, respectfully. The denominator in the calculation of PDC in the pre-index period is the total number of days from the first fill of a maintenance medication in the pre-index period until the index date. A patient was considered adherent if his/her PDC value is 0.8 or higher.

Operational definition of study outcome for Specific Aim 3

Specific Aim 3 examines the impact of long-term prescription opioid use (≥90-day supply in a one-year period) compared to no prescription opioid use on COPD exacerbations among a real-world, large sample of COPD patients after adjusting for other confounders. The outcomes measured in specific aim 3A and 3B were COPD-

related severe exacerbations, and a sum of COPD-related moderate and severe exacerbations, respectively.

COPD-related moderate exacerbations were defined as having an outpatient or emergency room visit with an ICD-9CM diagnosis for COPD, followed by a prescription claim for either a systemic corticosteroid or antibiotic within 7 days of this COPD-related outpatient or emergency room visit^{139,140}. COPD-related severe exacerbations were defined by either having an inpatient hospital stay with a primary diagnosis of COPD or having an inpatient hospital stay with a secondary diagnosis of COPD but with the primary diagnosis being respiratory failure (ICD-9CM codes: 518.81, 518.82, 518.84) ^{139,140}. Furthermore, if a moderate exacerbation occurred within 10 days of a severe exacerbation it was not categorized as a new exacerbation but was considered as a continuation of the original severe exacerbation¹⁴¹. If the same type of exacerbation occurred within 10 days of the original exacerbation, it was not counted as a new exacerbation but rather continuation of the original exacerbation¹⁴¹.

Operational definition of study outcome for Specific Aim 4

Specific aim 4 examines the impact of long-term prescription opioid use compared to no prescription opioid use on total all-cause healthcare costs among a real-world, large sample of COPD patients after adjusting for other confounders. The outcome measured in specific aim 4 was total all-cause healthcare costs.

The total, all-cause healthcare costs included costs associated with claims for patients' inpatient visits, emergency room visits, outpatient visits, and all prescription expenditures during the study period. This study was conducted from the payer's

perspective i.e. private insurance plans. All costs were adjusted to 2010 USD using the Medical Care component of the Consumer Price Index (CPI).

Data Analysis

Descriptive statistics were calculated and presented for sociodemographic characteristics, indicators of COPD severity, physician characteristics, clinical and priorutilization characteristics for COPD patients with and without the evidence of prescription opioid use. Separate descriptive characteristics were calculated for each specific aim and sub-group analysis. Frequencies and percentages were calculated for categorical variables and mean and standard deviation were reported for continuous variables.

Matching the exposed and the unexposed groups

A sample of prescription opioid users with COPD were matched to a sample of COPD patients not using prescription opioids, on a 1:1 ratio. Matching was performed on the variables listed in Table 10. An optimal matching technique, developed by Rosenbaum 1989, was utilized for matching the exposed group (prescription opioid users) to the control groups (non-users of prescription opioids)¹⁴².

Statistical analyses for Specific Aim 1

Specific aim 1 examines the impact of prescription opioid use compared to no opioid use on adherence to maintenance mediations for COPD, over four different time periods, among a real-world, large sample of COPD patients after adjusting for other confounders.

Variable	Matching criteria
Sex	Exact matching: Male Female
Age	Matching +/- 3 years
Adherent to maintenance	Exact matching:
medications in the pre-index period	Yes (PDC≥80%) No (PDC<80%)
Supplemental oxygen use in the	Exact matching:
pre-index period	Yes No
Short-acting beta agonist use in	Exact matching:
the pre-index period	Yes No
Moderate COPD exacerbations in	Exact matching:
the pre-index	0 ≥1
Severe COPD exacerbations in the	Exact matching:
pre-index	0 ≥1
Presence of asthma	Exact matching: Yes No

Table 10. Variables for matching the exposed and unexposed groups

To describe differences between patients who are adherent and non-adherent to COPD maintenance medications, descriptive statistics were provided for variables for sociodemographic characteristics, indicators of COPD severity, physician characteristics, and clinical and prior-utilization characteristics. For categorical variables, frequencies and percentages were calculated, and for continuous variables mean and standard deviation was reported. To describe differences in background characteristics between adherent and non-adherent patients to COPD maintenance medications, chi-squared test for categorical variables, t-test for continuous variables and Mann Whitney U tests for total healthcare cost variables were conducted.

Conditional logistic regression was utilized to identify the impact of prescription opioid use on adherence to maintenance medications for COPD (Table 11). Independent variables found significant at alpha<0.20 in univariate regression analysis were considered for inclusion in the multiple regression models. Multiple logistic regression analysis was conducted using step-wise backwards elimination procedure at alpha=0.20. Primary independent variable, for Specific Aims 1 was prescription opioid use and was categorized as no prescription opioid use and any prescription opioid use in the follow-up period. Primary independent variable, for Specific Aims 1 sub-group analyses was prescription opioid use and was categorized as no prescription opioid use, ≥30-day supply of prescription opioid in the follow-up, and <30-day supply of prescription opioid in the follow-up period. Other independent variables included in the analysis are listed in Table 7. The dependent variable was medication adherence to

Objective	Dependent variable	Measurement level	Statistical procedure	
	Specific aim 1			
To compare medication adherence to maintenance medications for COPD between prescription opioid users and non-users	Medication adherence (PDC)	Categorical	Conditional logistic regression	
	Specific a	aim 2		
To compare medication adherence to maintenance medications for COPD between long-term prescription opioid users (≥90 days) and non-users	Medication adherence (PDC)	Categorical	Conditional logistic regression	
	Specific a	aim 3		
(Specific Aim 3A) To compare the number of severe COPD exacerbations between long-term prescription opioid users (≥90 days) and non-users	Number of severe COPD exacerbations	Count	Negative binomial regression	
among COPD patients (Specific Aim 3B) To compare the total number of moderate and severe COPD exacerbations between long- term prescription opioid users (≥90 days) and non- users among COPD patients	Total number of moderate and severe COPD exacerbations	Count	Negative binomial regression	
	Specific aim 4			
To compare total COPD- related healthcare costs between long-term	Total medical costs	Continuous	Generalized linear model with gamma	

Table 11. Specific Aims and corresponding statistical tests

Objective	Dependent variable	Measurement level	Statistical procedure
prescription opioid users			distribution
(≥90 days) and non-users			and log-link
among COPD patients			function

*PDC, proportion of days covered

COPD maintenance medications and was categorized as adherent if PDC \geq 80% and non-adherent if PDC < 80%.

Statistical analyses for Specific Aim 2

Specific Aim 2 examines the impact of long-term prescription opioid use (≥90-day supply of prescription opioids in a one-year period) compared to no prescription opioid use on adherence to maintenance mediations for COPD, among a real-world, large sample of COPD patients after adjusting for other confounders.

Similar statistical analysis for Specific Aim 1 was conducted for Specific Aim 2. Conditional logistic regression was used to identify the impact of long-term (\geq 90-day supply of prescription opioids in a one-year period) compared to no prescription opioid use on adherence to COPD-related maintenance medications (Table 11). Independent variables found significant at alpha=0.20 in univariate regression analysis were considered for inclusion in the multiple regression models. Multiple logistic regression analysis was conducted using step-wise backwards elimination procedure at alpha=0.20. The dependent variable, medication adherence to COPD-related maintenance to COPD-related maintenance medications, was categorized as adherent if PDC \geq 80% and non-adherent if PDC < 80%. Primary independent variable was dichotomized as long-term (\geq 90-day supply of prescription opioids in a one-year period) no use of prescription opioids. Other independent variables included in the analysis are listed in Table 7.

Statistical analyses for specific aim 3

Specific aim 3 examines the impact of long-term prescription opioid use (≥90-day supply of prescription opioids in a one-year period) compared to no prescription opioid use on COPD exacerbations among a real-world, large sample of COPD patients after

adjusting for other confounders. The dependent variables measured in Specific Aim 3A and 3B were the number of COPD severe and sum of severe and moderate exacerbations, respectively.

Multivariable analysis was performed to examine the impact of long-term prescription opioid use (≥90-day supply of prescription opioids in a one-year period) versus no prescription opioid use on COPD exacerbations. The independent variables included in the analysis are listed in Table 7.

Incidence rate ratio were calculated using negative binomial regression analyses adjusting for independent variables. Independent variables found significant at alpha=0.20 in univariate regression analysis were considered for inclusion in the multiple regression models.

Statistical analyses for specific aim 4

Specific aim 4 examines the impact of long-term prescription opioid use (≥90-day supply of prescription opioids in a one-year period) compared to no prescription opioid use on total, all-cause healthcare costs among a real-world, large sample of COPD patients after adjusting for other confounders. The total, all-cause healthcare costs included all costs associated with claims for patients' inpatient visits, ER visits, outpatient visits, and prescription fills, during the follow-up period.

The unadjusted mean costs for prescription opioid users and non-users with COPD were reported. Independent variables found significant at alpha=0.20 in univariate regression analysis were considered for inclusion in the multiple regression models. Generalized linear regression model with a gamma distribution and log link function was utilized to compare to the adjusted healthcare costs between long-term

prescription opioid users (≥90-day supply of prescription opioids in a one-year period) and non-users with COPD (Table 11).

All statistical analysis and data management were conducted using SAS 9.4 (SAS Institute, Cary, NC). An a priori significance level of alpha = 0.05 was used for all statistical procedures.

Sample size estimation

For calculation of the required sample size we used Specific Aim 2, to examine the impact of long-term prescription opioid use (>90-day supply of prescription opioids in a one-year period) compared to no prescription opioid use on adherence to maintenance mediations for COPD among a real-world, large sample of COPD patients after adjusting for other confounders as a reference. The independent variable considered for the analysis was long-term use of prescription opioids and the dependent variable was adherence to COPD maintenance medications. The sample size calculations were performed using G*Power 3.1.9.2.

For estimating the required sample size, the two-tailed alpha value (the probability of rejecting the null hypothesis) was set as 0.05 and the required power was set to 0.80. As this is the first study to assess the impact of prescription opioid use on adherence to COPD maintenance medication, estimates of the required total sample size were adopted from a previous study among type 2 diabetes patients which reported rates of adherence to oral antihyperglycemic agents among type 2 diabetes patients with and without evidence of long-term prescription opioid use⁶⁵. As the previous study was not conducted among COPD patients, the odds ratios were varied over a wide range of values to calculate the required sample size. Medication adherence rates

among COPD patients is reported to be around 40%^{46–48}. Sample sizes were calculated assuming medication adherence rates of 40% and a worst-case scenario of 20%. The calculated sample sizes are reported in Table 12.

Based on the estimates obtained from the sample size calculation, a minimum sample size of 308 to a maximum of 4,683 was required to achieve a power of 80%.

IRB approval

Approval from the Institutional Review Board (IRB) at the University of New Mexico was sought prior to the analyses of the study objectives. The final approval letter from the Human Research Review Committee in presented in Appendix A.

Odds Ratio	COPD maintenance medication adherence rate	Percentage of COPD patients using prescription opioids	Two- tailed alpha	Power	Required sample size
0.50	40%	25%	0.05	0.8	424
0.60	40%	25%	0.05	0.8	739
0.70	40%	25%	0.05	0.8	1,459
0.78 ^a	40%	25%	0.05	0.8	2,940
0.50	40%	33%	0.05	0.8	355
0.60	40%	33%	0.05	0.8	623
0.70	40%	33%	0.05	0.8	1,233
0.78 ^a	40%	33%	0.05	0.8	2,487
0.50	40%	50%	0.05	0.8	308
0.60	40%	50%	0.05	0.8	543
0.70	40%	50%	0.05	0.8	1,081
0.78 ^a	40%	50%	0.05	0.8	2,187
0.50	20%	25%	0.05	0.8	745
0.60	20%	25%	0.05	0.8	1,250
0.70	20%	25%	0.05	0.8	2,384
0.78 ^a	20%	25%	0.05	0.8	4,683
0.50	20%	33%	0.05	0.8	619
0.60	20%	33%	0.05	0.8	1,045
0.70	20%	33%	0.05	0.8	2,003
0.78 ^a	20%	33%	0.05	0.8	3,947
0.50	20%	50%	0.05	0.8	526
0.60	20%	50%	0.05	0.8	898
0.70	20%	50%	0.05	0.8	1,737
0.78 ^a	20%	50%	0.05	0.8	3,444

Table 12. Sample size calculation for logistic regression

 $^{\rm a}$ Effect size obtained from Atreja N, 2016 $^{\rm 65}$

CHAPTER 4 RESULTS


This chapter provides the results of the study. The chapter begins with the description of the study sample including the baseline characteristics of the unmatched and matched sample of exposed (prescription opioid users) and unexposed (non-opioid users) groups of COPD patients. This is followed by a detailed description of the baseline characteristics of the unexposed and exposed groups corresponding to each specific aim of the study. Results of univariate analysis are presented according to each specific aim, followed by the results of the adjusted multiple regression analysis by specific aim.

Sample Selection

A total of 22,346,218 unique patients were identified from the Truven Health MarketScan Commercial Claims and Encounters Database from 2008 to 2010. After excluding patients without COPD diagnosis and patients with a diagnosis of selected conditions referred in Table 6, a total of 77,769 patients were left with a diagnosis of COPD and having at least 1 claim for a long-acting COPD maintenance medication. Of these patients 48,228 patients had a claim for a prescription opioid and the remaining 29,541 patients did not have a claim for a prescription opioid. Further applying the study inclusion and exclusion criteria, 5,935 (39.1%) COPD patients were classified as prescription opioid users and 9,242 (60.9%) COPD patients were classified as nonopioid users. A total of 5,541 exact matches of non-opioid users were identified for the prescription opioid group.

Figure 7: Study sample selection flowchart provides a flowchart of the final study sample after applying the study inclusion and exclusion criteria.





Baseline characteristics of prescription opioid users and non-users prematching:

Table 13 presents baseline characteristics of COPD patients with and without prescription opioid use. The mean age of prescription opioid users was significantly lower than non-opioid users [57.0 \pm 5.5 years (users) vs 57.4 \pm 5.4 years (non-users), p<0.0001], and a greater percentage of prescription opioid users were females (56.1%). Overall, prescription opioid users had higher number of comorbid conditions than non-opioid users. The mean Deyo-Charlson Comorbidity Index (D-CCI) score among prescription opioid users was significantly higher compared to non-opioid users (2.0 \pm 1.5 vs 1.7 \pm 1.1). Similarly, a higher percentage of prescription opioid users had more than 1 comorbid chronic condition (49.9% vs 33.6%) and comorbid pain conditions (52.5% vs 24.6%) compared to non-opioid users.

Baseline characteristics of prescription opioid user and non-users post matching:

Prescription opioid users were matched to non-opioid users on sex, age (±3 years), adherence to COPD maintenance medication in the pre-index period, supplemental oxygen use, SABA use, COPD-related severe and moderate exacerbations, and comorbid asthma. A total of 5,541 pairs of prescription opioid users and non-users were included after matching on the chosen variables and presented in Table 14. No significant differences were found between prescription opioid users and non-opioid users on the matching variables. MSA and mail-order index medication variables found significantly different before matching were not significant post-matching. However, the significant differences between prescription opioid users and

v	/ariable		ion Opioid s (n=9,242)		ion Opioid n=5,935)	P value
		N	Col % Row %	N	Col % Row %	
Sociodemogr characteristic						
Sex	Male	4,496	48.6	2,606	43.9	< 0.0001
		,	63.3	,	36.7	
	Female	4,746	51.4	3,329	56.1	
			58.8		41.2	
Age	mean (±sd)	57 / ves	ars (±5.4)	57 0 vez	ars (±5.5)	<0.0001
Aye	40 – 49 years	962	10.4	678	11.4	0.0002
		302	58.7	070	41.3	0.0002
	50 – 59 years	4,068	44.0	2,753	46.4	
	50 – 59 years	4,000	59.6	2,755	40.4	
	≥60 years	4,212	45.6	2,504	40.4	
		7,212	62.7	2,004	37.3	
Metropolitan Statistical Area	Urban	7,465	80.8	4,714	79.4	0.03
			61.3		38.7	
	Rural	1,732	18.7	1,201	20.2	
			59.1	,	40.9	
Region	Northeast	1591	17.2	681	11.5	0.0001
Region	Northeast	1001	70.0	001	30.0	0.0001
	North Central	3,279	35.5	2,079	35.0	
		0,210	61.2	2,010	38.8	
	South	3,120	33.8	2,356	39.7	
	Coun	0,120	57.0	2,000	43.0	
	West	1,201	13.0	799	13.5	
			60.1		40.0	
Insurance Plan Type	НМО	1,535	16.6	997	16.8	0.9243
пан туре			60.6		39.4	
	PPO	2,451	26.5	1,586	26.7	
		_,	60.7	.,	39.3	
	Other	5,191	56.2	3,320	55.9	
			61.0		39.0	
Clinical chara	acteristics					
Deyo- Charlson Comorbidity Index	mean (±sd)	1.7 (±1.1)		2.0 (±1.5)	<0.0001
Number of pain conditions	0	2,756	29.8	809	13.6	<0.0001
			77.3		22.7	
	1	4,214	45.6	2,009	33.9	
			67.7		32.3	

 Table 13: Baseline characteristics of the unmatched study sample

Variable			ion Opioid s (n=9,242)		on Opioid n=5,935)	P value
		N	Col % Row %	N	Col % Row %	
	≥2	2,272	24.6	3,117	52.5	
		,	42.2	- ,	57.8	
Number of						
comorbid conditions	0	2,531	27.4	1,003	16.9	<0.0001
			71.6		28.4	
	1	3,603	39.0	1,973	33.2	
			64.6		35.4	
	≥2	3,108	33.6	2,959	49.9	
			51.2		48.8	
Type of index maintenance medication	ICS+LABA	4,908	53.1	3,225	54.3	0.152
medication			60.3		39.7	
	LAMA+LABA or LAMA+ICS	85	0.9	63	1.1	
			57.4		42.6	
	ICS+LABA+LAMA	845	9.1	564	9.5	
			60.0		40.0	
	ICS or LABA or LAMA	3,404	36.8	2,083	35.1	
			62.0		38.0	
Mail-order index maintenance medication prescription	Yes	3,391	36.7	2,448	41.2	<0.0001
			58.1		41.9	
	No	5,851	63.3	3,487	58.8	
			62.7		37.3	
Adherence to COPD- maintenance medications in the pre- index period	Non-adherent if PDC < 80%	4,377	47.4	1,761	29.7	<0.0001
			71.3		28.7	
Adherent if PDC 80%	Adherent if PDC ≥ 80%	4,865	52.6	4,174	70.3	
			53.8		46.2	<u> </u>
COPD severity	/ indicators					
Supplemental oxygen use in the pre-index	No	7,483	81.0	4,675	78.8	0.0009

Va	ariable	Prescription Non-Users (n		Prescriptio Users (n=	=5,935)	P value
		Ν	Col % Row %	Ν	Col % Row %	
			61.5		38.5	
	Yes	1,759	19.0	1,260	21.2	
			58.3		41.7	
SABA use in the pre-index period	No	4,460	48.3	2,773	46.7	0.06
			61.7		38.3	
	Yes	4,782	51.7	3,162	53.3	
			60.2		39.8	
COPD-related severe exacerbations in the pre- index period	0	8,896	96.3	5,715	96.3	0.91
			60.9		39.1	
	≥1	346	3.7	220	3.7	
			61.1		38.9	
COPD-related moderate exacerbations in the pre- index period	0	8,050	87.1	5,051	85.1	0.0005
			61.4		38.6	
	≥1	1,192	<u>12.9</u> 57.4	884	14.9 42.6	
			57.4		42.0	
Physician cha	racteristics					
Pulmonologist visit in the pre-index period	No	6,845	74.1	4,234	71.3	0.0002
			61.8		38.2	
	Yes	2,397	25.9	1,701	28.7	
			58.5		41.5	
Prior utilizatio	n characteristics	+		+ +		
Total all- cause healthcare expenditures in the pre-	mean (±sd)	7,896.1 (±95,445.5)		15,684.25 (±122,558.1)		<0.0001
index period ^a	<\$2,844	3472	37.6	940	15.8	<0.0001
	-γ ∠ ,∨ τ⊤	5772	78.7		21.3	-0.0001
	\$2,844 - \$9,838	4286	46.4	2956	49.8	
		.200	59.2		40.8	
	>\$9,838	1484	16.1	2039	34.4	

Variable	Prescription Opioid Non-Users (n=9,242)		Prescription Opioid Users (n=5,935)		P value
	Z	Col % Row %	N	Col % Row %	
		42.1		57.9	

*sd denotes standard deviation; Col, column; HMO, health maintenance organization; PPO, preferred provider organization; ICS, inhaled corticosteroid; LABA, long-acting beta agonist; LAMA, long-acting muscarinic agent; SABA, shortacting beta agonist; and PDC, proportion of days covered. ^a adjusted to 2010 US \$

١	/ariable		ion Opioid s (n=5,541)		ion Opioid n=5,541)	P value
		Ν	Col % Row %	N	Col % Row %	
Sociodemogr characteristic						
Sex	Male	2,537	45.8	2,537	45.8	1
		,	50.0	,	50.0	
	Female	3,004	54.2	3,004	54.2	
			50.0		50.0	
-						
Age	mean (±sd)		ars (±5.4)		ars (±5.4)	0.83
	40 – 49 years	604	10.9	609	11.0	0.974
			49.8	-	50.2	
	50 – 59 years	2,555	46.1	2,544	45.9	
			50.1		49.9	
	≥60 years	2,382	43.0	2,388	43.1	
			49.9		50.1	
Metropolitan Statistical Area	Urban	4,408	79.6	4,405	79.5	0.84
			50.0		50.0	
	Rural	1,106	20.0	1,116	20.1	
			49.8		50.2	
Region	Northeast	910	16.4	614	11.1	<0.0001
			59.7		40.3	
	North Central	2,084	37.6	1,966	35.5	
			51.5		48.5	
	South	1,808	32.6	2,202	39.7	
		700	45.1	700	54.9	
	West	708	12.8	739	13.3	
			48.9		51.1	
Insurance	НМО	879	15.9	918	16.6	0.495
Plan Type		079		910		0.495
			48.9		51.1	
	PPO	3,118	56.3	3,115	56.2	
			50.0		50.0	
	Other	1,518	27.4	1,477	26.7	
		_	50.7		49.3	
Clinical chara						
Deyo- Charlson Comorbidity Index	mean (±sd)	1.7 ((±1.2)	2.0	(±1.5)	<0.0001
Number of pain conditions	0	1,624	29.3	776	14.0	<0.0001
			67.7		32.3	

Table 14: Baseline characteristics of the matched study sample

Va	ariable		ion Opioid s (n=5,541)		ion Opioid n=5,541)	P value
		N	Col %	N	Col %	
		IN	Row %		Row %	
	1	2,515	45.4	1,879	33.9	
			57.2		42.8	
	2	1,402	25.3	2,886	52.1	
			32.7		67.3	
Number of comorbid conditions	0	1,312	23.7	996	18.0	<0.0001
			56.8		43.2	
	1	2,168	39.1	1,862	33.6	
		_,	53.8	.,	46.2	
	2	2,061	37.2	2,683	48.4	
	-	2,001	43.4	2,000	56.6	
			-0		00.0	
Type of index maintenance medication	ICS+LABA	2,904	52.4	2,999	54.1	0.3034
			49.2		50.8	
	LAMA+LABA or LAMA+ICS	56	1.0	58	1.0	
			49.1		50.9	
	ICS+LABA+LAMA	538	9.7	531	9.6	
			50.3		49.7	
	ICS or LABA or LAMA	2,043	36.9	1,953	35.2	
			51.1		48.9	
Mail-order index maintenance medication prescription	Yes	3,353	60.5	3,261	58.9	0.075
			50.7		49.3	
	No	2,188	39.5	2,280	41.1	
			49.0		51.0	ļ
Adherence to COPD- maintenance medications in	Non-adherent if PDC < 80%	1,734	31.3	1,734	31.3	1
the pre-index period			50.0		50.0	
			50.0		50.0	
	Adherent if PDC ≥ 80%	3,807	68.7	3,807	68.7	
			50.0		50.0	
COPD severity	indicators					
Supplemental oxygen use in	No	4,425	79.9	4,425	79.9	1

Va	ariable	Prescriptio Non-Users	(n=5,541)	Prescripti Users (r	n=5,541)	P value
		Ν	Col %	Ν	Col %	
the pre-index			Row %		Row %	
period						
period			50.0		50.0	
	Yes	1,116	20.1	1,116	20.1	
	103	1,110	50.0	1,110	50.0	
			0010		00.0	
SABA use in						
the pre-index period	No	2,590	46.7	2,590	46.7	1
•			50.0		50.0	
	Yes	2,951	53.3	2,951	53.3	
			50.0		50.0	
COPD-related						
severe			·		c = -	
exacerbations in the pre-	0	5,380	97.1	5,380	97.1	1
index period						
		101	50.0	101	50.0	
	≥1	161	2.9	161	2.9	
			50.0		50.0	
COPD-related moderate exacerbations in the pre- index period	0	4,777	86.2	4,777	86.2	1
index period			50.0		50.0	
	≥1	764	13.8	764	13.8	
			50.0	-	50.0	
Physician char	acteristics					
Pulmonologist visit in the pre-index	No	4,072	73.5	3,967	71.6	0.03
period		+	50.7	+ +	49.3	
	Yes	1,469	26.5	1,574	<u>49.3</u> 28.4	
	162	1,409	48.3	1,374	<u> </u>	
		+ +	+0.J	+ +	51.7	
Prior utilization	n characteristics	+ +		+ +		
Total all- cause healthcare expenditures in the pre- index period ^a	mean (±sd)	6,988.4 (±11,358.8)		12,498.8 (±19,856)		<0.0001
	<\$2,844	1874	33.8	895	16.2	<0.0001
	·ψ ∠ ,Ο ι ι	10/7	67.7		32.3	30.0001
	\$2,844 - \$9,838	2752	49.7	2790	50.4	

Variable	Prescription Opioid Non-Users (n=5,541)			ion Opioid n=5,541)	P value
	N	Col % Row %	Ν	Col % Row %	
		49.7		50.3	
>\$9,838	915	16.5	1856	33.5	
		33.0		67.0	

*sd denotes standard deviation; Col, column; HMO, health maintenance organization; PPO, preferred provider organization; ICS, inhaled corticosteroid; LABA, long-acting beta agonist; LAMA, long-acting muscarinic agent; SABA, shortacting beta agonist; and PDC, proportion of days covered. ^a adjusted to 2010 US \$ non-users in terms of the number of comorbid conditions persisted after matching. The mean D-CCI score among prescription opioid users was significantly higher compared to non-opioid users ($2.0 \pm 1.5 \text{ vs } 1.7 \pm 1.2$, p<0.0001) after matching. Similarly, a significantly higher percentage of prescription opioid users had ≥ 1 comorbid chronic condition (82% vs 76.3%, p<0.0001) and ≥ 1 comorbid pain conditions (86% vs 70.7%, p<0.0001) compared to non-opioid users.

Results for Specific Aim 1

Specific Aim 1 was to examine the impact of prescription opioid use compared to no prescription opioid use on adherence to COPD maintenance medications, over four different time periods, among a real-world, large sample of COPD patients after adjusting for other confounders.

Results for Specific Aim 1A

Baseline characteristics as per specific aim 1A:

Specific aim 1A was to examine the impact of prescription opioid use compared to no prescription opioid use on adherence to COPD maintenance medications, within the first 90 days of initiating a prescription opioid, among a real-world, large sample of COPD patients after adjusting for other confounders. Table 15 provides baseline characteristics of the included sample of COPD patients and adherence to COPD maintenance medications in the 90-day follow-up period. Overall, 59.4% of the included matched sample of COPD patients were adherent (defined as PDC ≥0.8) to their COPD maintenance medications in the 90-day follow-up period after the index date. A smaller percentage of prescription opioid users were adherent to their COPD maintenance medications in the 90-day follow-up period after the index date. A smaller percentage of prescription opioid users were adherent to their COPD maintenance

	/ariable		erent in 90 1=4,502)		in 90 days 5,580)	P value
		N	Col %	Ν	Col %	
<u> </u>			Row %		Row %	
Sociodemogr characteristic						
Sex	Male	1,977	43.9	3,097	47.1	0.001
			39.0		61.0	
	Female	2,525	56.1	3,483	52.9	
			42.0		58.0	
Ago		50.4		57.0		0.0004
Age	mean (±sd)		ars (±5.8)		ars (±4.9)	< 0.0001
	40 – 49 years	699	15.5	514	7.8	<0.0001
	50 50	0.457	57.6	0.040	42.4	
	50 – 59 years	2,157	47.9	2,942	44.7	
	>60	4.040	42.3	0.404	57.7	
	≥60 years	1,646	36.6	3,124	47.5	
			34.5		65.5	
Metropolitan						
Statistical Area	Urban	3,566	79.2	5,247	79.7	0.34
			40.5		59.5	
	Rural	924	20.5	1,298	19.7	
			41.6		58.4	
Region	Northeast	568	12.6	956	14.5	<0.0001
			37.3	0.501	62.7	
	North Central	1,466	32.6	2,584	39.3	
		4.005	36.2	0.475	63.8	
	South	1,835	40.8	2,175	33.1	
		047	45.8	000	54.2	
	West	617	13.7	830	12.6	
			42.6		57.4	
Insurance Plan Type	НМО	874	19.4	923	14.0	<0.0001
71 -			48.6		51.4	
	PPO	2,444	54.3	3,789	57.6	
		, í	39.2		60.8	1
	Other	1,164	25.9	1,831	27.8	
			38.9		61.1	
Clinical chara	cteristics					
Prescription opioid use	No use	1,688	37.5	3,853	58.6	<0.0001
			30.5		69.5	
	Use	2,814	62.5	2,727	41.4	ļ
Dava i ri			50.8		49.2	
Prescription opioid use	No use	1,688	37.5	3,853	58.6	<0.0001
			30.5		69.5	

Table 15: Baseline characteristics for Specific Aim 1A

V	ariable	Non-Adhe days (n			in 90 days 5,580)	P value
		Ν	Col % Row %	Ν	Col % Row %	
	≤30 days supply of prescription opioids	2,492	55.4	2,402	36.5	
			50.9		49.1	
	>30 days supply of prescription opioids	322	7.2	325	4.9	
			49.8		50.2	
Deyo- Charlson Comorbidity Index	mean (±sd)	1.9 (:	±1.4)	1.8	(±1.3)	0.006
Number of						
pain conditions	0	851	18.9	1,549	23.5	<0.0001
			35.5		64.5	
	1	1696	37.7	2,698	41.0	
			38.6		61.4	
	2	1955	43.4	2,333	35.5	
			45.6		54.4	
NL selection of						
Number of comorbid conditions	0	878	19.5	1,430	21.7	0.0008
			38.0		62.0	
	1	1608	35.7	2,422	36.8	
			39.9		60.1	
	2	2016	44.8	2,728	41.5	
			42.5		57.5	
Type of index maintenance	ICS+LABA	2806	62.3	3,097	47.1	<0.0001
medication	IOUTEADA	2000	02.0	0,007	77.1	NO.000
			47.5		52.5	
	LAMA+LABA or LAMA+ICS	31	0.7	83	1.3	
			27.2		72.8	
	ICS+LABA+LAMA	295	6.6	774	11.8	
			27.6		72.4	
	ICS or LABA or LAMA	1370	30.4	2,626	39.9	
			34.3		65.7	<u> </u>
<u> </u>						
Mail-order index maintenance medication prescription	No	3599	79.9	3,015	45.8	<0.0001
preseription			54.4		45.6	

Variable			Non-Adherent in 90 days (n=4,502)		in 90 days 5,580)	P value
		Ν	Col %	N	Col %	
		IN	Row %	IN	Row %	
	Yes	903	20.1	3,565	54.2	
			20.2		79.8	
Adherence to COPD- maintenance	Non-adherent if					
medications in the pre-index period	PDC < 80%	2344	52.1	1,124	17.1	<0.0001
			67.6		32.4	
	Adherent if PDC ≥ 80%	2158	47.9	5,456	82.9	
			28.3		71.7	
	in dia atawa					
COPD severity Supplemental	Indicators					
oxygen use in the pre-index period	No	3744	83.2	5,106	77.6	<0.0001
			42.3		57.7	
	Yes	758	16.8	1,474	22.4	
			34.0	,	66.0	
SABA use in the pre-index period	No	2088	46.4	3,092	47.0	0.53
•			40.3		59.7	
	Yes	2414	53.6	3,488	53.0	
			40.9		59.1	
COPD-related						
severe exacerbations in the pre- index period	0	4382	97.3	6,378	96.9	0.213
			40.7		59.3	
	≥1	120	2.7	202	3.1	
			37.3		62.7	
COPD-related moderate						
exacerbations in the pre-	0	3894	86.5	5,660	86.0	0.475
index period			40.9		59.2	
	≥1	608	40.8	920	<u> </u>	-
		000	39.8	920	60.2	
					00.2	
Physician cha	acteristics			1		1

Va	Variable		rent in 90 =4,502)		in 90 days ,580)	P value
		Ν	Col % Row %	Ν	Col % Row %	
Pulmonologist visited in the pre-index period	No	3370	74.9	4,669	71.0	<0.0001
			41.9		58.1	
	Yes	1132	25.1	1,911	29.0	
			37.2		62.8	
Prior utilization	n characteristics					
Total all-cause healthcare expenditures in the pre- index period ^a	mean (±sd)	10,241.1 (±17,573.4)		9,403.2 (±15,552)		<0.0001
	<\$2,844	1355	30.1	1414	21.5	< 0.0001
			48.9		51.1	
	\$2,844 - \$9,838	1976	43.9	3566	54.2	
			35.7		64.3	
	>\$9,838	1171	26.0	1600	24.3	
			42.3		57.7	

*sd denotes standard deviation; Col, column; HMO, health maintenance organization; PPO, preferred provider organization; ICS, inhaled corticosteroid; LABA, long-acting beta agonist; LAMA, long-acting muscarinic agent; SABA, shortacting beta agonist; and PDC, proportion of days covered. ^a adjusted to 2010 US \$ 69.5%, p<0.0001). Patients who were non-adherent to their COPD maintenance medications in the 90-day follow-up period were more likely to be prescription opioid users than non-opioid users (62.5% vs 37.5%, p<0.0001). A greater percentage of patients non-adherent to their COPD maintenance medications in the 90-day follow-up period had comorbid conditions than patients adherent to their COPD maintenance medications. Non-adherent patients had a significantly higher mean D-CCI score (1.9 ± 1.4 vs 1.8 ± 1.3, p=0.006). Non-adherent patients also had a higher percentage of patients with ≥1 comorbid chronic conditions (80.5% vs 78.3%, p<0.001) and ≥1 comorbid pain conditions (81.1% vs 76.5%, p<0.0001).

Specific Aim 1A sub-analysis was to examine the impact of prescription opioid use (classified as having > 30-day supply of prescription opioids and \leq 30-day supply of prescription opioids) compared to no prescription opioid use, within the first 90 days of initiating a prescription opioid, among a real-world, large sample of COPD patients after adjusting for other confounders. A significantly lower percentage of prescription opioid users, either \leq 30-day supply of prescription (49.1% vs 69.5%, p<0.0001) or >30-day supply of prescription opioids (50.2% vs 69.5%, p<0.0001), were adherent to their COPD maintenance medications in the 90-day follow-up period compared to non-opioid users (69.5%) (Table 15).

Unadjusted logistic regression analyses:

Table 16 provides the results of the unadjusted logistic regression analysis of the odds of being adherent to COPD maintenance medications in the 90-day follow-up period for Specific Aim 1A. Prescription opioid users were found to have 0.36 times (95% CI 0.33-0.40, p<0.0001) significantly lower odds of being adherent to their COPD

Table 16: Unadjusted logistic regression predicting the odds of being adherent toCOPD maintenance medications in 90 days follow-up

Variable		Point Estimate	95% Confidence Interval		P-Value	
	lemographic					
char	acteristics					
Metropolitan						
Statistical	Rural					
Area		Reference				
	Urban	1.15	0.99	1.32	0.06	
Dagian	Northeast	Deference				
Region	North Central	Reference	0.70	4.05	0.45	
		0.86	0.73	1.05	0.15	
	South	0.64	0.53	0.77	< 0.0001	
	West	0.74	0.60	0.93	0.008	
	Health					
Insurance	maintenance					
Plan Type	organization	Reference				
	Preferred provider					
	organization	1.28	1.09	1.71	0.003	
	Other	1.42	1.18	1.71	<0.000	
		1.72	1.10	1.7 1	<u> </u>	
Clinical d	characteristics					
Prescription						
opioid use	No use	Reference				
	Use	0.36	0.33	0.40	< 0.0001	
Prescription	Nama					
opioid use	No use	Reference				
•	≤30-day supply of					
	prescription					
	opioids	0.37	0.33	0.40	<0.0001	
	>30-day supply of					
	prescription					
	opioids	0.33	0.25	0.44	<0.0001	
			0.20			
Deyo-						
Charlson						
Comorbidity						
Index		0.85	0.82	0.89	<0.0001	
Number of						
pain	0					
conditions		Reference				
	1	0.79	0.68	0.93	0.003	
	2	0.48	0.42	0.57	<0.0001	
Number of						
comorbid	0	Deference				
conditions		Reference	0.70	4.40	0.40	
	1	0.93	0.78	1.12	0.46	
	2	0.68	0.56	0.56	<0.0001	

Variable		Point Estimate	95% Confidence	Interval	P-Value	
Type of index						
maintenance	ICS+LABA					
medication		Reference				
	LAMA+LABA or					
	LAMA+ICS	1.70	0.99	2.94	0.05	
	ICS+LABA+LAMA	1.78	1.45	2.19	<0.0001	
	ICS or LABA or					
	LAMA	1.51	1.33	1.72	<0.0001	
Mail-order index maintenance medication	No					
prescription		Reference				
	Yes	3.28	2.87	3.75	<0.0001	
Physician	characteristics					
Pulmonologist						
visit in the pre-index	No					
period		Reference				
	Yes	1.05	0.92	1.20	0.48	
B						
	on characteristics					
Total all-						
cause						
healthcare expenditures						
in the pre-						
index period ^a	<\$2,844	Reference				
index period	\$2,844 - \$9,838	1.27	1.10	1.46	0.0009	
	>\$9,838	0.73	0.62	0.86	0.0003	
	~\u0,000	0.75	0.02	0.00	0.0002	

* ICS denotes inhaled corticosteroid; LABA, long-acting beta agonist; LAMA, long-acting muscarinic agent; SABA, short-acting beta agonist; and PDC, proportion of days covered. ^a adjusted to 2010 US \$

maintenance medications in the 90-day follow-up period compared to non-opioid users. In the sub-group analysis patients with ≤30-day supply of prescription opioids had 0.37 times (95% CI 0.33-0.40, p<0.0001) significantly lower odds of being adherent to their COPD maintenance medications in the 90-day follow-up period as compared to nonopioid users. Similarly, patients with >30-day supply of prescription opioids had 0.33 times (95% CI 0.25-0.44, p<0.0001) significantly lower odds of being adherent to their COPD maintenance medications in the 90-day follow-up period as compared to nonopioid users. Similarly, patients with >30-day supply of prescription opioids had 0.33 times (95% CI 0.25-0.44, p<0.0001) significantly lower odds of being adherent to their COPD maintenance medications in the 90-day follow-up period as compared to nonopioid users. MSA, region, insurance plan type, D-CCI, number of comorbid pain conditions, number of comorbid chronic conditions, type of index maintenance medication, mail-order index maintenance medication, and total all-cause healthcare expenditures were found significant at p<0.2 and were considered in the adjusted logistic regression analysis.

Multiple logistic regression analyses:

Table 17 provides the results of the adjusted multiple logistic regression analysis of the odds of being adherent to COPD maintenance medications in the 90-day followup period, for Specific Aim 1A. The overall model was statistically significant (Wald's x^2 =593.75, df=13, p<0.0001). The significant impact of prescription opioid use in the unadjusted logistic regression analysis persisted in the multiple logistic regression analysis, after adjusting for other factors. Prescription opioid users were found to have 0.29 times (95% CI 0.26-0.37, p<0.0001) significantly lower odds of being adherent to their COPD maintenance medications in the 90-day follow-up period compared to non-opioid users, independent of other factors. Region, D-CCI, number of pain conditions, type of index maintenance medication, mail-order index maintenance medication and

	/ariable	Point Estimate	95% Confidence	P-Value	
Sociodemog					1
characteristic					
Region	Northeast	Reference			
	North Central	1.03	0.82	1.29	0.82
	South	0.94	0.75	1.19	0.61
	West	1.31	0.98	1.73	0.06
Clinical chara	acteristics				
Prescription					
opioid use	No use	Reference			
	Use	0.29	0.26	0.37	<0.0001
Deyo-					
Charlson					
Comorbidity					
Index		0.91	0.85	0.96	0.001
			0.00	0.00	
Number of					
pain	0				
conditions	-	Reference			
	1	0.90	0.74	1.09	0.26
	2	0.82	0.67	1.01	0.06
			0.01		5.00
Type of					
index					
maintenance	ICS+LABA				
medication		Reference			
	LAMA+LABA or				
	LAMA+ICS	1.87	0.93	3.73	0.07
	ICS+LABA+LAMA	1.76	1.35	2.30	< 0.0001
	ICS or LABA or		1100	2.00	
	LAMA	1.60	1.36	1.88	<0.0001
Mail-order		Reference			
index					
maintenance	No				1
medication					
prescription					
procomption	Yes	4.56	3.84	5.42	< 0.0001
			0.01	0.12	10.0001
	on characteristics				
Total all-		Reference			
cause					
healthcare					
expenditures	<\$2,844				1
in the pre-					
index					
period ^a					
	\$2,844 - \$9,838	1.81	1.5	2.18	<0.0001
	>\$9,838	1.53	1.21	1.92	0.0003

 Table 17: Multiple logistic regression predicting the odds of being adherent to

 COPD maintenance medications in 90 days follow-up

* ICS denotes inhaled corticosteroid; LABA, long-acting beta agonist; LAMA, long-acting muscarinic agent; SABA, short-acting beta agonist; and PDC, proportion of days covered.

^a adjusted to 2010 US \$

total all-cause healthcare expenditures were retained in the backwards elimination model at p<0.20.

Multiple logistic regression analyses, sub-group analysis:

Table 18 provides the results of the adjusted multiple logistic regression analysis of the odds of being adherent to COPD maintenance medications in the 90-day followup period, for Specific Aim 1A sub-group analysis. The overall model was statistically significant (Wald's x^2 =593.56, df=14, p<0.0001). The significant impact of prescription opioid use (≤30-day and >30-day supply of prescription opioids) in the unadjusted logistic regression analysis persisted in the multiple logistic regression analysis after adjusting for other factors. In the sub-group analysis patients with ≤30-day supply of prescription opioids had 0.30 times (95% CI 0.26-0.34, p<0.0001) significantly lower odds of being adherent to their COPD maintenance medications in the 90-day follow-up period as compared to non-opioid users independent of other factors. Similarly, patients with >30-day supply of prescription opioids had 0.32 times (95% CI 0.23-0.44, p<0.0001) significantly lower odds of being adherent to their COPD maintenance medications in the 90-day follow-up period as compared to non-opioid users independent of other factors. Region, D-CCI, number of pain conditions, type of index maintenance medication, mail-order index maintenance medication and total all-cause healthcare expenditures were retained in the backwards elimination model at p<0.20.

Table 18: Multiple logistic regression predicting the odds of being adherent to COPD maintenance medications in 90 days follow-up (sub-group analysis)

Variable		Point Estimate	95% Confidence Interval		P-Value	
Sociodemographic						
characteristi						
Region	Northeast	Reference				
	North Central	1.03	0.82	1.29	0.83	
	South	0.94	0.75	1.19	0.61	
	West	1.30	0.98	1.73	0.07	
Clinical char	antoristics					
	No use	Reference				
Prescription opioid use						
	≤30-day supply of prescription opioids	0.30	0.26	0.34	<0.0001	
	>30-day supply of prescription opioids	0.32	0.23	0.44	<0.0001	
Deyo- Charlson Comorbidity Index		0.90	0.85	0.96	0.001	
Number of	0	Reference				
pain conditions	0	Reference				
Conditionio	1	0.90	0.74	1.09	0.27	
	2	0.82	0.67	1.01	0.06	
	-	0.02	0.01		0.00	
Type of index maintenance medication	ICS+LABA	Reference				
	LAMA+LABA or LAMA+ICS	1.87	0.93	3.74	0.08	
	ICS+LABA+LAMA	1.76	1.35	2.30	< 0.0001	
	ICS or LABA or LAMA	1.60	1.36	1.89	<0.0001	
Mail-order index maintenance medication prescription	No	Reference				
	Yes	4.57	3.85	5.42	< 0.0001	
				0		
Prior utilizati	on characteristics					
Total all- cause healthcare	<\$2,844	Reference				

V	ariable	Point Estimate	Point Estimate 95% Confidence Interval		P-Value
expenditures in the pre- index period ^a					
	\$2,844 - \$9,838	1.81	1.5	2.18	<0.0001
	>\$9,838	1.52	1.21	1.92	0.0004

* ICS denotes inhaled corticosteroid; LABA, long-acting beta agonist; LAMA, long-acting muscarinic agent; SABA, short-acting beta agonist; and PDC, proportion of days covered. a adjusted to 2010 US \$

Results for Specific Aim 1B

Baseline characteristics as per specific aim 1B:

Specific Aim 1B was to examine the impact of prescription opioid use compared to no prescription opioid use on adherence to COPD maintenance medications, within the first 180 days of initiating a prescription opioid, among a real-world, large sample of COPD patients after adjusting for other confounders. Table 19 provides baseline characteristics of the included sample of COPD patients and adherence to COPD maintenance medications in the 180-day follow-up period. Nearly half (50.9%) of the included matched sample of COPD patients were adherent (defined as PDC ≥ 0.8 PDC) to their COPD maintenance medications in the 180-day follow-up period after the index date. A smaller percentage of prescription opioid users were adherent to their COPD maintenance medications in the 180-day follow-up period as compared to non-opioid users (45.3% vs 56.6%, p<0.0001). Patients who were non-adherent to their COPD maintenance medications in the 180-day follow-up period were more likely to be prescription opioid users than non-opioid users (55.8% vs 44.2%, p<0.0001). A greater percentage of patients non-adherent to their COPD maintenance medications in the 180-day follow-up period had comorbid conditions than patients adherent to their COPD maintenance medications. Non-adherent patients had a significantly higher mean D-CCI score $(1.9 \pm 1.4 \text{ vs } 1.8 \pm 1.3, \text{ p}=0.0018)$. Non-adherent patients also had a higher percentage of patients with ≥ 1 comorbid chronic conditions (80.5% vs 77.9%, p=0.0004) and ≥ 1 comorbid pain conditions (79.6% vs 77.1%, p<0.0001).

Ŋ	Variable	Non-Adherent in 180 days (n=5,436)			in 180 days 5,646)	P value
		N	Col %	N	Col %	
		11	Row %		Row %	
Sociodemogr characteristic						
Sex	Male	2,395	44.1	2,679	47.4	0.0003
			47.2		52.8	
	Female	3,041	55.9	2,967	52.6	
			50.6		49.4	
Age	mean (±sd)	56.3 vea	ars (±5.8)	58 vea	l rs (±4.9)	<0.0001
<u>J</u> -	40 – 49 years	797	14.7	416	7.4	< 0.0001
			65.7		34.3	
	50 – 59 years	2,619	48.2	2,480	43.9	
		,	51.4	,	48.6	
	≥60 years	2,020	37.2	2,750	48.7	
		,	42.3	,	57.7	
Metropolitan Statistical Area	Urban	4,323	79.5	4,490	79.5	0.85
			49.1		50.9	
	Rural	1,095	20.1	1,127	20.0	
			49.3		50.7	
Region	Northeast	693	12.7	831	14.7	<0.0001
			45.5		54.5	
	North Central	1,850	34.0	2,200	39.0	
			45.7		54.3	
	South	2,130	39.2	1,880	33.3	
			53.1		46.9	
	West	741	13.6	706	12.5	
			51.2		48.8	
Insurance Plan Type	НМО	989	18.2	808	14.3	<0.0001
Пантурс			55.0		45.0	
	PPO	3,024	55.6	3,209	56.8	
		0,021	48.5	0,200	51.5	
	Other	1,392	25.6	1,603	28.4	
		.,002	46.5	.,	53.5	
Clinical chara	cteristics			1		
Prescription opioid use	No use	2,404	44.2	3,137	55.6	<0.0001
			43.4		56.6	
	Use	3,032	55.8	2,509	44.4	
			54.7		45.3	
Prescription opioid use	No use	2,404	44.2	3,137	55.6	<0.0001
			43.4	1	56.6	

Table 19: Baseline characteristics for Specific Aim 1B

Variable			erent in 180 n=5,436)		in 180 days 5,646)	P value
		Ν	Col % Row %	Ν	Col % Row %	
	≤30-day supply of prescription opioids	2,513	46.2	2,072	36.7	
			54.8		45.2	
	>30-day supply of prescription opioids	519	9.5	437	7.7	
			54.3		45.7	
Deyo- Charlson Comorbidity Index	mean (±sd)	1.9	(±1.4)	1.8 ((±1.3)	0.0018
Number of pain conditions	0	1,107	20.4	1,293	22.9	<0.0001
			46.1		53.9	
	1	2,063	38.0	2,331	41.3	
			47.0		53.0	
	2	2,266	41.7	2,022	35.8	
			52.8		47.2	
Number of comorbid conditions	0	1,059	19.5	1,249	22.1	0.0004
			45.9		54.1	
	1	1,963	36.1	2,067	36.6	
			48.7		51.3	
	2	2,414	44.4	2,330	41.3	
			50.9		49.1	
Type of index maintenance medication	ICS+LABA	3,378	62.1	2,525	44.7	<0.0001
			57.2		42.8	
	LAMA+LABA or LAMA+ICS	36	0.7	78	1.4	
			31.6		68.4	
	ICS+LABA+LAMA	356	6.5	713	12.6	
			33.3		66.7	
	ICS or LABA or LAMA	1,666	30.6	2,330	41.3	
			41.7		58.3	
Mail-order index maintenance	No	3,812	70.1	2,802	49.6	<0.0001

Variable			rent in 180 n=5,436)		in 180 days 5,646)	P value
		Ν	Col % Row %	N	Col % Row %	
medication prescription						
F			57.6		42.4	
	Yes	1,624	29.9	2,844	50.4	
		7 -	36.3	,-	63.7	
Adherence to COPD- maintenance medications in the pre-index period	Non-adherent if PDC < 80%	2,629	48.4	839	14.9	<0.0001
			75.8		24.2	
	Adherent if PDC ≥ 80%	2,807	51.6	4,807	85.1	
			36.9		63.1	
COPD severity	indicators					
Supplemental oxygen use in the pre-index period	No	4,563	83.9	4,287	75.9	<0.0001
•			51.6		48.4	
	Yes	873	16.1	1,359	24.1	
			39.1		60.9	
SABA use in the pre-index period	No	2,567	47.2	2,613	46.3	0.32
			49.6		50.4	
	Yes	2,869	52.8	3,033	53.7	
			48.6		51.4	
COPD-related severe exacerbations in the pre- index period	0	5,306	97.6	5,454	96.6	0.002
ł			49.3		50.7	
	≥1	130	2.4	192	3.4	
			40.4		59.6	
COPD-related moderate exacerbations in the pre- index period	0	4,741	87.2	4,813	85.2	0.003
			49.6		50.4	
	≥1	695	12.8	833	14.8	
			45.5		54.5	

V	ariable	Non-Adher days (n:		Adherent in 180 days (n=5,646)		P value
		Ν	Col % Row %	Ν	Col % Row %	
Physician cha	racteristics					
Pulmonologist visit in the pre-index period	No	4,072	74.9	3,967	70.3	<0.0001
•			50.7		49.3	
	Yes	1,364	25.1	1,679	29.7	
			44.8		55.2	
Prior utilizatio	n characteristics					
Total all- cause healthcare expenditures in the pre- index period ^a	mean (±sd)	9,827.7 (±17,555.5)		9,662.6 (±15,222)		<0.0001
	<\$2,844	1645	30.3	1124	19.9	< 0.0001
			59.4		40.6	
	\$2,844 - \$9,838	2440	44.9	3102	54.9	
			44.0		56.0	
	>\$9,838	1351	24.9	1420	25.2	
			48.8		51.2	

*sd denotes standard deviation; Col, column; HMO, health maintenance organization; PPO, preferred provider organization; ICS, inhaled corticosteroid; LABA, long-acting beta agonist; LAMA, long-acting muscarinic agent; SABA, shortacting beta agonist; and PDC, proportion of days covered. ^a adjusted to 2010 US \$ Specific Aim 1B sub-analysis was to examine the impact of prescription opioid use (classified as having > 30-day supply of prescription opioids and \leq 30-day supply of prescription opioids) compared to no prescription opioid use, within the first 180 days of initiating a prescription opioid, among a real-world, large sample of COPD patients after adjusting for other confounders. A significantly lower percentage (p<0.0001) of prescription opioid users, either \leq 30-day supply of prescription (45.2%) or >30-day supply of prescription opioids (45.7%), were adherent to their COPD maintenance medications in the 180-day follow-up period as compared to nonopioid users (56.6%) (Table 19).

Unadjusted logistic regression analyses:

Table 20 provides the results of the unadjusted logistic regression analysis of the odds of being adherent to COPD maintenance medications in the 180-day follow-up period, for specific aim 1B. Prescription opioid users were found to have 0.59 times (95% CI 0.54-0.64, p<0.0001) significantly lower odds of being adherent to their COPD maintenance medications in the 180-day follow-up period compared to non-opioid users. In the sub-group analysis patients with <30-day supply of prescription opioids had 0.59 times (95% CI 0.54-0.64, p<0.0001) significantly lower odds of being adherent to their adherent to their COPD maintenance medications in the 180-day follow-up period compared to non-opioid users. In the sub-group analysis patients with <30-day supply of prescription opioids had 0.59 times (95% CI 0.54-0.64, p<0.0001) significantly lower odds of being adherent to their COPD maintenance medications in the 180-day supply of prescription opioids had 0.61 times (95% CI 0.40-0.75, p<0.0001) significantly lower odds of being adherent to their COPD maintenance medications in the 180-day follow-up period as compared to non-opioid users. Similarly, patients with >30-day supply of prescription opioids had 0.61 times (95% CI 0.40-0.75, p<0.0001) significantly lower odds of being adherent to their COPD maintenance medications in the 180-day follow-up period as compared to non-opioid users. Region, insurance plan type, D-CCI, number of comorbid pain conditions, number of comorbid chronic conditions, type of index maintenance

Variable Sociodemographic		Point Estimate	95% Confidence Interval		P-Value	
characteristic	s					
Metropolitan						
Statistical	Rural					
Area		Reference				
	Urban	0.96	0.83	1.10	0.57	
Region	Northeast	Reference				
- J -	North Central	0.83	0.69	0.99	0.04	
	South	0.68	0.57	0.82	< 0.0001	
	West	0.70	0.57	0.89	0.002	
Insurance	Health					
Plan Type	maintenance	Deferrers				
, , , , , , , , , , , , , , , , , , ,	organization	Reference				
	Preferred provider	1 4 0	0.00	4.00	0.4.40	
	organization	1.13	0.96	1.33	0.142	
	Other	1.37	1.14	1.64	0.0008	
Clinical chara	octeristics					
Prescription						
opioid use	No use	Reference				
	Use	0.59	0.54	0.64	<0.0001	
Prescription	No use					
opioid use		Reference				
	≤30-day supply of					
	prescription					
	opioids	0.59	0.54	0.64	<0.0001	
	>30-day supply of					
	prescription					
	opioids	0.61	0.40	0.75	<0.0001	
Deyo-						
Charlson						
Comorbidity						
Index		0.86	0.83	0.90	<0.0001	
Number of						
	0					
pain conditions	U	Reference				
CONULIONS	1	0.89	0.77	1.04	0.14	
	2	0.68	0.77	0.79	<0.0001	
	<u>∠</u>	0.00	0.09	0.79	<0.0001	
Number of						
comorbid	0					
conditions		Reference				
	1	0.91	0.76	1.08	0.28	
	2	0.69	0.57	0.84	< 0.001	

Table 20: Unadjusted logistic regression predicting the odds of being adherent toCOPD maintenance medications in 180 days follow-up

Va	ariable	Point Estimate	95% Confidence I	nterval	P-Value
Type of index					
maintenance	ICS+LABA				
medication		Reference			
	LAMA+LABA or				
	LAMA+ICS	1.90	1.10	3.28	0.02
	ICS+LABA+LAMA	1.91	1.56	2.33	< 0.0001
	ICS or LABA or				
	LAMA	1.67	1.47	1.89	<0.0001
Mail-order index maintenance medication prescription	No	Reference			
prescription	Yes	1.66	1.47	1.87	<0.0001
	165	1.00	1.47	1.07	<0.0001
Physician cha	racteristics				
Pulmonologist					
visit in the pre-index	No	Deference			
period		Reference	0.05	4.04	0.00
	Yes	1.09	0.95	1.24	0.22
Prior utilizatio	n characteristics				
Total all-					
cause					
healthcare expenditures					
in the pre-	*				
index period ^a	<\$2,844	Reference			
	\$2,844 - \$9,838	1.39	1.21	1.61	<0.0001
	>\$9,838	0.95	0.81	1.12	0.52

* ICS denotes inhaled corticosteroid; LABA, long-acting beta agonist; LAMA, long-acting muscarinic agent; SABA, short-acting beta agonist; and PDC, proportion of days covered. ^a adjusted to 2010 US \$

medication, mail-order index maintenance medication, and total all-cause healthcare expenditures were found significant at p<0.2 and were considered in the adjusted logistic regression analysis.

Multiple logistic regression analyses:

Table 21 provides the results of the adjusted multiple logistic regression analysis of the odds of being adherent to COPD maintenance medications in the 180-day follow-up period, for Specific Aim 1B. The overall model was statistically significant (Wald's x^2 =317.98, df=10, p<0.0001). The significant impact of prescription opioid use in the unadjusted logistic regression analysis persisted in the multiple logistic regression analysis after adjusting for other factors. Prescription opioid users were found to have 0.55 times (95% CI 0.50-0.61, p<0.0001) significantly lower odds of being adherent to their COPD maintenance medications in the 180-day follow-up period as compared to non-opioid users, independent of other predictors. Insurance plan type, D-CCI, type of index maintenance medication, mail-order index maintenance medication and total all-cause healthcare expenditures were retained in the backwards elimination model at p<0.20.

Multiple logistic regression analyses, sub-group analysis:

Table 22 provides the results of the adjusted multiple logistic regression analysis of the odds of being adherent to COPD maintenance medications in the 180-day followup period, for Specific Aim 1B sub-group analysis. The overall model was statistically significant (Wald's x^2 =318.03, df=11, p<0.0001). The significant impact of prescription opioid use (<30-day and >30-day supply of prescription opioids) in the unadjusted logistic regression analysis persisted in the multiple logistic regression analysis after

Table 21: Multiple logistic regression predicting the odds of being adherent toCOPD maintenance medications in 180 days follow-up

	Variable		95% Confidence I	nterval	P-Value	
Sociodemog						
characteristic						
Insurance	Health					
Plan Type	maintenance					
тап туре	organization	Reference				
	Preferred provider					
	organization	1.00	0.84	1.20	0.99	
	Other	1.21	0.99	1.48	0.06	
Clinical chara						
Prescription						
opioid use	No use	Reference				
	Use		0.50	0.61	-0.0001	
	Use	0.55	0.50	0.61	<0.0001	
Deyo-						
Charlson						
Comorbidity						
Index		0.88	0.83	0.92	<0.0001	
Turne of						
Type of index						
	ICS+LABA					
maintenance medication		Deference				
medication		Reference				
	LAMA+LABA or	0.04	4.07	4.40	0.000	
	LAMA+ICS	2.31	1.27	4.18	0.006	
	ICS+LABA+LAMA	1.87	1.50	2.33	<0.0001	
	ICS or LABA or	4 70	4 50	0.00	0.0004	
	LAMA	1.76	1.53	2.02	<0.0001	
Mail-order						
index						
maintenance	No					
medication						
prescription		Reference				
· · ·	Yes	1.63	1.43	1.86	<0.0001	
Prior utilizati	on characteristics					
Total all-						
Cause						
healthcare						
expenditures	<\$2,844					
in the pre-						
index period		Reference				
nuez penod	\$2,844 - \$9,838		1 51	2.00	<0.0001	
		1.78	1.51	2.09	<0.0001	
	>\$9,838		1.26	1.88	<0.0001	

* ICS denotes inhaled corticosteroid; LABA, long-acting beta agonist; LAMA, longacting muscarinic agent; SABA, short-acting beta agonist; and PDC, proportion of days covered.

^a adjusted to 2010 US \$

Table 22: Multiple logistic regression predicting the odds of being adherent to COPD maintenance medications in 180 days follow-up (sub-group analysis)

Variable		Point Estimate	95% Confidence Interval		P-Value	
Sociodemographic						
characteristics	1					
Insurance Plan	Health					
Туре	maintenance					
Туре	organization	Reference				
	Preferred provider					
	organization	1.00	0.84	1.20	0.99	
	Other	1.21	0.99	1.48	0.06	
Clinical charact	teristics					
Prescription opioid use	No use	Reference				
	≤30-day supply of					
	prescription					
	opioids	0.55	0.50	0.61	<0.0001	
	>30-day supply of					
	prescription					
	opioids	0.58	0.46	0.72	<0.0001	
<u> </u>						
Deyo-Charlson						
Comorbidity						
Index		0.88	0.83	0.92	<0.0001	
Type of index						
maintenance	ICS+LABA					
medication	100 TEXER	Reference				
modication	LAMA+LABA or					
	LAMA+ICS	2.30	1.27	4.17	0.006	
	ICS+LABA+LAMA	1.87	1.50	2.33	< 0.0001	
	ICS or LABA or	1.07	1.50	2.55	<0.0001	
		1 76	1 50	2.02	-0.0001	
	LAMA	1.76	1.53	2.02	<0.0001	
Mail-order						
index						
maintenance	No					
medication						
prescription		Reference				
	Yes	1.63	1.43	1.87	<0.0001	
Prior utilization	characteristics					
Total all-cause						
healthcare						
expenditures in						
the pre-index						
period	<\$2,844	Reference				
	\$2,844 - \$9,838	1.78	1.51	2.09	<0.0001	
	>\$9,838	1.54	1.26	1.87	< 0.0001	

* ICS denotes inhaled corticosteroid; LABA, long-acting beta agonist; LAMA, long-acting muscarinic agent; SABA, short-acting beta agonist; and PDC, proportion of a adjusted to 2010 US \$

adjusting for other factors. In the sub-group analysis patients with \leq 30-day supply of prescription opioids had 0.55 times (95% CI 0.50-0.61, p<0.0001) significantly lower odds of being adherent to their COPD maintenance medications in the 180-day follow-up period as compared to non-opioid users independent of other factors. Similarly, patients with >30-day supply of prescription opioids had 0.58 times (95% CI 0.46-0.72, p<0.0001) significantly lower odds of being adherent to their COPD maintenance medications in the 180-day follow-up period compared to non-opioid users independent of other factors. Similarly, patients with >30-day supply of prescription opioids had 0.58 times (95% CI 0.46-0.72, p<0.0001) significantly lower odds of being adherent to their COPD maintenance medications in the 180-day follow-up period compared to non-opioid users independent of other factors. Insurance plan type, D-CCI, type of index maintenance medication, mail-order index maintenance medication and total all-cause healthcare expenditures were retained in the backwards elimination model at p<0.20.

Results for Specific Aim 1C

Baseline characteristics as per Specific Aim 1C:

Specific aim 1C was to examine the impact of prescription opioid use compared to no prescription opioid use on adherence to COPD maintenance medications, within the first 270 days of initiating a prescription opioid, among a real-world, large sample of COPD patients after adjusting for other confounders. Table 23 provides baseline characteristics of the included sample of COPD patients and adherence to COPD maintenance medications in the 270 days follow-up period. Less than half (47.3%) of the included matched sample of COPD patients were adherent (defined as PDC \geq 0.8) to their COPD maintenance medications in the 270-day follow-up period after the index date. A smaller proportion of prescription opioid users were adherent to their COPD maintenance medications in the 270-day follow-up period as compared to non-opioid users (43.3% vs 51.2%, p<0.0001). Patients who were non-adherent to their COPD

· · ·	Variable	Non-Adherent in 270 days (n=5,845)			n 270 days ,237)	P value
		N	Col %	N	Col %	
<u> </u>			Row %		Row %	
Sociodemogr characteristic						
Sex	Male	2,547	43.6	2,527	48.3	<0.0001
			50.2		49.8	
	Female	3,298	56.4	2,710	51.7	
			54.9		45.1	
Age	mean (±sd)	56.3 vea	ars (±5.8)	58 1 vea	urs (±4.8)	<0.0001
	40 – 49 years	849	14.5	364	7.0	< 0.0001
		0.0	70.0		30.0	
	50 – 59 years	2,799	47.9	2,300	43.9	
		.,	54.9	,	45.1	
	≥60 years	2,197	37.6	2,573	49.1	
		,	46.1		53.9	
Metropolitan Statistical Area	Urban	4,665	79.8	4,148	79.2	0.54
			52.9		47.1	
	Rural	1,160	19.8	1,062	20.3	
			52.2		47.8	
Region	Northeast	776	13.3	748	14.3	<0.0001
0			50.9		49.1	
	North Central	1,996	34.1	2,054	39.2	
			49.3		50.7	
	South	2,260	38.7	1,750	33.4	
			56.4		43.6	
	West	789	13.5	658	12.6	
			54.5		45.5	
Insurance Plan Type	НМО	1,046	17.9	751	14.3	<0.0001
			58.2		41.8	
	PPO	3,266	55.9	2,967	56.7	
		-,	52.4	,	47.6	
	Other	1,494	25.6	1,501	28.7	1
		,	49.9		50.1	
Clinical chara	octeristics					
Prescription opioid use	No use	2,703	46.2	2,838	54.2	<0.0001
			48.8		51.2	
	Use	3,142	53.8	2,399	45.8	
			56.7		43.3	
Prescription opioid use	No use	2,703	46.2	2,838	54.2	<0.0001
			48.8		51.2	

Table 23: Baseline characteristics for Specific Aim 1C

Variable			rent in 270 =5,845)	Adherent i (n=5		P value
		Ν	Col % Row %	Ν	Col % Row %	
	≤30-day supply of prescription opioids	2,467	42.2	1,881	35.9	
			56.7		43.3	
	>30-day supply of prescription opioids	675	11.5	518	9.9	
			56.6		43.4	
Deyo- Charlson Comorbidity Index	mean (±sd)	1.9 (±1.4)	1.8 (:	±1.2)	0.0003
Number of pain conditions	0	1,196	20.5	1,204	23.0	<0.0001
			49.8		50.2	
	1	2,236	38.3	2,158	41.2	
			50.9		49.1	
	2	2,413	41.3	1,875	35.8	
			56.3		43.7	
Number of comorbid conditions	0	1,137	19.5	1,171	22.4	<0.0001
			49.3		50.7	
	1	2,098	35.9	1,932	36.9	
		0.040	52.1	0.404	47.9	
	2	2,610	44.7	2,134	40.7	
			55.0		45.0	
Type of index maintenance medication	ICS+LABA	3,590	61.4	2,313	44.2	<0.0001
			60.8		39.2	
	LAMA+LABA or LAMA+ICS	39	0.7	75	1.4	
		00.4	34.2	005	65.8	
	ICS+LABA+LAMA	384	6.6	685	13.1	
	ICS or LABA or		35.9		64.1	
	LAMA	1,832	31.3	2,164	41.3	
			45.8		54.2	
Mail-order index maintenance medication prescription	No	4,012	68.6	2,602	49.7	<0.0001

Variable		Non-Adhe days (n			n 270 days ,237)	P value
		Ν	Col %	N	Col %	
			Row %		Row %	
	Mar	4 000	60.7	0.005	39.3	
	Yes	1,833	31.4	2,635	50.3	
			41.0		59.0	
Adherence to COPD- maintenance medications in the pre-index	Non-adherent if PDC < 80%	2,754	47.1	714	13.6	0.0004
period			79.4		20.6	<0.0001
	Adherent if PDC ≥		79.4		20.0	
	80%	3,091	52.9	4,523	86.4	
	0070		40.6		59.4	
COPD severity	indicators					
Supplemental oxygen use in the pre-index period	No	4,931	84.4	3,919	74.8	<0.0001
•			55.7		44.3	
	Yes	914	15.6	1,318	25.2	
			40.9		59.1	
SABA use in the pre-index period	No	2,764	47.3	2,416	46.1	0.224
			53.4		46.6	
	Yes	3,081	52.7	2,821	53.9	
			52.2		47.8	
COPD-related severe exacerbations in the pre- index period	0	5,700	97.5	5,060	96.6	0.005
•			53.0		47.0	
	≥1	145	2.5	177	3.4	
			45.0		55.0	
COPD-related moderate exacerbations in the pre- index period	0	5,095	87.2	4,459	85.1	0.002
			53.3		46.7	
	≥1	750	12.8	778	14.9	
			49.1		50.9	
Physician char	acteristics					

Variable		Non-Adher days (n=		Adherent in 270 days (n=5,237)		P value
		Ν	Col % Row %	N	Col % Row %	
Pulmonologist visit in the pre-index period	No	4,389	75.1	3,650	69.7	<0.0001
			54.6		45.4	
	Yes	1,456	24.9	1,587	30.3	
			47.8		52.2	
Prior utilizatio	n characteristics					
Total all- cause healthcare expenditures in the pre- index period ^a	mean (±sd)	9,724.9 (±17,360.4)		9,764.5 (±15,275.8)		<0.0001
•	<\$2,844	1751	30.0	1018	19.4	< 0.0001
			63.2		36.8	
	\$2,844 - \$9,838	2654	45.4	2888	55.1	
			47.9		52.1	
	>\$9,838	1440	24.6	1331	25.4	
			52.0		48.0	

*sd denotes standard deviation; Col, column; HMO, health maintenance organization; PPO, preferred provider organization; ICS, inhaled corticosteroid; LABA, long-acting beta agonist; LAMA, long-acting muscarinic agent; SABA, shortacting beta agonist; and PDC, proportion of days covered. ^a adjusted to 2010 US \$ maintenance medications in the 270-day follow-up period were more likely to be prescription opioid users than non-opioid users (53.8% vs 46.2%, p<0.0001). A greater percentage of patients non-adherent to their COPD maintenance medications in the 270-day follow-up period had comorbid conditions than patients adherent to their COPD maintenance medications. Non-adherent patients had a significantly higher mean D-CCI score ($1.9 \pm 1.4 \text{ vs } 1.8 \pm 1.2$, p=0.0003). Non-adherent patients also had a percentage of patients with ≥ 1 comorbid chronic conditions (80.5% vs 77.6%, p<0.0001) and ≥ 1 comorbid pain conditions (79.5% vs 77%, p<0.0001).

Specific Aim 1C sub-analysis was to examine the impact of prescription opioid use (classified as having > 30-day supply of prescription opioids and \leq 30-day supply of prescription opioids) compared to no prescription opioid use, within the first 270 days of initiating a prescription opioid, among a real-world, large sample of COPD patients after adjusting for other confounders. A significantly lower percentage of prescription opioid users (p<0.0001), either \leq 30-day supply of prescription (43.3%) or >30-day supply of prescription opioids (43.4%), were adherent to their COPD maintenance medications in the 270-day follow-up period as compared to non-users of prescription opioid users (51.2%) (Table 23).

Unadjusted logistic regression analyses:

Table 24 provides the results of the unadjusted logistic regression analysis of the odds of being adherent to COPD maintenance medications in the 270-day follow-up period, for Specific Aim 1C. Prescription opioid users were found to have 0.69 times (95% CI 0.63-0.74, p<0.0001) significantly lower odds of being adherent to their COPD maintenance medications in the 270-day follow-up period as compared to non-opioid

Table 24: Unadjusted logistic regression predicting the odds of being adherent toCOPD maintenance medications in 270 days follow-up

Variable		Point Estimate	95% Confidence Interval		P-Value	
Sociodemographic						
characteristic	s					
Metropolitan						
Statistical	Rural					
Area		Reference				
	Urban	0.94	0.83	1.08	0.37	
Region	Northeast	Reference				
•	North Central	0.93	0.78	1.18	0.45	
	South	0.78	0.65	0.93	0.006	
	West	0.82	0.65	1.02	0.07	
Insurance Plan Type	Health maintenance organization	Reference				
	Preferred provider					
	organization	1.14	0.97	1.35	0.0002	
	Other	1.42	1.18	1.71	0.12	
Clinical chara	acteristics					
Prescription						
opioid use	No use	Reference				
	Use	0.69	0.63	0.74	<0.0001	
Prescription opioid use	No use	Reference				
	≤30-day supply of prescription opioids	0.68	0.62	0.75	<0.0001	
	>30-day supply of prescription opioids	0.70	0.59	0.84	<0.0001	
<u> </u>						
Deyo- Charlson Comorbidity Index		0.85	0.81	0.89	<0.0001	
Number of						
pain	0					
conditions		Reference				
	1	0.88	0.76	1.03	0.12	
	2	0.71	0.61	0.83	<0.001	
Number of comorbid	0	Deference				
conditions	4	Reference	0.74	4.00	0.04	
	1	0.90	0.74	1.08	0.24	
	2	0.66	0.55	0.80	<0.0001	

Va	ariable	Point Estimate	95% Confide	ence Interval	P-Value
Type of index					
maintenance	ICS+LABA				
medication		Reference			
	LAMA+LABA or				
	LAMA+ICS	2.02	1.14	3.58	0.02
	ICS+LABA+LAMA	1.93	1.58	2.37	<0.0001
	ICS or LABA or				
	LAMA	1.62	1.42	1.84	<0.0001
Mail-order index maintenance medication prescription	No	Reference			
preseription	Yes	1.61	1.42	1.82	<0.0001
	163	1.01	1.42	1.02	<0.0001
Physician cha	racteristics				
Pulmonologist visit in the pre-index period	Other	Reference			
ponou	Pulmonologist	1.07	0.93	1.22	0.35
Drior utilizatio	n characteristics				
Total all-					
Cause					
healthcare expenditures					
in the pre-					
index period ^a	<\$2,844	Ref			
-	\$2,844 - \$9,838	1.36	1.18	1.58	< 0.0001
	>\$9,838	0.96	0.81	1.14	0.66

* ICS denotes inhaled corticosteroid; LABA, long-acting beta agonist; LAMA, long-acting muscarinic agent; SABA, short-acting beta agonist; and PDC, proportion of days covered. ^a adjusted to 2010 US \$

users. Patients with \leq 30-day supply of prescription opioids had 0.68 times (95% CI 0.62-0.75, p<0.0001) significantly lower odds of being adherent to their COPD maintenance medications in the 270-day follow-up period as compared to non-opioid users. Similarly, patients with >30-day supply of prescription opioids had 0.70 times (95% CI 0.59-0.84, p<0.0001) significantly lower odds of being adherent to their COPD maintenance medications in the 270-day follow-up period as compared to non-opioid users. Region, insurance plan type, D-CCI, number of comorbid pain conditions, number of comorbid chronic conditions, type of index maintenance medication, mail-order index maintenance medication, and total all-cause healthcare expenditures were found significant at p<0.2 and were considered in the adjusted logistic regression analysis.

Multiple logistic regression analyses:

Table 25 provides the results of the adjusted multiple logistic regression analysis of the odds of being adherent to COPD maintenance medications in the 270-day followup period, for specific aim 1C. The overall model was statistically significant (Wald's $x^2=248.29$, df=10, p<0.0001). The significant impact of prescription opioid use in the unadjusted logistic regression analysis persisted in the multiple logistic regression analysis after adjusting for other factors. Prescription opioid users were found to have 0.66 times (95% CI 0.60-0.73, p<0.0001) significantly lower odds of being adherent to their COPD maintenance medications in the 270-day follow-up period as compared to non-opioid users, independent of other predictors. Insurance plan type, D-CCI, type of index maintenance medication, mail-order index maintenance medication and total all-

Table 25: Multiple logistic regression predicting the odds of being adherent toCOPD maintenance medications in 270 days follow-up

V	ariable	Point Estimate	95% Confide	nce Interval	P-Value
Sociodemog					
characteristi					
Insurance	Health	Reference			
Plan Type	maintenance				
	organization	4.04	0.07	4.05	0.00
	Preferred provider	1.04	0.87	1.25	0.68
	organization Other	1.29	1.05	1.57	0.01
	Other	1.29	1.05	1.57	0.01
Clinical chara	acteristics				
Prescription opioid use	No use	Reference			
	Use	0.66	0.60	0.73	<0.0001
Deyo- Charlson Comorbidity Index		0.85	0.81	0.90	<0.0001
Type of index maintenance medication	ICS+LABA	Reference			
	LAMA+LABA or LAMA+ICS	2.33	1.26	4.29	0.006
	ICS+LABA+LAMA	1.90	1.52	2.36	< 0.0001
	ICS or LABA or LAMA	1.66	1.45	1.91	<0.0001
Mail-order index maintenance medication prescription	No	Reference			
	Yes	1.57	1.38	1.79	< 0.0001
Prior utilizati	on characteristics				
Total all- cause healthcare expenditures in the pre- index period ^a	<\$2,844	Reference			
	\$2,844 - \$9,838	1.64	1.4	1.93	<0.0001
	>\$9,838	1.46	1.2	1.79	0.0002

* ICS denotes inhaled corticosteroid; LABA, long-acting beta agonist; LAMA, longacting muscarinic agent; SABA, short-acting beta agonist; and PDC, proportion of days covered.

^a adjusted to 2010 US \$

cause healthcare expenditures were retained in the backwards elimination model at p<0.20.

Multiple logistic regression analyses, sub-group analysis:

Table 26 provides the results of the adjusted multiple logistic regression analysis of the odds of being adherent to COPD maintenance medications in the 270-day followup period, for Specific Aim 1C sub-group analysis. The overall model was statistically significant (Wald's x²=248.34, df=11, p<0.0001). The significant impact of prescription opioid use (≤30-day and >30-day supply of prescription opioids) in the unadjusted logistic regression analysis persisted in the multiple logistic regression analysis after adjusting for other factors. In the sub-group analysis patients with ≤30-day supply of prescription opioids had 0.66 times (95% CI 0.59-0.73, p<0.0001) significantly lower odds of being adherent to their COPD maintenance medications in the 270-day followup period as compared to non-opioid users independent of other factors. Similarly, patients with >30-day supply of prescription opioids had 0.68 times (95% CI 0.56-0.83, p<0.0001) significantly lower odds of being adherent to their COPD maintenance medications in the 270-day follow-up period as compared to non-opioid users independent of other factors. Insurance plan type, D-CCI, type of index maintenance medication, mail-order index maintenance medication and total all-cause healthcare expenditures were retained in the backwards elimination model at p<0.20.

Table 26: Multiple logistic regression predicting the odds of being adherent to COPD maintenance medications in 270 days follow-up (sub-group analysis)

	Variable		95% Confidence	e Interval	P-Value
Sociodemog					
characteristic					
Insurance	Health	Reference			
Plan Type	maintenance				
	organization				
	Preferred provider	1.04	0.87	1.25	0.68
	organization				
	Other	1.29	1.05	1.57	0.01
Clinical chara					
Prescription	No use	Reference			
opioid use	NO USE	Reference			
	≤30-day supply of	0.66	0.59	0.73	<0.0001
	prescription				
	opioids				
	>30-day supply of	0.68	0.56	0.83	0.0001
	prescription				
	opioids				
Davia		0.05	0.04	0.00	0.0004
Deyo-		0.85	0.81	0.90	<0.0001
Charlson					
Comorbidity					
Index					
Type of	ICS+LABA	Reference			
index					
maintenance					
medication					
	LAMA+LABA or	2.33	1.26	4.29	0.007
	LAMA+ICS				
	ICS+LABA+LAMA	1.90	1.52	2.36	< 0.0001
	ICS or LABA or	1.66	1.45	1.91	< 0.0001
	LAMA				
Mail-order	No	Reference			
index					
maintenance					
medication					
prescription					
procomption	Yes	1.57	1.38	1.80	<0.0001
Prior utilizati	on characteristics				
Total all-	<\$2,844	Reference			
cause					
healthcare					
expenditures					
in the pre-					
index					
period ^a					
	\$2,844 - \$9,838	1.64	1.4	1.93	<0.0001

Variable	Point Estimate	95% Confidence Ir	nterval	P-Value
>\$9,838	1.46	1.19	1.79	0.0002

* ICS denotes inhaled corticosteroid; LABA, long-acting beta agonist; LAMA, long-acting muscarinic agent; SABA, short-acting beta agonist; and PDC, proportion of days covered. a adjusted to 2010 US \$

Results for Specific Aim 1D

Baseline characteristics as per Specific Aim 1D:

Specific Aim 1D was to examine the impact of prescription opioid use compared to no prescription opioid use on adherence to COPD maintenance medications, within the first 365 days of initiating a prescription opioid, among a real-world, large sample of COPD patients after adjusting for other confounders. Table 27 provides baseline characteristics of the included sample of COPD patients and adherence to COPD maintenance medications in the 365 days follow-up period. Less than half (45.9%) of the included matched sample of COPD patients were adherent (defined as PDC ≥ 0.8) to their COPD maintenance medications in the 365-day follow-up period after the index date. A smaller percentage of prescription opioid users were adherent to their COPD maintenance medications in the 365-day follow-up period as compared to their non-user counterparts (42.1% vs 49.7%, p<0.0001). Patients who were non-adherent to their COPD maintenance medications in the 365-day follow-up period were more likely to be prescription opioid users than non-opioid users (53.6% vs 46.4%, p<0.0001). A greater percentage of patients non-adherent to their COPD maintenance medications in the 365-day follow-up period had comorbid conditions than patients adherent to their COPD maintenance medications. Non-adherent patients had a significantly higher mean D-CCI score $(1.9 \pm 1.4 \text{ vs } 1.8 \pm 1.2, \text{ p}=0.0006)$. Non-adherent patients also had a percentage of patients with ≥ 1 comorbid chronic conditions (80.8% vs 77.3%, p<0.0001) and ≥ 1 comorbid pain conditions (79.7% vs 76.8%, p<0.0001).

Specific Aim 1D sub-analysis was to examine the impact of prescription opioid use (classified as having >30-day supply of prescription opioids and ≤30-day supply of

,	/ariable		Non-Adherent in 365 days (n=5,996)		n 365 days ,086)	P value
		N	Col %	N	Col %	
<u> </u>			Row %		Row %	
Sociodemogr characteristic						
Sex	Male	2,630	43.9	2,444	48.1	<0.0001
			51.8		48.2	
	Female	3,366	56.1	2,642	51.9	
			56.0		44.0	
Age	mean (±sd)	56.4 vea	ars (±5.7)	59.1 vea	ars (±4.8)	<0.0001
<u> </u>	40 – 49 years	861	14.4	352	6.9	< 0.0001
			71.0		29.0	
	50 – 59 years	2,880	48.0	2,219	43.6	
		,	56.5	, -	43.5	
	≥60 years	2,255	37.6	2,515	49.4	
		,====	47.3	,	52.7	
Metropolitan Statistical Area	Urban	4,769	79.5	4,044	79.5	0.95
			54.1		45.9	
	Rural	1,204	20.1	1,018	20.0	
			54.2		45.8	
Region	Northeast	807	13.5	717	14.1	<0.0001
			53.0		47.0	
	North Central	2,044	34.1	2,006	39.4	
			50.5		49.5	
	South	2,316	38.6	1,694	33.3	
			57.8		42.2	
	West	802	13.4	645	12.7	
			55.4		44.6	
Insurance Plan Type	НМО	1,062	17.7	735	14.5	<0.0001
			59.1		40.9	
	PPO	3,340	55.7	2,893	56.9	
			53.6	_,000	46.4	
	Other	1,555	25.9	1,440	28.3	
		,	51.9	,	48.1	
Clinical chara	cteristics					
Prescription opioid use	No use	2,785	46.4	2,756	54.2	<0.0001
			50.3		49.7	
	Use	3,211	53.6	2,330	45.8	
			57.9		42.1	
Prescription opioid use	No use	2,785	46.4	2,756	54.2	<0.0001
			50.3		49.7	

Table 27: Baseline characteristics for Specific Aim 1D

V	ariable	Non-Adher days (n	=5,996)	Adherent i (n=5	,086)	P value
		Ν	Col % Row %	N	Col % Row %	
	≤30-day supply of prescription opioids	2,408	40.2	1,762	34.6	
			57.7		42.3	
	>30-day supply of prescription opioids	803	13.4	568	11.2	
			58.6		41.4	
Deyo- Charlson Comorbidity Index	mean (±sd)	1.9 (=	⊥ ±1.4)	1.8 (:	±1.2)	0.0006
Number of pain conditions	0	1,219.00	20.3	1,181	23.2	<0.0001
			50.8		49.2	
	1	2,296.00	38.3	2,098	41.3	
			52.3		47.7	
	2	2,481.00	41.4	1,807	35.5	
			57.9		42.1	
Number of comorbid conditions	0	1,154	19.2	1,154	22.7	<0.0001
			50.0		50.0	
	1	2,167	36.1	1,863	36.6	
		0.075	53.8	0.000	46.2	
	2	2,675	44.6 56.4	2,069	40.7 43.6	
			50.4		43.0	
Type of index maintenance medication	ICS+LABA	3,658	61.0	2,245	44.1	<0.0001
			62.0		38.0	
	LAMA+LABA or LAMA+ICS	42	0.7	72	1.4	
		466	36.8	000	63.2	
	ICS+LABA+LAMA	406	6.8	663	13.0	
	ICS or LABA or		38.0		62.0	
	LAMA	1,890	31.5	2,106	41.4	
			47.3		52.7	
Mail-order index maintenance medication	No	4,083	68.1	2,531	49.8	
prescription						<0.0001

Va	ariable	Non-Adhei days (n	=5,996)	Adherent i (n=5		P value
		Ν	Col %	N	Col %	
	1		Row %		Row %	
			61.7		38.3	
	Yes	1,913	31.9	2,555	50.2	
			42.8		57.2	
Adherence to COPD- maintenance medications in	Non-adherent if PDC < 80%	2,788	46.5	680	13.4	
the pre-index						0.0004
period			00.4		10.0	<0.0001
			80.4		19.6	
	Adherent if PDC ≥ 80%	3,208	53.5	4,406	86.6	
	0070		42.1		57.9	
			76.1		01.0	
COPD severity	indicators					
Supplemental oxygen use in	No	5,054	84.3	3,796	74.6	
the pre-index period		-,				<0.0001
		0.40	57.1	4 000	42.9	
	Yes	942	15.7	1,290	25.4	
			42.2		57.8	
SABA use in the pre-index period	No	2,834	47.3	2,346	46.1	0.231
			54.7		45.3	0.201
	Yes	3,162	52.7	2,740	53.9	
		, , , , , , , , , , , , , , , , , , ,	53.6	,	46.4	
COPD-related severe exacerbations in the pre-	0	5,844	97.5	4,916	96.7	
index period			54.0		45.7	0.012
		450	54.3	470	45.7	
	≥1	152	2.5	170	3.3	
			47.2		52.8	
COPD-related moderate exacerbations in the pre-	0	5,238	87.4	4,316	84.9	
index period						0.0001
			54.8		45.2	
	≥1	758	12.6	770	15.1	
			49.6		50.4	
<u></u>						
Physician char	acteristics					

v	ariable	Non-Adher days (n=		Adherent in (n=5,0		P value
		Ν	Col % Row %	N	Col % Row %	
Pulmonologist visit in the pre-index period	No	4,465	74.5	3,574	70.3	<0.0001
			55.5		44.5	
	Yes	1,531	25.5	1,512	29.7	
			50.3		49.7	
Prior utilizatio	n characteristics					
Total all- cause healthcare expenditures in the pre- index period ^a	mean (±sd)	9,739.9 (±17,164.6)		9,748 (±15,469.4)		<0.0001
	<\$2,844	1765	29.4	1004	19.7	<0.0001
			63.7		36.3	
	\$2,844 - \$9,838	2736	45.6	2806	55.2	
			49.4		50.6	
	>\$9,838	1495	24.9	1276	25.1	
			54.0		46.0	

*sd denotes standard deviation; Col, column; HMO, health maintenance organization; PPO, preferred provider organization; ICS, inhaled corticosteroid; LABA, long-acting beta agonist; LAMA, long-acting muscarinic agent; SABA, shortacting beta agonist; and PDC, proportion of days covered. ^a adjusted to 2010 US \$ prescription opioids) compared to no prescription opioid use, within the first 365 days of initiating a prescription opioid, among a real-world, large sample of COPD patients after adjusting for other confounders. A significantly lower percentage (p<0.0001) of prescription opioid users, either \leq 30-day supply of prescription (42.3%) or >30-day supply of prescription opioids (41.4%), were adherent to their COPD maintenance medications in the 365-day follow-up period as compared to non-users of prescription opioid users (49.7%) (Table 27).

Unadjusted logistic regression analyses:

Table 28 provides the results of the unadjusted logistic regression analysis of the odds of being adherent to COPD maintenance medications in the 365-day follow-up period for Specific Aim 1D. Prescription opioid users were found to have 0.69 times (95% CI 0.64-0.75, p<0.0001) significantly lower odds of being adherent to their COPD maintenance medications in the 365-day follow-up period as compared to non-opioid users. In the sub-group analysis patients with ≤30-day supply of prescription opioids had 0.69 times (95% CI 0.63-0.76, p<0.0001) significantly lower odds of being adherent to their COPD maintenance medications in the 365-day follow-up period as compared to non-opioid users. Similarly, patients with >30-day supply of prescription opioids had 0.69 times (95% CI 0.58-0.81, p<0.0001) significantly lower odds of being adherent to their COPD maintenance medications in the 365-day follow-up period as compared to non-opioid users. Similarly, patients with >30-day supply of prescription opioids had 0.69 times (95% CI 0.58-0.81, p<0.0001) significantly lower odds of being adherent to their COPD maintenance medications in the 365-day follow-up period as compared to non-opioid users. Similarly, patients with >30-day supply of prescription opioids had 0.69 times (95% CI 0.58-0.81, p<0.0001) significantly lower odds of being adherent to their COPD maintenance medications in the 365-day follow-up period as compared to non-opioid users. Region, insurance plan type, D-CCI, number of comorbid pain conditions, number of comorbid chronic conditions, type of index maintenance medication, mail-order index maintenance medication, and total all-cause healthcare

Table 28: Unadjusted logistic regression predicting the odds of being adherent toCOPD maintenance medications in 365 days follow-up

V	Variable		95% Confide	nce Interval	P-Value	
Sociodemogr						
characteristic	s					
Metropolitan						
Statistical	Rural	Defense				
Area		Reference	0.00	4.44	0.01	
	Urban	0.96	0.83	1.11	<0.61	
Region	Northeast	Reference				
	North Central	0.92	0.77	1.11	0.39	
	South	0.76	0.63	0.91	0.003	
	West	0.81	0.65	1.01	0.06	
Insurance Plan Type	Health maintenance organization	Reference				
	Preferred provider					
	organization	1.15	0.97	1.36	0.0006	
	Other	1.38	1.15	1.67	0.11	
Clinical chara	acteristics					
Prescription	Neuro					
opioid use	No use	Reference				
	Use	0.69	0.64	0.75	<0.0001	
Prescription						
opioid use	No use	Reference				
·	≤30-day supply of				0.000/	
	rescription opioids	0.69	0.63	0.76	<0.0001	
	>30-day supply of prescription opioids	0.69	0.58	0.81	<0.0001	
Deyo- Charlson Comorbidity						
Index		0.86	0.82	0.90	<0.0001	
Number of						
pain	0					
conditions	-	Reference				
	1	0.85	0.73	1.00	0.05	
	2	0.66	0.57	0.77	<0.0001	
Number of						
comorbid	0					
conditions		Reference				
	1	0.83	0.69	0.99	0.04	
	2	0.63	0.52	0.76	<0.0001	
				0.1.0		

Va	ariable	Point Estimate	95% Confide	nce Interval	P-Value
Type of index					
maintenance	ICS+LABA				
medication		Reference			
	LAMA+LABA or				
	LAMA+ICS	1.95	1.15	3.31	0.014
	ICS+LABA+LAMA	1.83	1.48	2.25	< 0.0001
	ICS or LABA or				
	LAMA	1.49	1.31	1.70	< 0.0001
Mail-order index maintenance medication prescription	No	Reference			
<u></u>	Yes	1.54	1.36	1.74	< 0.0001
Physician cha	racteristics				
Pulmonologist visit in the pre-index period	No	Reference			
P • • • • •	Yes	1.05	0.92	1.19	0.52
Prior utilizatio	n characteristics				
Total all- cause healthcare expenditures in the pre- index period ^a	<\$2,844	Reference			
•	\$2,844 - \$9,838	1.28	1.11	1.48	0.0007
	>\$9,838	0.92	0.78	1.09	0.33

* ICS denotes inhaled corticosteroid; LABA, long-acting beta agonist; LAMA, long-acting muscarinic agent; SABA, short-acting beta agonist; and PDC, proportion of days covered. a adjusted to 2010 US \$

expenditures were found significant at p<0.2 and were considered in the adjusted logistic regression analysis.

Multiple logistic regression analyses:

Table 29 provides the results of the adjusted multiple logistic regression analysis of the odds of being adherent to COPD maintenance medications in the 365-day follow-up period, for Specific Aim 1D. The overall model was statistically significant (Wald's x^2 =221.03, df=12, p<0.0001). The significant impact of prescription opioid use in the unadjusted logistic regression analysis persisted in the multiple logistic regression analysis after adjusting for other factors. Prescription opioid users were found to have 0.69 times (95% CI 0.63-0.76, p<0.0001) significantly lower odds of being adherent to their COPD maintenance medications in the 365-day follow-up period as compared to non-opioid users, independent of other predictors. Insurance plan type, D-CCI, number of pain conditions, type of index maintenance medication, mail-order index maintenance medication and total all-cause healthcare expenditures were retained in the backwards elimination model at p<0.20.

Multiple logistic regression analyses, sub-group analysis:

Table 30 provides the results of the adjusted multiple logistic regression analysis of the odds of being adherent to COPD maintenance medications in the 365-day follow-up period, for Specific Aim 1D sub-group analysis. The overall model was statistically significant (Wald's x^2 =221.07, df=13, p<0.0001). The significant impact of prescription opioid use (≤30-day and >30-day supply of prescription opioids) in the unadjusted logistic regression analysis persisted in the multiple logistic regression analysis after adjusting for other factors. In the sub-group analysis patients with ≤30-day supply of

Table 29: Multiple logistic regression predicting the odds of being adherent toCOPD maintenance medications in 365 days follow-up

Va	Variable		95% Confide	ence Interval	P-Value	
Sociodemographic characteristics						
Insurance Plan Type	Health maintenance organization	Reference				
	Preferred provider organization	1.06	0.88	1.27	0.54	
	Other	1.25	1.03	1.55	0.02	
Clinical characte	ristics					
Prescription opioid use	No use	Reference				
•	Use	0.69	0.63	0.76	<0.0001	
Deyo-Charlson Comorbidity Index		0.87	0.83	0.92	<0.0001	
Number of pain conditions	0	Reference				
	1	0.86	0.73	1.01	0.07	
	2	0.80	0.67	0.95	0.01	
Type of index maintenance medication	ICS+LABA	Reference				
	LAMA+LABA or LAMA+ICS	2.19	1.24	3.86	0.006	
	ICS+LABA+LAMA	1.81	1.45	2.25	< 0.0001	
	ICS or LABA or LAMA	1.52	1.33	1.75	<0.0001	
Mail-order index maintenance medication prescription	No	Reference				
• •	Yes	1.51	1.32	1.72	<0.0001	
Prior utilization of	haracteristics					
Total all-cause healthcare expenditures in the pre-index period ^a	<\$2,844	Reference				
	\$2,844 - \$9,838	1.57	1.34	1.84	<0.0001	
	>\$9,838	1.42	1.16	1.74	0.0006	

* ICS denotes inhaled corticosteroid; LABA, long-acting beta agonist; LAMA, long-acting muscarinic agent; SABA, short-acting beta agonist; and PDC, proportion of a adjusted to 2010 US \$

Table 30: Multiple logistic regression predicting the odds of being adherent to COPD maintenance medications in 365 days follow-up (sub-group analysis)

, v	Variable	Point Estimate	95% Confiden	ce Interval	P-Value
Sociodemogra	aphic characteristics				
Insurance Plan Type	Health maintenance organization	Reference			
	Preferred provider organization	1.06	0.88	1.27	0.53
	Other	1.26	1.03	1.55	0.02
Clinical chara	cteristics				
Prescription opioid use	No use	Reference			
	≤30-day supply of prescription opioids	0.69	0.62	0.77	<0.0001
	>30-day supply of prescription opioids	0.71	0.59	0.85	0.0003
Deyo- Charlson Comorbidity Index		0.87	0.83	0.92	<0.0001
Number of pain conditions	0	Reference			
	1	0.86	0.73	1.01	0.07
	2	0.79	0.66	0.95	0.01
Type of index maintenance medication	ICS+LABA	Reference			
	LAMA+LABA or LAMA+ICS	2.19	1.25	3.87	0.007
	ICS+LABA+LAMA	1.81	1.45	2.25	< 0.0001
	ICS or LABA or LAMA	1.52	1.33	1.75	<0.0001
Mail-order index maintenance medication prescription	No				
	Yes	1.51	1.32	1.72	<0.0001
Prior utilizatio	on characteristics				
Total all- cause healthcare expenditures in the pre- index period ^a	<\$2,844	Reference			
muer penou	\$2,844 - \$9,838	1.57	1.34	1.84	<0.0001

Variable	Point Estimate	95% Confidence	e Interval	P-Value
>\$9,838	1.42	1.16	1.74	0.0006

* ICS denotes inhaled corticosteroid; LABA, long-acting beta agonist; LAMA, longacting muscarinic agent; SABA, short-acting beta agonist; and PDC, proportion of days covered.

^a adjusted to 2010 US \$

prescription opioids had 0.69 times (95% CI 0.62-0.77, p<0.0001) significantly lower odds of being adherent to their COPD maintenance medications in the 365-day followup period compared to non-opioid users independent of other factors. Similarly, patients with >30-day supply of prescription opioids had 0.71 times (95% CI 0.59-0.85, p<0.0003) significantly lower odds of being adherent to their COPD maintenance medications in the 365-day follow-up period compared to non-opioid users independent of other factors. Insurance plan type, D-CCI, number of pain conditions, type of index maintenance medication, mail-order index maintenance medication and total all-cause healthcare expenditures were retained in the backwards elimination model at p<0.20.

Sample for Specific Aims 2, 3 and 4

Specific Aims 2, 3 and 4 were answered using long-term prescription opioid users and non-opioid users among COPD patients. Baseline characteristics of longterm prescription opioid users and non-users among COPD patients are presented in Table 31.

A total of 566 COPD patients on maintenance medications were classified as long-term prescription opioid users, representing 10.2% of all the matched prescription opioid users. Long-term prescription opioid users were similar to non-opioid users in terms of baseline sex, age, MSA, insurance plan type, type of index maintenance medication, mail-order index maintenance medication, adherence in the pre-index period, pre-index moderate COPD exacerbations, and pulmonary physician visit. Similar to prescription opioid users, long-term prescription opioid users had significantly higher number of mean comorbid conditions compared to non-opioid users. The mean D-CCI score among long-term prescription opioid users was significantly higher compared to

Table 31: Baseline characteristics of long-term and non-users of prescriptionopioids in one-year follow-up period for Specific Aims 2, 3, and 4

Variable	(n=5,541)			Long-term opioid users (n=566)	
	N	Col % Row %	N	Col % Row	
Male	2,537	45.8	267	47.2	0.53
	, ,	90.5		9.5	
Female	3,004	54.2	299	52.8	
		90.9		9.1	
mean (+sd)	57.2 102	$rs(\pm 5.4)$	57.3 10	$are(\pm 5.2)$	0.73
					0.73
40 – 43 years	004		50		0.01
50 - 59 years	2 555		260		
<u> </u>	2,000		203		
>60 years	2 382		247		
	2,302		247		
Urban	4,408	79.6	441	77.9	0.32
		90.9		9.1	
Rural	1,106	20.0	123	21.7	
	,	90.0		10.0	
Northeast	910	16.4	52	9.2	<0.0001
North Central	2,084		232		
	,				
South	1,808		213		
	,				
West	708		67		
		91.4		8.6	
НМО	879	15.9	92	16.3	0.96
PPO	1,518		153		
Other	3118		319		
acteristics		30.7		3.3	
mean (±sd)	1.7 (±1.2)	2.4	(±1.8)	<0.0001
	Female Female $mean (\pm sd)$ 40 - 49 years 50 - 59 years $\geq 60 years$ \vee Urban Urban Rural Rural Northeast Northeast Northeast West HMO PPO Other Other Acteristics	Variable(n=5NraphiccsMale2,537Female3,004Female3,004mean (\pm sd)57.2 yea40 - 49 years60450 - 59 years2,555260 years2,382Urban4,408Rural1,106Northeast910Northeast910South1,808West708HMO879PPO1,518Other3118acteristics1	(n=5,541) N Col % Row % caphic Male 2,537 45.8 Male 2,537 45.8 Male 2,537 45.8 90.5 Female 3,004 54.2 mean (\pm sd) 57.2 years (\pm 5.4) 40 – 49 years 604 10.9 40 – 49 years 604 10.9 92.4 50 – 59 years 2,555 46.1 90.5 ≥60 years 2,382 43.0 90.5 ≥60 years 2,382 43.0 Urban 4,408 79.6 90.9 90.9 90.9 Rural 1,106 20.0 90.0 90.0 Northeast 910 16.4 94.6 North Central 2,084 37.6 90.0 South 1,808 32.6 89.5 West 708 12.8 90.7 HMO 879 15.9 90.5 PPO 1,518 27.4 90.7	Variable (n=5,541) Col % Row % N aphic N $Col %$ Row % N aphic 90.5 N Male 2,537 45.8 267 90.5 90.5 S S Female 3,004 54.2 299 90.9 90.9 S S mean (±sd) 57.2 years (±5.4) 57.3 years 40 – 49 years 604 10.9 50 90.5 92.4 S S 50 – 59 years 2,555 46.1 269 90.6 90.5 S S S $Vrban$ 4,408 79.6 441 90.9 S S S $Vrban$ 4,408 79.6 441 90.0 S S S S 910 16.4 52 S 910 16.4 52 S 910 16.4 S	Image: Normal system Image: No

V	ariable	Non-Opioid users (n=5,541)			opioid users =566)	P value
		Ν	Col % Row %	Ν	Col % Row %	
Number of pain conditions	0	1624	29.3	37	6.5	<0.0001
conditions			97.8		2.2	
	1	2,515	45.4	116	20.5	
		_,	95.6		4.4	
	2	1,402	25.3	413	73.0	
			77.2		22.8	
Number of comorbid conditions	0	1,312	23.7	76	13.4	<0.0001
			94.5		5.5	
	1	2,168	39.1	169	29.9	
			92.8		7.2	
	2	2,061	37.2	321	56.7	
			86.5		13.5	
Type of index maintenance medication	ICS+LABA	2,904	52.4	284	50.2	0.3
			91.1		8.9	
	LAMA+LABA or LAMA+ICS	56	1.0	10	1.8	
			84.8		15.2	
	ICS+LABA+LAMA	538	9.7	60	10.6	
			90.0		10.0	
	ICS or LABA or LAMA	2043	36.9	212	37.5	
			90.6		9.4	
Mail-order index maintenance medication prescription	No	3,353	60.5	324	57.2	0.13
			91.2		8.8	
	Yes	2,188	39.5	242	42.8	
			90.0		10.0	
Adherence to COPD- maintenance medications in the pre-index period	Non-adherent if PDC < 80%	1,734	31.3	170	30.0	0.54
			91.1		8.9	
	Adherent if PDC ≥ 80%	3,807	68.7	396	70.0	
			90.6		9.4	

Variable		Non-Opio (n=5,	541)	Long-term o (n=5	566)	P value
		Ν	Col % Row %	Ν	Col % Row %	
COPD severity	indicators					
Supplemental oxygen use in the pre-index period	No	4,425	79.9	407	71.9	<0.0001
•			91.6		8.4	
	Yes	1,116	20.1	159	28.1	
			87.5		12.5	
SABA use in the pre-index period	No	2,590	46.7	232	41.0	0.009
•			91.8		8.2	
	Yes	2,951	53.3	334	59.0	
			89.8		10.2	
COPD-related severe exacerbations in the pre- index period	0	5,380	97.1	536	94.7	0.002
			90.9		9.1	
	≥1	161	2.9	30	5.3	
			84.3		15.7	
COPD-related moderate exacerbations in the pre- index period	0	4,777	86.2	473	83.6	0.08
			91.0		9.0	
	≥1	764	13.8	93	16.4	
			89.1		10.9	
Physician cha	racteristics					
Pulmonologist visit in the pre-index period	No	4,072	73.5	406	71.7	0.37
·			90.9		9.1	
	Yes	1,469	26.5	160	28.3	
			90.2		9.8	
Prior utilization	n characteristics					
Total all- cause healthcare expenditures in the pre- index period ^a	mean (±sd) [median interquartile range]	6,988.4 (±11,358.8)	[4,059 (5059)]	15,427.4 (±27,780.0)	[7,774 (11,074)]	<0.0001

Variable	Non-Opioid users (n=5,541)		Long-term c (n=5	P value	
	Ν	Col % Row %	N	Col % Row %	
<\$2,844	1874	33.8	70	12.4	<0.0001
		96.4		3.6	
\$2,844 - \$9,838	2752	49.7	269	47.5	
		91.1		8.9	
>\$9,838	915	16.5	227	40.1	
		80.1		19.9	

*sd denotes standard deviation; Col, column; HMO, health maintenance organization; PPO, preferred provider organization; ICS, inhaled corticosteroid; LABA, long-acting beta agonist; LAMA, long-acting muscarinic agent; SABA, shortacting beta agonist; and PDC, proportion of days covered. ^a adjusted to 2010 US \$ non-users of prescription opioids ($2.4 \pm 1.8 \text{ vs} 1.7 \pm 1.2$, p<0.0001). Similarly, a higher proportion of long-term prescription opioid users had presence of one or more comorbid chronic conditions (86.6% vs 76.3%, p<0.0001) and comorbid pain conditions (93.5% vs 70.7%, p<0.0001). Also, significantly higher percentage of long-term prescription opioid users had pre-index supplemental oxygen use (28.1% vs 20.1%, p<0.0001), SABA use (59% vs 53.3%, p<0.009), severe COPD exacerbations (5.3% vs 2.9%, p=0.002), and higher mean total all-cause healthcare costs (Table 31).

Results for Specific Aim 2

Baseline characteristics as per Specific Aim 2:

Specific Aim 2 was to examine the impact of long-term prescription opioid use (≥90-day supply in a one-year period) compared to no-opioid use on adherence to COPD maintenance medications among a real-world, large sample of COPD patients after adjusting for other confounders. Table 32 provides baseline characteristics of the included sample of long-term and non-opioid users among COPD patients according to adherence to COPD maintenance medications in one-year follow-up period. Overall, 49.1% of the included sample of COPD patients were adherent (defined as PDC ≥0.8) to their COPD maintenance medications in the one-year follow-up period after the index date. A smaller percentage of long-term prescription opioid users were adherent to their COPD maintenance medications as compared to non-opioid users (42.6% vs 49.7%, p=0.001). A higher percentage of patients who had comorbid conditions were non-adherent to their COPD maintenance medications than patients who did not have comorbid conditions. A significantly higher percentage of non-adherent patients had

Var	iable	Non-Adhe days (n		Adherent in 365 days (n=2,997)		P value
		N	Col %	Ν	Col %	
C = = : = : = : = : = : = : = : = : = :			Row %		Row %	
Sociodemographi	Male	4.070	111	1,432	47.0	0.004
Sex	Iviale	1,372	44.1 48.9	1,432	47.8	0.004
	Famala	1 700		1 666	51.1	
	Female	1,738	55.9	1,565	52.2	
			52.6		47.4	
Age	mean (±sd)	56.4 yea	re (±5.7)	58 1 100	ars (±4.9)	<0.0001
Лус	40 – 49 years	434	14.0	220	7.3	<0.0001
	40 – 49 years	434	66.4	220	33.6	<0.0001
	50 – 59 years	1,526	49.1	1,298	43.3	
	50 – 59 years	1,520	54.0	1,230	46.0	
	≥60 years	1,150	37.0	1,479	49.3	
		1,130	43.7	1,419	49.3 56.3	
			43.7		50.5	
Metropolitan Statistical Area	Urban	2,471	79.5	2,378	79.3	0.97
			51.0		49.0	
	Rural	627	20.2	602	20.1	
			51.0		49.0	
Region	Northeast	492	15.8	470	15.7	< 0.0001
			51.1		48.9	
	North Central	1,086	34.9	1,230	41.0	
			46.9		53.1	
	South	1,113	35.8	908	30.3	
			55.1		44.9	
	West	403	13.0	372	12.4	
			52.0		48.0	
Insurance Plan Type	НМО	546	17.6	425	14.2	0.001
			56.2		43.8	
	PPO	1,723	55.4	1,714	57.2	
			50.1		49.9	
	Other	823	26.5	848	28.3	
			49.3		50.7	
Oliniaal abarrat						
Clinical characteri	STICS					
Prescription opioid use	Non user	2785	89.5	2756	92.0	0.001
		0.05	50.3	0.1.1	49.7	
	Long-term user	325	10.5	241	8.0	
			57.4		42.6	
Deyo-Charlson Comorbidity Index	mean (±sd)	1.8 (:	±1.3)	1.7 ((±1.2)	0.297

Table 32: Baseline characteristics for specific aim 2

Variable		Non-Adherent in 365 days (n=3,110)		Adhere days (i	P value	
	-	Ν	Col % Row %	Ν	Col % Row %	
Number of pain conditions	0	814	26.2	847	28.3	<0.0001
			49.0		51.0	
	1	1,264	40.6	1,367	45.6	
			48.0		52.0	
	2	1,032	33.2	783	26.1	
			56.9		43.1	
Number of						
comorbid conditions	0	654	21.0	734	24.5	0.004
			47.1		52.9	
	1	1,203	38.7	1,134	37.8	
			51.5		48.5	
	2	1,253	40.3	1,129	37.7	
			52.6		47.4	
Type of index						
maintenance medication	ICS+LABA	1,871	60.2	1317	43.9	<0.0001
			58.7		41.3	
	LAMA+LABA or LAMA+ICS	19	0.6	47	1.6	
			28.8		71.2	
	ICS+LABA+LAMA	203	6.5	395	13.2	
			33.9		66.1	
	ICS or LABA or LAMA	1017	32.7	1238	41.3	
			45.1		54.9	
Mail-order index						
maintenance medication prescription	No	2,172	69.8	1,505	50.2	<0.0001
<u>, </u>			59.1		40.9	
	Yes	938	30.2	1,492	49.8	
			38.6	•	61.4	
Adherence to COPD-	Non-adherent if					
maintenance medications in the pre-index period	PDC < 80%	1,487	47.8	417	13.9	<0.0001
			78.1		21.9	
	Adherent if PDC ≥ 80%	1,623	52.2	2,580	86.1	
			38.6		61.4	1

Variable		Non-Adher days (n=	3,110)	Adherer days (n	=2,997)	P value	
		Ν	Col % Row %	N	Col % Row %		
Supplemental oxygen use in the pre-index period	No	2,609	83.9	2,223	74.2	<0.0001	
· ·			54.0		46.0		
	Yes	501	16.1	774	25.8		
			39.3		60.7		
SABA use in the pre-index period	No	1,427	45.9	1,395	46.5	0.6	
			50.6		49.4		
	Yes	1,683	54.1 51.2	1,602	53.5 48.8		
COPD-related							
severe exacerbations in the pre-index period	0	3,025	97.3	2,891	96.5	0.07	
			51.1		48.9		
	≥1	85	2.7	106	3.5		
			44.5		55.5		
COPD-related moderate exacerbations in the pre-index period	0	2,703	86.9	2,547	85.0	0.03	
	≥1	407	51.5	450	48.5 15.0		
	21	407	13.1 47.5	450	52.5		
Physician characte	ristics						
Pulmonologist visit	No	2,359	75.9	2,119	70.7	<0.0001	
			52.7		47.3		
	No	751	24.1	878	29.3		
			46.1		53.9		
Prior utilization ch	aracteristics						
Total all-cause healthcare expenditures in the pre-index period ^a	mean (±sd) [median ± interquartile range]	7,672.5 (±15,023.7)	[3,847 (5,545)]	7,872.4 (±12,731)	[4,678 (5,393)]	<0.0001	
•	<\$2,844	1153	37.1	791	26.4	<0.0001	
			59.3		40.7		
	\$2,844 - \$9,838	1396	44.9	1625	54.2		
			46.2		53.8		
	>\$9,838	561	18.0	581	19.4		

Variable	Non-Adherent in 365 days (n=3,110)		Adherent in 365 days (n=2,997)		P value
	N	Col % Row %	N	Col % Row %	
		49.1		50.9	

*sd denotes standard deviation; Col, column; HMO, health maintenance organization; PPO, preferred provider organization; ICS, inhaled corticosteroid; LABA, long-acting beta agonist; LAMA, long-acting muscarinic agent; SABA, shortacting beta agonist; and PDC, proportion of days covered. ^a adjusted to 2010 US \$ comorbid chronic conditions (79% vs 75.5%, p<0.001) and comorbid pain conditions (73.8% vs 71.7%, p<0.0001). However, the mean D-CCI scores were not significantly different between adherent and non-adherent COPD patients (1.8 \pm 1.3 vs 1.7 \pm 1.2, p=0.297).

Unadjusted logistic regression analyses:

Table 33 provides the results of the unadjusted logistic regression analysis of the odds of being adherent to COPD maintenance medications in one-year follow-up period for Specific Aim 2. In the unadjusted logistic regression analysis, long-term prescription opioid users were found to have 0.68 times (95% CI 0.52-0.88, p=0.003) significantly lower odds of being adherent to their COPD maintenance medications in the one-year follow-up period as compared to non-opioid users. D-CCI, number of comorbid pain conditions, and total all-cause healthcare expenditures were found significant at p<0.2 and were considered in the multiple logistic regression analysis.

Multiple logistic regression analyses:

Table 34 provides the results of the adjusted multiple logistic regression analysis of the odds of being adherent to COPD maintenance medications in one-year follow-up period, for Specific Aim 2. The overall model was statistically significant (Wald's $x^2=26.3$, df=7, p=0.0004). The significant impact of long-term prescription opioid use in the unadjusted logistic regression analysis persisted in the multiple logistic regression analysis after adjusting for other factors. Long-term prescription opioid users were found to have 0.63 times (95% CI 0.46-0.88, p=0.005) significantly lower odds of being adherent to their COPD maintenance medications in one-year follow-up period as compared to non-opioid users, independent of other predictors. D-CCI, type of index

Table 33: Unadjusted logistic regression predicting the odds of being adherent toCOPD maintenance medications in one-year follow-up

Variable		Point Estimate	95% Confide	ence Interval	P-Value
Sociodemoar	aphic characteristics				
Metropolitan Statistical Area	Rural	Reference			
	Urban	0.79	0.51	1.21	0.28
Region	Northeast	Reference			
	North Central	0.79	0.45	1.39	0.41
	South	0.71	0.40	1.23	0.22
	West	0.55	0.26	1.20	0.22
Insurance Plan Type	Health maintenance organization	Reference			
	Preferred provider organization	0.80	0.46	1.38	0.42
	Other	1.30	0.71	2.40	0.4
Clinical chara					
Prescription opioid use	No use	Reference			
	Long-term	0.68	0.52	0.88	0.003
Deyo- Charlson Comorbidity Index		0.88	0.77	1.00	0.05
Number of pain conditions	0	Reference			
	1	1.05	0.64	1.74	0.84
	2	0.70	0.44	1.12	0.14
Number of comorbid conditions	0	Reference			
	1	0.86	0.49	1.51	0.6
	2	0.79	0.44	1.42	0.43
Type of index maintenance medication	ICS+LABA	Reference	<u></u>		
	LAMA+LABA or LAMA+ICS	2.42	0.56	10.50	0.24
	ICS+LABA+LAMA	2.11	1.13	3.97	0.02
	ICS or LABA or LAMA	2.02	1.31	3.10	0.001
Mail-order index	No	Reference			

Variable		Point Estimate	95% Confide	ence Interval	P-Value
maintenance medication prescription					
	Yes	1.12	0.77	1.63	0.56
Physician char	acteristics				
Type of physician visited in the pre-index period	Other	Reference			
	Pulmonologist	1.28	0.83	1.98	0.27
Prior utilization	n characteristics				
Total all-cause healthcare expenditures in the pre- index period ^a	<\$2,844	Reference			
•	\$2,844 - \$9,838	1.32	0.83	2.11	0.19
	>\$9,838	0.87	0.52	1.46	0.6

* ICS denotes inhaled corticosteroid; LABA, long-acting beta agonist; LAMA, long-acting muscarinic agent; SABA, short-acting beta agonist; and PDC, proportion of days covered. a adjusted to 2010 US \$

Table 34: Multiple logistic regression predicting the odds of being adherent to
COPD maintenance medications in one-year follow-up

V	/ariable	Point Estimate	95% Confide	nce Interval	P-Value
Clinical charac	teristics				
Prescription opioid use	No use	Reference			
	Long-term use	0.63	0.46	0.88	0.005
Deyo- Charlson Comorbidity Index		0.89	0.76	1.04	0.14
Type of index maintenance medication	ICS+LABA	Reference			
	LAMA+LABA or LAMA+ICS	3.33	0.68	16.42	0.14
	ICS+LABA+LAMA	2.37	1.21	4.61	0.01
	ICS or LABA or LAMA	2.18	1.39	3.42	0.0007
Prior utilization	n characteristics				
Total all-cause healthcare expenditures in the pre- index period ^a	<\$2,844	Reference			
•	\$2,844 - \$9,838	2.03	1.18	3.5	0.01
	>\$9,838	1.64	0.85	3.16	0.14

* ICS denotes inhaled corticosteroid; LABA, long-acting beta agonist; LAMA, longacting muscarinic agent; SABA, short-acting beta agonist; and PDC, proportion of a adjusted to 2010 US \$

maintenance medication, and total all-cause healthcare expenditures were retained in the backwards elimination model at p<0.20.

COPD patients having an index fill of ICS+LABA+LAMA combination had 2.37 times (95% CI 1.21-4.61, p=0.01) higher odds of being adherent to COPD maintenance medications compared to having an index fill of ICS+LABA combination, independent of other factors. Similarly, patients having an index fill of either ICS or LABA or LAMA alone had 2.18 times (95% CI 1.39-3.42, p=0.0007) significantly higher odds of being adherent to COPD maintenance medications compared to patients having an index fill of ICS+LABA combination, independent of other factors. Having pre-index all cause healthcare expenditures between \$2,844 to \$9,838 was associated with 2.0 times (95% CI 1.18-3.5, p=0.01) higher odds of being adherent to COPD maintenance medications compared to having pre-index all cause healthcare expenditures less than \$2,844, independent of other factors.

Results for Specific Aim 3

Specific Aim 3 was to examine the impact of long-term prescription opioid use (≥90-day supply in a one-year period) compared to no prescription opioid use on COPD exacerbations among a real-world, large sample of COPD patients after adjusting for other confounders.

Results for Specific Aim 3 A

Baseline characteristics as per Specific Aim 3A:

Specific Aim 3A was to examine the impact of long-term prescription opioid use (≥90-day supply in a one-year period) compared to no-opioid use on the number of severe COPD exacerbations among a real-world, large sample of COPD patients after

Table 35: Baseline characteristics for Specific Aim 3A

Variable		Severe COPD exacerbations		ere COPD ons (n=5,842)		e COPD ions (n=265)	P value
		mean (±sd)	N	Col % Row %	Ν	Col % Row %	
Sociodemograp	hic characteristics						
Sex	Male	0.05 (±0.28)	2,700	46.2	104	39.2	0.03
				96.3		3.7	
	Female	0.06 (±0.28)	3,142	53.8	161	60.8	
				95.1		4.9	
Age	mean (±sd)		57.1 ye	ars (±5.4)	58.6 ye	ars (±4.7)	<0.0001
	40 – 49 years	0.02 (±0.15)	643	11.0	11	4.2	<0.0001
	-	, , , , , , , , , , , , , , , , , , , ,		98.3		1.7	
	50 – 59 years	0.05 (±0.28)	2,719	46.5	105	39.6	
				96.3		3.7	
	≥60 years	0.07 (±0.3)	2,480	42.5	149	56.2	
				94.3		5.7	
Metropolitan Statistical Area	Urban	0.05 (±0.28)	4,648	79.6	201	75.8	0.132
				95.9		4.1	
	Rural	0.06 (±0.27)	1,166	20.0	63	23.8	
				94.9		5.1	
Region	Northeast	0.06 (±0.28)	918	15.7	44	16.6	0.032
				95.4		4.6	
	North Central	0.06 (±0.29)	2,197	37.6	119	44.9	
				94.9		5.1	
	South	0.05 (±0.27)	1,942	33.2	79	29.8	
				96.1		3.9	
	West	0.03 (±0.28)	753	12.9	22	8.3	
				97.2		2.8	
Insurance Plan Type	НМО	0.04 (±0.28)	936	16.0	35	13.2	0.41
				96.4		3.6	
	PPO	0.05 (±0.28)	3,280	56.1	157	59.2	

Variable		Severe COPD exacerbations		ere COPD ons (n=5,842)		e COPD ions (n=265)	P value
		mean (±sd)	N	Col % Row %	Ν	Col % Row %	
				95.4		4.6	
	Other	0.06 (±0.29)	1,601	27.4	70	26.4	
			,	95.8		4.2	
Clinical characte	eristics						
Prescription opioid use	No use	0.05 (±0.26)	5,321	91.1	220	83.0	<0.0001
				96.0		4.0	
	Long-term use	0.11 (±0.41)	521	8.9	45	17.0	
				92.0		8.0	
Deyo-Charlson Comorbidity Index	mean (±sd)		1.7	(±1.2)	2.3	(±1.4)	<0.0001
Number of pain conditions	0	0.01 (±0.08)	1,650	28.2	11	4.2	<0.0001
				99.3		0.7	
	1	0.06 (±0.29)	2,488	42.6	143	54.0	
				94.6		5.4	
	2	0.08 (±0.35)	1,704	29.2	111	41.9	
				93.9		6.1	
Number of comorbid conditions	0	0.03 (±0.19)	1,351	23.1	37	14.0	<0.0001
				97.3		2.7	
	1	0.03 (±0.20)	2,272	38.9	65	24.5	
				97.2		2.8	
	2	0.09 (±0.36)	2,219	38.0	163	61.5	
				93.2		6.8	
Type of index maintenance medication	ICS+LABA	0.04 (±0.22)	3,069	52.5	119	44.9	0.08
				96.3		3.7	

	Variable	Severe COPD exacerbations		ere COPD ons (n=5,842)		e COPD ions (n=265)	P value
		mean (±sd)	N	Col % Row %	Ν	Col % Row %	
	LAMA+LABA or LAMA+ICS	0.09 (±0.38)	62	1.1	4	1.5	
				93.9		6.1	
	ICS+LABA+LAMA	0.07 (±0.32)	565	9.7	33	12.5	
				94.5		5.5	
	ICS or LABA or LAMA	0.06 (±0.33)	2,146	36.7	109	41.1	
				95.2		4.8	
Mail-order index maintenance	No		2.520	60.5		52.0	
medication prescription	No	0.05 (±0.28)	3,536		141	53.2	0.02
				96.2		3.8	
	Yes	0.06 (±0.27)	2,306	39.5	124	46.8	
				94.9		5.1	
Adherence to COPD- maintenance medications in the pre-index period	Non-adherent if PDC < 80%	0.04 (±0.24)	1,831	31.3	73	27.5	0.19
•				96.2		3.8	
	Adherent if PDC ≥ 80%	0.06 (±0.29)	4,011	68.7	192	72.5	
				95.4		4.6	
COPD coverity in	diastoro						
COPD severity in Supplemental oxygen use in the pre-index period	No	0.03 (±0.17)	4,722	80.8	110	41.5	<0.0001
•				97.7		2.3	
	Yes	0.16 (±0.49)	1,120	19.2	155	58.5	
		· · · · ·		87.8		12.2	

Variable		Severe COPD exacerbations		ere COPD ons (n=5,842)	Severe COPD exacerbations (n=265)		P value
	1	mean (±sd)	N	Col % Row %	Ν	Col % Row %	
SABA use in the pre-index period	No	0.03 (±0.23)	2,741	46.9	81	30.6	<0.0001
· · ·				97.1		2.9	
	Yes	0.07 (±0.32)	3,101	53.1	184	69.4	
				94.4		5.6	
COPD-related severe exacerbations in the pre-index	0	0.05 (±0.26)	5,686	97.3	230	86.8	0.0001
period				96.1		3.9	<0.0001
	≥1	0.26 (±0.63)	156	2.7	35	13.2	
	<u> </u>	0.20 (±0.03)	130	81.7		18.3	
COPD-related moderate exacerbations in the pre-index period	0	0.04 (±0.23)	5,063	86.7	187	70.6	<0.0001
				96.4		3.6	
	≥1	0.13 (±0.48)	779	13.3	78	29.4	
				90.9		9.1	
Physician charac	toristics						
Pulmonologist visit in the pre- index period	No	0.05 (±0.26)	4,312	73.8	166	62.6	<0.0001
				96.3		3.7	
	Yes	0.08 (±0.33)	1,530	26.2	99	37.4	
				93.9		6.1	
Prior utilization c	haracteristics						

	Variable	Severe COPD exacerbations	No sever exacerbatior		Severe COPD exacerbations (n=265)		P value
		mean (±sd)	N	Col % Row %	N	Col % Row %	
Total all-cause healthcare expenditures in the pre-index period ^a	mean (±sd)		7,538.6 (±13,592.2)		12,884.8 (±19,569.2)		<0.0001
•	<\$2,844	0.03 (±0.21)	1,891	32.4	53	20.0	< 0.0001
				97.3		2.7	
	\$2,844 - \$9,838	0.05 (±0.25)	2,893	49.5	128	48.3	
				95.8		4.2	
	>\$9,838	0.1 (±0.40)	1,058	18.1	84	31.7	
				92.6		7.4	

*sd denotes standard deviation; Col, column; HMO, health maintenance organization; PPO, preferred provider organization; ICS, inhaled corticosteroid; LABA, long-acting beta agonist; LAMA, long-acting muscarinic agent; SABA, short-acting beta agonist; and PDC, proportion of days covered.

^a adjusted to 2010 US \$

adjusting for other confounders. Table 35 provides baseline characteristics of the included sample of long-term and non-opioid users among COPD patients as per evidence of severe COPD exacerbation in a one-year follow-up period. Overall, 4.3% of the included sample of COPD patients experienced a severe COPD exacerbation in a one-year follow-up period after the index date. A higher percentage of long-term prescription opioid users experienced a severe COPD exacerbation in a one-year follow-up period compared to non-opioid users (8% vs 4%, p<0.0001). Also, long-term prescription opioid users had a higher mean number of severe COPD exacerbation compared to non-opioid users $(0.11 \pm 0.41 \text{ vs } 0.05 \pm 0.26, \text{ p} < 0.001)$. A greater proportion of females, patients older than 50 years, patients having a mail-order index maintenance medication, patients who used supplemental oxygen, had previous SABA use, had pre-index severe or moderate exacerbations, had visited a pulmonologist, and had higher baseline healthcare costs experienced a severe COPD exacerbation in oneyear follow-up period. A higher proportion of patients who had comorbid conditions experienced a severe COPD exacerbation in one-year follow-up period than patients who did not have comorbid conditions. Patients who experienced a severe COPD exacerbation in a one-year follow-up period had higher mean D-CCI scores compared to patients who did not experience a severe COPD exacerbation $(2.3 \pm 1.4 \text{ vs } 1.7 \pm 1.2)$ p<0.0001). A greater percentage of patients who had comorbid chronic (p>0.0001) or comorbid pain conditions (p>0.0001) experienced a severe COPD exacerbation in oneyear follow-up period compared to patients who did not have comorbid chronic or pain conditions.

Negative binomial regression: Number of severe COPD exacerbation in one-year follow-up:

In the univariate negative binomial regression analysis, long-term prescription opioid users were found to have 2.0 times (95% CI, 1.45-2.76, p<0.0001) significantly higher rate of severe COPD exacerbations in one-year follow-up period. Age group, sex, metropolitan statistical area, region of residence, comorbid pain and chronic conditions, type of index COPD maintenance medication, mail-order index maintenance medication, pulmonologist visit, D-CCI, cost quartile, supplemental oxygen use, SABA use, and pre-index moderate and severe exacerbation variables were found significantly associated with the number of severe COPD exacerbation in one-year follow up period at p<0.2 and were included in the final adjusted multiple negative binomial regression analysis.

Table 36 presents the results of the final adjusted multiple negative binomial regression analysis model. After adjusting for other covariates, long-term prescription opioid use was not significantly associated with number of severe COPD exacerbations in one-year follow-up period (incidence rate ratio 1.32, 95% Cl 0.93-1.87, p=0.12). Patients \geq 60 years old had 2.06 times (95% Cl 1.10-3.85, p=0.02) higher rate of severe COPD exacerbations compared to patients who were 40-49 years old. Patients residing in the west had 0.57 times (95% Cl 0.34-0.96, p=0.04) lower rate of severe COPD exacerbations compared to patients who resided in the northeast. Patients having 1 or \geq 2 number of comorbid pain conditions had 6.0 times (95% Cl 3.13-11.47, p<0.0001) and 6.09 times (95% Cl 3.13-11.85, p<0.0001) higher rate of severe COPD exacerbations compared to patients who did not have any comorbid pain conditions,

Table 36: Adjusted negative binomial regression: Number of severe COPDexacerbation in one-year follow-up

V	ariable	Incidence Rate Ratios	95% Confide	nce Interval	P value	
Sociodemogra characteristic						
Sex	Male	Reference				
	Female	1.13	0.87	1.45	0.36	
Age	40 – 49 years	Reference				
0	50 – 59 years	1.48	0.79	2.79	0.22	
	≥60 years	2.06	1.10	3.85	0.02	
Metropolitan Statistical Area	Rural	Reference				
/	Urban	0.85	0.64	1.13	0.26	
		0.00	0.01		0.20	
Region	Northeast	Reference		1		
	North Central	0.95	0.67	1.34	0.76	
	South	0.78	0.54	1.14	0.21	
	West	0.57	0.34	0.96	0.04	
Clinical chara	cteristics					
Prescription opioid use	No use	Reference				
	Long-term use	1.32	0.93	1.87	0.12	
Deyo- Charlson Comorbidity Index		1.04	0.95	1.14	0.43	
Number of pain conditions	0	Reference				
Conditions	1	6.00	3.13	11.47	<0.0001	
	2	6.09	3.13	11.85	< 0.0001	
Number of comorbid	0	Defenses				
conditions	4	Reference	0.02	1.40	0.01	
	1 2	0.95	0.63	1.43	0.81	
	2	1.65	1.10	2.47	0.02	
Type of index maintenance medication	ICS+LABA	Reference				
	LAMA+LABA or					
	LAMA+ICS	1.04	0.38	2.85	0.94	
	ICS+LABA+LAMA	1.02	0.69	1.51	0.92	
	ICS or LABA or LAMA	1.14	0.87	1.48	0.34	

Va	ariable	Incidence Rate Ratios	95% Confiden	ce Interval	P value	
COPD severity	/ indicators					
Supplemental						
oxygen use in						
the pre-index	No					
period		Reference				
	Yes	3.55	2.71	4.65	<.0001	
SABA use in						
the pre-index	No					
period		Reference				
	Yes	1.50	1.15	1.97	0.003	
COPD-related						
severe						
exacerbations	0					
in the pre-						
index period		Reference				
•	≥1	2.21	1.45	3.37	0.0002	
COPD-related						
moderate						
exacerbations	0					
in the pre-						
index period		Reference				
	≥1	1.45	1.09	1.94	0.01	
Physician cha	racteristics					
Pulmonologist						
visit in the	No					
pre-index						
period		Reference				
	Yes	1.09	0.84	1.43	0.51	
					ļ	
	n characteristics					
Total all-						
cause						
healthcare						
expenditures						
in the pre-	#0.044	Defense				
index period ^a	<\$2,844	Reference	0.57		0.40	
	\$2,844 - \$9,838	0.79	0.57	1.11	0.18	
	>\$9,838	0.56	0.37	0.87	0.009	

* ICS denotes inhaled corticosteroid; LABA, long-acting beta agonist; LAMA, long-acting muscarinic agent; SABA, short-acting beta agonist; and PDC, proportion of a adjusted to 2010 US \$

respectively. Patients having ≥ 2 number of comorbid chronic conditions had 1.6 times (95% CI 1.10-2.47, p=0.02) higher rate of severe COPD exacerbations compared to patients who did not have any comorbid chronic conditions. Patients who had supplemental oxygen use had 3.55 times (95% CI 2.71-4.65, p<0.0001) higher rate of severe COPD exacerbations as patients who did not have any supplemental oxygen use in the pre-index period. Patients who had SABA use had 1.5 times (95% CI 1.15-1.97, p=0.003) higher rate of severe COPD exacerbations as patients who did not have any SABA use in the pre-index period. Patients who had high pre-index total healthcare costs (>\$9,838) had 0.56 times (95% CI 0.37-0.8, p=0.009) lower rate of severe COPD exacerbations as patients who lowest pre-index total healthcare costs (<\$2,844) in the pre-index period. Presence of pre-index COPD exacerbation either severe or moderate was associated with 2.21 times (95% CI 1.45-3.37, p=0.0002) and 1.45 times (95% CI 1.09-1.94, p=0.01) significantly higher rate of severe COPD exacerbations in the oneyear follow-up compared to not having a pre-index severe or moderate COPD exacerbation, respectively.

Results for Specific Aim 3B

Baseline characteristics as per Specific Aim 3B:

Specific Aim 3B was to examine the impact of long-term prescription opioid use (≥90-day supply in a one-year period) compared to no prescription opioid use on the number of moderate and severe COPD exacerbations among a real-world, large sample of COPD patients after adjusting for other confounders. Table 37 provides baseline characteristics of the included sample of long-term and non-opioid users among COPD patients according to total moderate and severe COPD exacerbations in

Table 37: Baseline characteristics for specific aim 3B

	Variable	Total COPD exacerbations		xacerbations 4,881)	Total COPD exacerbations (n=1,226)		P value
		mean (±sd)	N	Col % Row %	Ν	Col % Row %	
Sociodemograp	hic characteristics			/0		/0	
Sex	Male	0.29 (±0.84)	2,296	47.0	508	41.4	0.0004
			_,	81.9		18.1	
	Female	0.35 (±0.87)	2,585	53.0	718	58.6	
			,	78.3		21.7	
Age	mean (±sd)		57 0 ve	ars (±5.5)	57 9 ve	ars (±5.0)	<0.0001
	40 – 49 years	0.20 (±0.55)	559	11.5	95	7.7	< 0.0001
				85.5		14.5	
	50 – 59 years	0.32 (±0.86)	2,270	46.5	554	45.2	
			,	80.4		19.6	
	≥60 years	0.36 (±0.90)	2,052	42.0	577	47.1	
				78.1		21.9	
Metropolitan Statistical Area	Urban	0.32 (±0.86)	3,896	79.8	953	77.7	0.14
				80.3		19.7	
	Rural	0.34 (±0.85)	964	19.8	265	21.6	
				78.4		21.6	
Region	Northeast	0.32 (±0.88)	779	16.0	183	14.9	0.08
				81.0		19.0	
	North Central	0.35 (0.89)	1,824	37.4	492	40.1	
				78.8		21.2	
	South	0.32 (±0.87)	1,612	33.0	409	33.4	
				79.8		20.2	
	West	0.30 (±0.66)	642	13.2	133	10.8	
				82.8		17.2	
Insurance Plan Type	НМО	0.32 (±0.85)	780	16.0	191	15.6	0.67
				80.3		19.7	
	PPO	0.32 (±0.82)	2,735	56.0	702	57.3	

Variable		Total COPD exacerbations		No COPD exacerbations (n=4,881)		exacerbations 1,226)	P value
		mean (±sd)	N	Col % Row	N	Col % Row	
				%		%	
				79.6		20.4	
	Other	0.33 (±0.86)	1,347	27.6	324	26.4	
				80.6		19.4	
Clinical characte	eristics						
Prescription opioid use	No use	0.31 (±0.82)	4,465	91.5	1,076	87.8	<0.0001
•				80.6		19.4	
	Long-term use	0.50 (±1.14)	416	8.5	150	12.2	
				73.5		26.5	
Deyo-Charlson Comorbidity Index	mean (±sd)		1.7 (±1.2)	1.9 (±1.3)		0.0002
Number of pain conditions	0	0.16 (±0.50)	1,461.00	29.9	200	16.3	<0.0001
				88.0		12.0	
	1	0.36 (±0.85)	2,033.00	41.7	598	48.8	
				77.3		22.7	
	2	0.43 (±1.07)	1,387.00	28.4	428	34.9	
				76.4		23.6	
Number of comorbid conditions	0	0.24 (±0.70)	1,166	23.9	222	18.1	<0.0001
				84.0		16.0	
	1	0.27 (±0.73)	1,917	39.3	420	34.3	
				82.0		18.0	
	2	0.42 (±1.02)	1,798	36.8	584	47.6	
				75.5		24.5	
Type of index maintenance medication	ICS+LABA	0.28 (±0.71)	2,592	53.1	596	48.6	0.03

	Variable			No COPD exacerbations (n=4,881)		exacerbations 1,226)	P value
		mean (±sd)	N	Col % Row %	N Col % Row %		
				81.3		18.7	
	LAMA+LABA or LAMA+ICS	0.53 (±1.08)	49	1.0	17	1.4	
				74.2		25.8	
	ICS+LABA+LAMA	0.42 (±1.09)	466	9.5	132	10.8	
				77.9		22.1	
	ICS or LABA or LAMA	0.36 (±0.95)	1,774	36.3	481	39.2	
				78.7		21.3	
Mail-order index maintenance medication prescription	No	0.33 (±0.88)	2,949	60.4	728	59.4	0.51
				80.2		19.8	
	Yes	0.32 (±0.80)	1,932	39.6	498	40.6	
				79.5		20.5	
Adherence to COPD- maintenance medications in the pre-index period	Non-adherent if PDC < 80%	0.27 (±0.70)	1,547	31.7	357	29.1	0.08
period				81.3		18.8	
	Adherent if PDC ≥ 80%	0.35 (±0.91)	3,334	68.3	869	70.9	
	0078			79.3		20.7	
COPD severity in		0.00 (+0.50)	4.440	04.0	700	50.7	0.0001
Supplemental oxygen use in the pre-index period	No	0.20 (±0.58)	4,112	84.2	720	58.7	<0.0001
			1	85.1		14.9	

١	/ariable	Total COPD exacerbations	No COPD exacerbations (n=4,881)		Total COPD exacerbations (n=1,226)		P value
		mean (±sd)	N	Col % Row %	N	Col % Row %	
	Yes	0.78 (±1.40)	769	15.8	506	41.3	
				60.3		39.7	
SABA use in the pre-index period	No	0.22 (±0.65)	2,401	49.2	421	34.3	<0.0001
				85.1		14.9	
	Yes	0.41 (±0.99)	2,480	50.8	805	65.7	
				75.5		24.5	
COPD-related severe exacerbations in the pre-index period	0	0.31 (±0.80)	4,775	97.8	1,141	93.1	<0.0001
				80.7		19.3	
	≥1	1.20 (±1.77)	106	2.2	85	6.9	
				55.5		44.5	
COPD-related moderate exacerbations in the pre-index period	0	0.22 (±0.60)	4,396	90.1	854	69.7	<0.0001
P 0.10 G				83.7		16.3	
	≥1	0.94 (±1.60)	485	9.9	372	30.3	
				56.6		43.4	
Physician charac	teristics						
Pulmonologist visit in the pre- index period	No	0.29 (±0.80)	3,625	74.3	853	69.6	0.0009
				81.0		19.0	
	Yes	0.41 (±0.98)	1,256	25.7	373	30.4	
				77.1		22.9	

	Variable	Total COPD exacerbations	No COPD ex (n=4,		Total COPD exacerbations (n=1,226)		P value
		mean (±sd)	N	Col % Row %	N	Col % Row %	
Prior utilization	characteristics						
Total all-cause healthcare expenditures in the pre-index period ^a	mean (±sd)		7,397.7 (±13,872.3)		9,255.1 (±14,139.3)		<0.0001
•	<\$2,844	0.22 (±0.57)	1,618	33.1	326	26.6	<0.0001
				83.2		16.8	
	\$2,844 - \$9,838	0.31 (±0.84)	2,437	49.9	584	47.6	
				80.7		19.3	
	>\$9,838	0.54 (±1.19)	826	16.9	316	25.8	
				72.3		27.7	

*sd denotes standard deviation; Col, column; HMO, health maintenance organization; PPO, preferred provider organization; ICS, inhaled corticosteroid; LABA, long-acting beta agonist; LAMA, long-acting muscarinic agent; SABA, short-acting beta agonist; and PDC, proportion of days covered. ^a adjusted to 2010 US \$ a one-year follow-up period. Overall, 20.1% of the included sample of COPD patients experienced either a moderate or severe COPD exacerbation in a one-year follow-up period after the index date. A higher percentage of long-term prescription opioid users experienced a moderate or severe COPD exacerbation in a one-year follow-up compared to non-opioid users (26.5% vs 19.4%, p<0.0001). Long-term prescription opioid users had a higher mean number of moderate and severe COPD exacerbations compared to non-opioid users $(0.50\pm1.14 \text{ vs } 0.31\pm0.82, p=0.0003)$. A higher percentage of females, patients older than 50 years, patients who used supplemental oxygen, had previous SABA use, had pre-index severe or moderate exacerbations, had visited a pulmonologist, and had higher baseline healthcare costs experienced a moderate or severe COPD exacerbation in one-year follow-up period. A higher proportion of patients who had comorbid conditions experienced a moderate or severe COPD exacerbation in one-year follow-up period than patients who did not have comorbid conditions. Patients who experienced a moderate or severe COPD exacerbation in a one-year follow-up had higher mean D-CCI scores compared to patients who did not experience a moderate or severe COPD exacerbation $(1.9 \pm 1.3 \text{ vs } 1.7 \pm 1.2, \text{ p}=0.0002)$. A higher percentage of patients who had comorbid chronic (p>0.0001) or comorbid pain conditions (p>0.0001) experienced a moderate or severe COPD exacerbation in one-year follow-up period compared to patients who did not have comorbid chronic or pain conditions.

Negative binomial regression: Number of moderate and severe COPD

exacerbations in one-year follow-up

In the univariate negative binomial regression analysis, long-term prescription opioid users were found to have 1.36 times (95% CI, 1.15-1.62, p=0.0004) higher

number of moderate and severe COPD exacerbations in one-year follow-up period. Age group, sex, metropolitan statistical area, comorbid pain and chronic conditions, type of index COPD maintenance medication, pulmonologist visit, D-CCI, cost quartile, preindex maintenance medication adherence, supplemental oxygen use, SABA use, and pre-index moderate and severe exacerbation variables were found statistically significantly associated with number of moderate and severe COPD exacerbation in one-year follow up at p<0.2. These variables were included in the final adjusted multiple negative binomial regression analysis.

Table 38 presents the results of the final multiple negative binomial regression analysis model. After adjusting for other covariates, long-term prescription opioid use was not significantly associated with number of moderate and severe COPD exacerbations in one-year follow-up period (incidence rate ratio 1.12, 95% CI 0.93-1.35, p=0.23). Patients having 1 or \geq 2 number of comorbid pain conditions had 1.53 times (95% CI 1.30-1.81, p<0.0001) and 1.51 times (95% CI 1.26-1.82, p<0.0001) higher rate of moderate and severe COPD exacerbations as patients who did not have any comorbid pain conditions, respectively. Patients having ≥ 2 number of comorbid chronic conditions had 1.34 times (95% CI 1.12-1.60, p=0.002) higher rate of moderate and severe COPD exacerbations as patients who did not have any comorbid chronic conditions. Patients who had supplemental oxygen use had 2.12 times (95% CI 1.87-2.41, p<0.0001) higher rate of moderate and severe COPD exacerbations as patients who did not have any supplemental oxygen use in the pre-index period. Patients who had SABA use had 1.35 times (95% CI 1.20-1.53, p<0.0001) higher rate of moderate and severe COPD exacerbations as patients who did not have any SABA use in the

Table 38: Adjusted negative binomial regression: Number of moderate and severeCOPD exacerbation in one-year follow-up

V	ariable	Incidence Rate Ratios	Confiden	ce Interval	P value
Sociodemogra characteristics					
Sex	Male	Reference			
	Female	1.09	0.97	1.23	0.15
Age	40 – 49 years	Reference			
5	50 – 59 years	1.14	0.91	1.42	0.25
	≥60 years	1.22	0.98	1.53	0.08
Metropolitan Statistical Area	Rural	Reference			
	Urban	0.96	0.84	1.11	0.6
Clinical charac					
Prescription opioid use	No use	Reference			
•	Long-term use	1.12	0.93	1.35	0.23
Deyo- Charlson Comorbidity Index		0.97	0.92	1.02	0.2
Number of pain conditions	0	Reference			
	1	1.53	1.30	1.81	<.0001
	2	1.51	1.26	1.82	<.0001
Number of comorbid conditions	0	Reference			
	1	1.07	0.91	1.27	0.4
	2	1.34	1.12	1.60	0.002
Type of index maintenance medication	ICS+LABA	Reference			
	LAMA+LABA or LAMA+ICS	1.06	0.65	1.73	0.8
	ICS+LABA+LAMA	0.98	0.81	1.19	0.83
	ICS or LABA or LAMA	1.09	0.96	1.23	0.17
COPD severity	/ indicators				
Supplemental oxygen use in the pre-index period	No	Reference			

V	ariable	Incidence Rate Ratios	Confiden	ce Interval	P value
	Yes	2.12	1.87	2.41	<.0001
SABA use in the pre-index period	No	Reference			
•	Yes	1.35	1.20	1.53	<.0001
COPD-related severe exacerbations in the pre- index period	0	Reference			
	≥1	1.21	0.95	1.55	0.13
COPD-related moderate exacerbations in the pre- index period	0	Reference			
····· F ···· F	≥1	2.03	1.78	2.32	<.0001
Physician cha	racteristics				
Pulmonologist visit in the pre- index period	No	Reference			
•	Yes	0.94	0.83	1.07	0.36
Prior utilization	n characteristics				
Total all-cause healthcare expenditures in the pre- index period ^a	<\$2,844	Reference			
	\$2,844 - \$9,838	0.85	0.73	0.98	0.02
	>\$9,838	0.82	0.68	0.99	0.04

* ICS denotes inhaled corticosteroid; LABA, long-acting beta agonist; LAMA, longacting muscarinic agent; SABA, short-acting beta agonist; and PDC, proportion of days covered.

^a adjusted to 2010 US \$

pre-index period. Patients who had moderate (\$2,844-\$9,838) and high (>\$9,838) preindex total healthcare costs had 0.85 times (95% CI 0.73-0.98, p=0.02) and 0.82 times (95% CI 0.68-0.99, p=0.04) lower rate of moderate and severe COPD exacerbations as patients who lowest pre-index total healthcare costs (<\$2,844) in the pre-index period. Patients who had pre-index moderate COPD exacerbation were associated with 2.03 times (95% CI 1.78-2.32, p<0.0001) higher rate of moderate and severe COPD exacerbations in the one-year follow-up compared to patients not having a pre-index moderate COPD exacerbation.

Results for Specific Aim 4

Specific Aim 4 was to examine the impact of long-term prescription opioid use $(\geq 90\text{-}day \text{ supply in a one-year period})$ compared to no prescription opioid use on allcause total healthcare costs (prescription medication and medical costs) among a realworld, large sample of COPD patients after adjusting for other confounders. Table 40 provides the unadjusted all-cause total healthcare costs for long-term prescription opioid users and non-opioid users. The unadjusted costs for long-term prescription opioid users were significantly higher than non-opioid users (p<0.0001).

In the unadjusted univariate regression analysis type of health insurance plan, number of comorbid pain and chronic conditions, type of index maintenance medication, whether mail-order index maintenance medication, D-CCI, visit to a pulmonologist, cost quartiles, age groups, pre-index adherence to maintenance medications, supplemental oxygen use, SABA use, and history of severe and moderate COPD exacerbations were found significant at p<0.20 and were included in the multiple regression analysis.

Table 39: Unadjusted all-cause total healthcare costs for long-term prescriptionopioid users and non-opioid users

	Non-opioid user	Long-term opioid	p-value
		user	
Mean (SD)	14,686.09	37,402.29	<0.0001
	(21,229.42)	(40,537.40)	
Median (IQR)	9,794	24,501.50	<0.0001
	(10,283)	(28,956)	

Generalized linear model with a gamma distribution and a log link function was used to calculate adjusted all-cause total healthcare costs for long-term prescription opioid users and non-opioid users. The adjusted all-cause total healthcare costs were significantly higher for long-term prescription opioid users compared to non-opioid users [23,996 (1,106.22) vs 13,947 (512.67), p<0.0001]. Results of adjusted regression analysis for all-cause total healthcare costs are presented in Table 41.

Table 40: Adjusted all-cause total healthcare costs using generalized linear modelwith a gamma distribution and log-link function

Variable Sociodemographic characteristics		Coefficient	Confidence Interval		P value
Sex	Male	Reference			
	Female				
Age	40 – 49 years	Reference			
	50 – 59 years	0.11	0.0468	0.1687	0.0005
	≥60 years	0.14	0.0760	0.2011	<0.0001
Metropolitan Statistical Area	Rural	Reference			
	Urban				
Insurance Plan Type	НМО	Reference			
	PPO	-0.01	-0.0650	0.0375	0.60
	Other	0.06	0.0053	0.1191	0.03
Clinical chara		Deferrers			
Prescription opioid use	No use	Reference			
	Long-term use	0.57	0.5034	0.6345	<0 0001
Deyo- Charlson Comorbidity Index		0.11	0.0926	0.1285	<0.0001
Number of pain conditions	0	Reference			
	1	0.18	0.1365	0.2261	< 0.0001
	2	0.32	0.2646	0.3679	<0.0001
Number of comorbid conditions	0	Reference			
	1	0.15	0.1049	0.2003	< 0.0001
	2	0.40	0.3444	0.4540	<0.0001
Type of index maintenance medication	ICS+LABA	Reference			
	LAMA+LABA or LAMA+ICS	0.24	0.0621	0.4104	0.008
	ICS+LABA+LAMA	0.01	-0.0580	0.0680	0.88
	ICS or LABA or LAMA	-0.00	-0.0397	0.0379	0.96

Variable		Coefficient	Confidence Interval		P value
Mail-order index maintenance medication	No	Reference			
medication	Yes	0.10	0.0605	0.1376	<0.0001
COPD severity	indicators				
Supplemental oxygen use in the pre-index period	No	Reference			
	Yes	0.31	0.27	0.36	<0.0001
Adherent to maintenance medication in the pre-index period	No	Reference			
	Yes	0.07	0.03	0.11	0.0006
SABA use in the pre-index period	No	Reference			
	Yes	0.05	0.01	0.08	0.009
COPD-related severe exacerbations in the pre- index period	0	Reference			
index period	≥1	-0.26	-0.37	-0.15	<0.0001
COPD-related moderate exacerbations in the pre- index period	0	Reference			
	≥1	0.02	-0.03	0.08	0.38
Physician abo					
Physician char Pulmonologist visit in the pre- index period	No	Reference			
	Yes	0.04	-0.0032	0.0807	0.07
	n characteristics				
Total all-cause healthcare expenditures in the pre- index period ^a	<\$2,844	Reference			
	\$2,844 - \$9,838	0.33	0.2885	0.3728	<0.0001

Variable	Coefficient	Confidence Interval		P value
>\$9,838	0.76	0.698	0.8180	<0.0001

* HMO denotes health maintenance organization; PPO, preferred provider organization; ICS, inhaled corticosteroid; LABA, long-acting beta agonist; LAMA, long-acting muscarinic agent; SABA, short-acting beta agonist; and PDC, proportion of days covered.

^a adjusted to 2010 US \$

CHAPTER 5 DISCUSSION

This chapter provides a discussion on the findings of the study. Results of the study are discussed as per the specific aims. The discussion of the results is followed by the limitations of the study along with proposals on how future studies should be conducted based on the strengths and limitations of the current study. Finally, the implications and final conclusions of the study results are discussed.

Discussion for Specific Aim 1

Prescription opioid users and non-users differed significantly in terms of their baseline characteristics prior to matching. The mean age of prescription opioid users was significantly lower than non-opioid users (Table 13), and a greater percentage of prescription opioid users were females. The variables sex, age, metropolitan statistical area (MSA), region, Deyo-Charlson Comorbidity Index (D-CCI), number of pain and chronic comorbid conditions, mail-order index maintenance medications, adherence to maintenance medications in the pre-index period, supplemental oxygen use, moderate COPD exacerbations, pulmonologist visits in the pre-index period and pre-index total all-cause healthcare expenditures were all statistically significantly different between prescription opioid users and non-users prior to matching (Table 13).

After matching, the matched variables, age, sex, adherence to maintenance medications in the pre-index period, supplemental oxygen use, SABA use, moderate and severe COPD exacerbations, and comorbid asthma were similar between prescription opioid users and non-users (Table 14). Most of the baseline characteristics were equally distributed between matched groups of prescription opioid users and nonusers among COPD patients. However, there were certain important difference between

prescription opioid users and non-users after matching. The significant difference between prescription opioid users and non-users in terms of the number of comorbid conditions persisted after matching. The mean D-CCI score among prescription opioid users was significantly higher compared to non-opioid users (2.0 ± 1.5 vs 1.7 ± 1.2 , p<0.0001) after matching (Table 14). Higher mean D-CCI score signifies that prescription opioid users had higher number of comorbid conditions at baseline compared to non-opioid users. Similarly, a significantly higher percentage of prescription opioid users had ≥ 1 comorbid chronic condition (82% vs 76.3%, p<0.0001) and ≥1 comorbid pain condition (86% vs 70.7%, p<0.0001) compared to non-opioid users. Higher mean number of comorbid conditions may signify that prescription opioid users were overall more complex patients and these differences may translate into poor health care outcomes such as higher healthcare resource utilization and its associated costs, and higher mortality as compared to non-opioid users. Significantly different variables between prescription opioid users and non-users, after matching, were considered in the multiple regression models for all specific aims to adjust for their impact on the study outcomes.

Specific Aim 1 was to examine the impact of prescription opioid use compared to no prescription opioid use on adherence to COPD maintenance medications, over four different time periods, among a real-world, large sample of COPD patients after adjusting for other confounders. Adherence to COPD maintenance medications was assessed over 90 days, 180 days, 270 days and 365 days follow-up periods.

Overall, 59.4% of the included matched sample of COPD patients were adherent (defined as PDC ≥0.8) to their COPD maintenance medications in the 90-day follow-up

period after the index date. However, as the follow-up period increased from 90 days up to 365 days the number of people adherent to their COPD maintenance medications decreased. Nearly half (50.9%) of the included matched sample of COPD patients were adherent to their COPD maintenance medications in the 180-day follow-up period after the index date. In the 270-day follow-up period, this number decreased to less than half (47.3%) of the included matched sample of all COPD patients. About 54% of the included matched sample of COPD patients were found to be non-adherent to COPD maintenance medications in the 365-day follow-up period after the index date which is high, however not surprising. This means that about 54% of COPD patients were not receiving optimal long-term controller medication therapy to manage their COPD symptoms. Previous studies have reported that about 60% of COPD patients exhibit poor adherence to COPD treatment and even more do not use their inhalers correctly⁴⁶⁻ ^{48,143,144}. Thus, the high non-adherence to controller medication among COPD patients observed in the current study is comparable to previous studies among COPD patients. Also, COPD patients commonly have chronic comorbidities which may lower the adherence to COPD maintenance medications^{8,44,45}. Similarly, in the current study about 79% of the overall COPD patients had at least one comorbid chronic condition.

In the current study, prescription opioid users were found to have lower adherence to COPD maintenance medications compared to non-opioid users in all the four follow-up time periods (Table 41) and the differences were statistically significant. As the follow-up time increased from 90 days up to 365 days the adherence levels decreased for both prescription opioid users and non-opioid users. When prescription

Table 41: Adherence to COPD maintenance medications among prescription opioid users and non-opioid users among COPD patients in the four different follow-up periods

	Adherent to COPD Maintenance Medications (PDC≥0.8)			
Follow-up period	Prescription opioid user (n=5,541)	Non-opioid user (n=5,541)	P-Value	
90-day follow-up period	49.2%	69.5%	<0.0001	
180-day follow-up period	45.3%	56.6%	<0.0001	
270-day follow-up period	43.3%	51.2%	<0.0001	
365-day follow-up period	42.1%	49.7%	<0.0001	

opioid use was further classified as >30-day supply of prescription opioids and ≤30-day supply of prescription opioids (sub-group analyses), the adherence levels for both the groups of prescription opioid users remained lower than non-opioid users in all the four follow-up time periods (Table 42). The classification of prescription opioid use as >30-day supply and ≤30-day supply has been utilized in a previously published peer-review study conducted among a sample of VA patients¹⁴⁵.

In the multivariate regression analyses, prescription opioid users were found to have significantly lower odds of being adherent to their COPD maintenance medications in the 90-day follow-up period as compared to non-opioid users, independent of other predictors. This association remained significant when other follow-up times were assessed as well (Table 43). Similar results were observed in the sub-group analyses for Specific Aim 1 where use of prescription opioids was further classified as > 30-day supply of prescription opioids and \leq 30-day supply of prescription opioids (Table 44).

Although we matched prescription opioid users and non-opioid users on various confounders reported in Table 10, it is important to consider that there were certain baseline characteristics that varied significantly between prescription opioid users and non-opioid users. Prescription opioid users and non-opioid users differed significantly on the presence of baseline comorbidities. Overall, a higher percentage of prescription opioid users. The mean D-CCI score among prescription opioid users was significantly higher compared to non-opioid users ($2.0 \pm 1.5 \text{ vs } 1.7 \pm 1.2$, p<0.0001). Significantly different baseline characteristics between prescription opioid users and non-users among COPD patients

Table 42: Adherence to COPD maintenance medications among prescriptionopioid users and non-opioid users among COPD patients in the four differentfollow-up periods as per Specific Aim 1 sub group analyses

	Adherent to COPD Maintenance Medications (PDC≥0.8			
Follow-up period	≤ 30-day supply of prescription opioids	> 30-day supply of prescription opioids	Non- opioid user	P- Value
90-day follow-up period	49.1%	50.2%	69.5%	<0.0001
180-day follow-up period	45.2%	45.7%	56.6%	<0.0001
270-day follow-up period	43.3%	43.4%	51.2%	<0.0001
365-day follow-up period	42.3%	41.4%	49.7%	<0.0001

Table 43: Summary of the logistic regression results of the odds of being adherent to COPD maintenance medications among prescription opioid users and non-opioid users among COPD patients in the four different follow-up periods

Prescription Opioid use	Point estimate	95% Confidence interval	P-Value
No Use	Reference		
Use in the following periods:			
90-day follow-up period	0.29	(0.26 – 0.37)	<0.0001
180-day follow-up period	0.55	(0.50 – 0.61)	<0.0001
270-day follow-up period	0.66	(0.60 – 0.73)	<0.0001
365-day follow-up period	0.69	(0.63 – 0.76)	<0.0001

*Adjusted for other covariates

Table 44: Summary of the logistic regression results of the odds of being adherent to COPD maintenance medications among prescription opioid users and non-opioid users among COPD patients in the four different follow-up periods as per Specific Aim 1 sub group analyses

Prescription Opioid use		Point estimate	95% Confidence interval	P-Value
No Use		Reference		
Use in the following periods:				
90-day follow-up period	≤ 30-day supply of prescription opioids	0.30	(0.26 – 0.34)	<0.0001
	> 30-day supply of prescription opioids	0.32	(0.23 – 0.44)	<0.0001
180-day follow-up period	≤ 30-day supply of prescription opioids	0.55	(0.50 – 0.61)	<0.0001
	> 30-day supply of prescription opioids	0.58	(0.46 – 0.72)	<0.0001
270-day follow-up period	≤ 30-day supply of prescription opioids	0.66	(0.59 – 0.73)	<0.0001
	> 30-day supply of prescription opioids	0.68	(0.56 – 0.83)	0.0001
365-day follow-up period	≤ 30-day supply of prescription opioids	0.69	(0.62 – 0.77)	<0.0001
	> 30-day supply of prescription opioids	0.71	(0.59 – 0.85)	0.0003

*Adjusted for other covariates

were adjusted in the multivariate regression analyses.

Similarly, a significantly higher percentage of prescription opioid users had ≥ 1 comorbid chronic condition (82% vs 76.3%, p<0.0001) and ≥ 1 comorbid pain condition (86% vs 70.7%, p<0.0001) compared to non-opioid users. Having a higher number of comorbid chronic conditions and specifically pain conditions could translate into higher need for prescription opioids to alleviate pain among these patients. In the 2015 Medicare Payment Advisory Commission report, the committee reported that concurrent use of prescription opioids may have adverse effects including unintentional overdoses which may interfere with treatment of comorbid conditions¹⁴⁶. Along with having a high number of comorbid conditions and use of prescription opioids for treatment of pain conditions the use of prescription opioids may translate into lower adherence among COPD patients using prescription opioids as observed in this study.

In summary, concurrent prescription opioid use among COPD patients using maintenance medications was found to be associated with lower medication adherence to COPD-related maintenance medications compared to non-opioid users. This association was significant in all the four follow-up time periods (90 days, 180 days, 270 days, and 365 days).

Discussion for Specific Aim 2

Specific Aim 2 was to examine the impact of long-term prescription opioid use (≥90-day supply in a one-year period) compared to no prescription opioid use on adherence to COPD maintenance medications among a real-world, large sample of COPD patients after adjusting for other confounders. For Specific Aims 2 to 4, only long-term prescription opioid users among COPD patients were included in the

analyses, and COPD patients with <90-day supply of prescription opioids in a one-year follow-up period were excluded. The control group of non-opioid users among COPD patients however, remained the same.

Although long-term prescription opioid users had similar characteristics as overall prescription opioid users among COPD patients there were certain characteristics which differed between long-term prescription opioid users and non-opioid users which were not significantly different in the matched sample of overall prescription opioid users and non-opioid users. Supplemental oxygen use, SABA use and severe COPD exacerbations in the pre-index period which were similar between overall prescription opioid users among COPD patients were however, significantly different between long-term prescription opioid user and non-opioid users among COPD patients were however, significantly different between long-term prescription opioid user and non-opioid users among COPD patients (Table 31). A higher percentage of long-term prescription opioid users had supplemental oxygen use (28.1% vs 20.1%, p<0.0001), SABA use (59% vs 53.3%, p=0.009), and severe COPD exacerbations (5.3% vs 2.9%, p=0.002) compared to non-opioid users among COPD patients.

Similar to any prescription opioid users, long-term prescription opioid users had a significantly higher number of mean comorbid conditions compared to non-opioid users. The mean D-CCI score among long-term prescription opioid users was significantly higher compared to non-users of prescription opioids ($2.4 \pm 1.8 \text{ vs } 1.7 \pm 1.2, \text{ p} < 0.0001$). Similarly, a higher proportion of long-term prescription opioid users had presence of one or more comorbid chronic conditions (86.6% vs 76.3%, p<0.0001) and comorbid pain conditions (93.5% vs 70.7%, p<0.0001).

Similar to any prescription opioid users in Specific Aim 1, a smaller percentage of long-term prescription opioid users were adherent to their COPD maintenance medications as compared to non-opioid users (42.6% vs 49.7%, p=0.001) (Table 32). Long-term prescription opioid users were found to have 0.63 times (95% CI 0.46-0.88, p=0.005) significantly lower odds of being adherent to their COPD maintenance medications in one-year follow-up period as compared to non-opioid users, independent of other predictors (Table 34).

Rose A et al, 2009 conducted a study among patients with diabetes mellitus to assess the impact of chronic prescription opioid use versus no use of prescription opioids on clinical end-points associated with treatment of diabetes¹⁴⁷. Older diabetes patients were identified from the Veteran Affairs (VA) Medicare database from 2004. The authors defined chronic prescription opioid use as ≥ 6 fills of prescription opioid in a one-year period. Rose A and colleagues reported that diabetes patients using prescription opioids on a chronic basis had 0.90 (95% CI, 0.84 - 0.96) significantly lower odds of having glycosylated hemoglobin (A1C) control compared to diabetes patients who had not received any prescription opioids¹⁴⁷. Similarly, the odds of lowdensity lipoprotein cholesterol (LDL-C) control was also statistically significantly lower (OR 0.87; 95% CI, 0.82 – 0.94) among diabetes patients using prescription opioids on a chronic basis compared to diabetes patients not using prescription opioids. The authors believed that diabetes patients concurrently using prescription opioids on a chronic basis are likely to be distracted and concerned about their use of prescription opioids which may affect their diabetes performance¹⁴⁷. Their reasoning was based on a previous study by Krein et al which showed that presence of chronic pain among patient

with diabetes may distract them from adhering to medications¹⁴⁸. Although Rose A et al, 2009 study did not assess the impact of prescription opioid use on adherence to diabetes medications, the association of long-term prescription opioid use and poor medication adherence among COPD patients, as observed in the current study, may likely be explained by distraction due to prescription opioid use as proposed by Krein et al and Rose A et al^{147,148}.

Jeevanjee S and colleagues conducted a study to identify the association between prescription opioid use and misuse and adherence to antiretrovirals (ARV) among HIV-infected patients¹⁴⁹. The authors interviewed 258 HIV-infected patients and classified opioid use as self-reported use of physician prescribed opioids and further identified misuse of prescription opioids. Adherence to ARVs was reported in the 7 days before the study interview. The authors reported that receipt of prescription opioids among HIV-infected patients was not significantly associated with adherence to ARVs. However, misuse of prescription opioids was associated with statistically significantly higher odds (OR 1.47; 95% CI 1.06 – 2.03; p 0.022) of suboptimal adherence to ARVs¹⁴⁹. It is important to consider that study was conducted among lower income HIV patients recruited from homeless shelters, free meal program and single room occupancy hotels. Medication adherence was reported and measure over a period of 7 days. The current study was conducted among commercially insured patients enrolled in employer sponsored healthcare plans and adherence to COPD maintenance medications was assessed over 365-day follow-up period after the initiation of prescription opioids. Due to the administrative claims nature of the data utilized in the current study prescription opioid misuse could not be assessed. Also, patients are more

likely to misuse prescription opioids when taken on a long-term basis as assessed in the current study²⁷. COPD patients taking prescription opioids on a long-term basis may likely misuse prescription opioids which may explain the non-adherence to COPD maintenance medications observed in the study.

Although there is established validity for the use of prescription opioids acutely, there is little evidence for their use on a long-term basis for conditions other than cancer^{12–15}. A Cochrane literature review of studies assessing safety, efficacy and effectiveness of long-term prescription opioid use in chronic non-cancer pain (CNCP) patients reported that there was very limited evidence for clinically meaningful amount of alleviation of pain associated with long-term use of prescription opioids¹³. Despite lacking evidence for effectiveness, the use of prescription opioids on a long-term basis is highly prevalent in the US population. Overall, about 11 million people in 2005 were prescribed long-term prescription opioid therapy¹⁷. In the current study, a total of 566 COPD patients on maintenance medications were classified as long-term prescription opioid users, representing 10.2% of all matched COPD prescription opioid users. Vozoris et al, 2016 have warned that COPD patients using prescription opioids may suffer from adverse respiratory effects from opioid use expressed through various mechanisms such as "respiratory depression, reduced mucous clearance through cough suppression, and immunosuppressive effects"⁶⁴.

In the current study long-term use of prescription opioids was found to be significantly associated with lower adherence to COPD maintenance medications, independent of other factors. This association could be explained due to various theories mentioned above. Use of prescription opioids on a long-term basis may distract

patients from adhering to COPD maintenance medications as hypothesized by Krein et al and Rose A et al among diabetes patients using prescription opioids^{147,148}. COPD patients taking prescription opioids on a long-term basis may likely misuse prescription opioids, as reported by Jeevanjee S et al among HIV patients, which may explain the non-adherence to COPD maintenance medications observed in the study¹⁴⁹. Also, COPD patients taking prescription opioids on a long-term basis may suffer from adverse respiratory effects from opioid use expressed through various mechanisms such as "respiratory depression, reduced mucous clearance through cough suppression, and immunosuppressive effects" which may impact their medication adherence⁶⁴. As this is the first study to assess the impact of prescription opioid use and long-term prescription opioid use on adherence to COPD maintenance medications among a sample of COPD patients, future studies are needed to replicate the methods from the current study in other COPD populations to test the reproducibility of the results in other COPD patient populations.

Discussion for Specific Aim 3

Specific Aim 3 was to examine the impact of long-term prescription opioid use (≥90-day supply in a one-year period) compared to no prescription opioid use on COPD exacerbations among a real-world, large sample of COPD patients after adjusting for other confounders. Only about 4.3% (n=265) of the included sample of COPD patients using maintenance medications in specific aim 3 experienced a severe COPD exacerbation in a one-year follow-up period. About 20.1% (n=1,226) of the overall sample of COPD patients using maintenance medications experienced either a severe or moderate COPD exacerbation in a one-year follow-up period. The low rates of COPD

exacerbations observed in the current study are comparable to rates reported in published studies. A study by Stanford RH and colleagues in 2016 which used a similar set of criteria for identification of severe and moderate COPD exacerbations as the current study, found incidence of COPD exacerbation rates similar to rates found in the current study¹⁴⁰. About 13.8% of COPD patients were classified as having one or more moderate COPD exacerbations and 8.5% were classified as having one or more severe COPD exacerbation in a one-year follow-up period¹⁴¹. Patients having either a moderate or severe COPD exacerbations were 22.3% in the Stanford RH et al study compared to 20.1% in this study¹⁴⁰.

The mean number of severe exacerbations in the overall sample of COPD patients using maintenance medications was 0.05 (± 0.28) in a one-year follow-up period. When both severe and moderate exacerbations were measured the mean increased to 0.20 (± 0.40). It is however, important to consider that many COPD exacerbations experienced by COPD patients cannot be captured when using secondary datasets such as administrative claims which require patients to have an interaction with the healthcare system. Studies in the past have shown that nearly 50% of COPD exacerbations go unreported as COPD patients may not always interact with healthcare systems when experiencing exacerbations of their COPD symptoms^{147,148}. These unreported exacerbations are identified only when assessment of patients' recording of COPD symptoms in daily diaries are analyzed¹⁴³. Wedzicha J, et al 2003 suggest that COPD patients commonly experience changes in symptoms, and along with having comorbid symptoms of depression and anxiety COPD patients accept their symptoms as part of their disease and do not seek treatment^{147–150} Previously published

studies have reported the mean rate of exacerbations among COPD patients to range from 0.6 to 3.0 annually ^{148,151–153}. However, these studies varied from the current study on various parameters such as patients maintaining a daily diary to report symptoms, studies including mostly older COPD patients >65 years old, and combining mild, moderate and severe COPD exacerbations, utilization of various methods of classifying exacerbations, variable follow-up times, and study samples belonging to various countries.

A significantly higher percentage of long-term prescription opioid users experienced severe exacerbations (8% vs. 4%, p<0.0001; Table 35) in a one-year follow-up period compared to non-opioid users. Long-term prescription opioid users also had a higher mean number of severe COPD exacerbation compared to non-opioid users (0.11 \pm 0.41 vs 0.05 \pm 0.26, p<0.001; Table 35). Similarly, a significantly higher percentage of long-term prescription opioid users experienced either a severe or moderate exacerbation (26.5% vs 19.4%, p<0.0001; Table 37) in a one-year follow-up period compared to non-opioid users. Long-term prescription opioid users also had a significantly higher mean number of moderate and severe COPD exacerbations compared to non-opioid users (0.50 \pm 1.14 vs 0.31 \pm 0.82, p=0.0003; Table 37).

After adjusting for confounders, the impact of long-term prescription opioid use on the number of the severe COPD exacerbations in a one-year follow-up period was not found to be significant (Table 36). The non-significant result persisted when the sum of moderate and severe COPD exacerbations was evaluated (Table 38). In separate analysis the impact of long-term prescription opioid use versus no use was assessed on the likelihood of having a severe COPD exacerbation and either moderate or severe

COPD exacerbation using conditional logistic regression analysis (not reported here). The non-significant results from Specific Aims 3A and 3B persisted in the conditional logistic regression analysis. History of COPD exacerbations has been established as a significant predictor of future COPD exacerbations⁷⁹. After adjusting for the effect of preindex COPD exacerbations the impact of long-term prescription opioid use was not significant on adherence to COPD controller medications.

Vozoris N et al, 2016 conducted a study to identify the impact of prescription opioid use on adverse respiratory outcomes, including exacerbations, among COPD patients⁶⁴. Vozoris N et al, 2016 study reported no significant association between incident prescription opioid use and COPD-related hospitalizations (hazard ratio 1.08, 95% CI 1.00 – 1.29; p=0.15), which translate into severe COPD exacerbations in the current study. Similarly, in the current study long-term use of prescription opioids was not significantly associated with severe COPD exacerbations (Table 36). However, the authors found that incident prescription opioid use was associated with decreased outpatient COPD exacerbations (hazard ratio 0.88, 95% CI 0.83 – 0.94; p<0.001). When the analysis was conducted among users of more potent opioid-only agents, the use of opioids was associated with significantly increased outpatient COPD exacerbations (hazard ratio 1.27, 95% CI 1.14 – 1.41; p<0.0001). The current study combined moderate and severe COPD exacerbations in Specific Aim 3B and found no association between long-term prescription opioid use and the sum of severe and moderate COPD exacerbations.

There are however various differences between the current study and the Vozoris N et al, 2016 study which should be considered when comparing the results

from the two studies. Vozoris N et al, 2016 measured only outpatient COPD exacerbations which corresponds to moderate COPD exacerbations in the current study. However, in the current study emergency room visits were also included in the classification of moderate COPD exacerbations whereas Vozoris N et al, 2016 excluded emergency COPD visits in the classification of outpatient COPD exacerbations. In the current study moderate COPD exacerbation were not assessed stand-alone as an outcome variable, as in the Vozoris N et al, 2016 study, but were combined with severe COPD-exacerbations. In the Vozoris N et al, 2016 study outpatient COPD exacerbations and COPD-related hospitalizations were measured only within 30 days of incident prescription opioid use compared to the current study in which COPD exacerbations were measured in a one-year follow-up period. The Vozoris N et al, 2016 study was conducted only among older COPD patients above 65 years old (mean age 77.0 \pm 7.0 years) whereas the current study included COPD patients between 40 to 64 years old (mean age 57.2 \pm 5.4 years). The Vozoris N et al, 2016 study was conducted among a sample of Canadian COPD patients whereas the current study included COPD patients residing the US.

In summary, the current study did not find any association between long-term prescription opioid use and severe and moderate COPD exacerbations among COPD patients, after adjusting for other confounders.

Discussion for Specific Aim 4

Specific Aim 4 was to examine the impact of long-term prescription opioid use (≥90-day supply in a one-year period) compared to no prescription opioid use on allcause total healthcare costs (prescription medication and medical costs) among a real-

world, large sample of COPD patients after adjusting for other confounders. The adjusted mean all-cause total healthcare costs were significantly higher for long-term prescription opioid users compared to non-opioid users [$$23,996 (\pm $1,106.22) vs.$ $$13,947 (\pm $512.67), p<0.0001$] (Table 40).

The adjusted prescription drug costs among long-term prescription opioid users was statistically significantly higher [\$7,782 (± \$301) vs. \$6,686 (± \$205), p<0.0001] compared to non-opioid users. The higher adjusted prescription drug costs among longterm prescription opioid users despite having statistically significantly lower medication adherence to COPD maintenance medications compared to non-opioid users is not surprising. Long-term prescription opioid users had significantly higher mean number of comorbid medical conditions as compared to non-opioid users. With higher mean comorbid conditions, long-term prescription opioid users may fill higher number of prescriptions attributed to conditions other than COPD. Also, the costs associated with using prescription opioids may be reflected in the higher total prescription drug costs among long-term prescription opioid users. The significantly higher all-cause total healthcare costs among long-term prescription opioid users as compared to non-opioid users is likely driven by higher total medical costs (sum of costs associated with inpatient, outpatient and emergency room visits). The adjusted total medical costs among long-term prescription opioid users was statistically significantly higher [\$15,684 $(\pm$ \$1,197) vs. \$6,679 $(\pm$ \$401), p<0.0001] compared to non-opioid users.

This is the first study to assess the impact of prescription opioid use on healthcare costs among patients with COPD. It is important to consider that the current study assessed all-cause total healthcare costs among COPD patients. This higher all-

cause total healthcare costs among COPD patients may be related to higher healthcare resource utilization associated with management of COPD or higher healthcare utilization associated with management of other comorbid conditions among COPD patients. The current study however, did not assess COPD-related costs independently, but rather assessed all-cause total healthcare costs. It was found that long-term prescription opioid users had significantly higher number of mean comorbid conditions compared to non-opioid users (Table 31). The mean D-CCI score among long-term prescription opioid users was significantly higher compared to non-users of prescription opioids $(2.4 \pm 1.8 \text{ vs } 1.7 \pm 1.2, \text{ p} < 0.0001)$. Similarly, a higher proportion of long-term prescription opioid users had presence of one or more comorbid chronic conditions (86.6% vs 76.3%, p<0.0001) and comorbid pain conditions (93.5% vs 70.7%, p<0.0001). D-CCI score, number of comorbid conditions and number of comorbid pain conditions were all significantly associated with higher all-cause total healthcare costs among COPD patients in the generalized linear model with a gamma distribution and log-link function (Table 40). These differences in the presence of comorbidities among long-term prescription opioid users and non-opioid users could translate into higher allcause total healthcare costs among COPD patients.

In summary, long-term prescription opioid use was significantly associated with all-cause total healthcare costs among COPD patients, after adjusting for other confounders. Long-term prescription opioid use may be associated with higher all-cause total healthcare costs among COPD patients. As this is the first study to assess the impact of long-term prescription opioid use on healthcare costs among COPD patients,

future studies are needed to provide evidence on the reproducibility of these results among similar or different population of COPD patients.

Study limitations

Limitations associated with the use of administrative claims database are applicable to this study¹⁵⁷. Medication adherence when assessed using administrative claims data is unable to ascertain whether the patient is taking the right prescribed quantity of dose or whether the doses were taken in a timely prescribed manner. Patients may refill their prescriptions on time but may be non-adherent to their regimen by not taking their medications as prescribed and this is not captured in the analysis. However, filling a prescription is a necessary step which leads to utilization of the prescribed drug and PDC has been utilized on a wide scale by researchers, and validated and recommended by the Pharmacy Quality Alliance (PQA) and the National Quality Forum (NQF) as a measure of medication adherence¹²¹.

Just observing a refill of a prescription in an administrative claims data may not be a good indicator of medication adherence. Patients in the study may also have other sources of acquiring medications which may not be captured by the dataset. Including only patients who have a prescription fill for a COPD maintenance medication has the potential to exclude patients who do not fill any prescribed maintenance medications, thus missing on important non-adherent patients. When a patient discontinues a therapy for COPD maintenance medication, it is possible that the patient discontinued the therapy due to physician's recommendations, however according to the PDC method the patient is assumed to be non-adherent.

Many factors may have an impact on medication adherence such as social support, perceived susceptibility to adverse events and others; however, these factors are not captured in the dataset and thus cannot be adjusted for their impact on medication adherence. Medication adherence is also impacted by the severity of a disease^{158,159}. Proxy values for the severity of COPD such as history of COPD-related moderate or severe exacerbations, use of short acting beta agonists, oral corticosteroids, and oxygen therapy were used in the analyses. These measures although predictive of future COPD exacerbation and health care utilization may not always accurately predict the level of airflow limitation and may be subject to measurement bias. As administrative datasets do not capture clinical information, spirometry information cannot be measured and therefore COPD exacerbations history are used as proxy measures for COPD symptom severity.

An important limitation of the study relates to the inability to identify diagnosis associated with the use of prescription opioids among COPD patients. COPD patients who use prescription opioids for chronic non-cancer pain (CNCP) may have significantly different characteristics compared to patients using prescription opioids for dyspnea or patients using opioids for acute pain conditions. Although, baseline characteristics were adjusted in the multiple regression analyses there may be certain unobservable factors such as diet, exercise, smoking status, not captured due to the administrative claims nature of the Truven MarketScan Commercial Claims and Encounters database which may introduce bias in the studied outcomes.

Certain factors are related to the use of prescription opioids such as the daily dosage of prescription opioids measured using morphine equivalent dosing, use of

either long-acting or short-acting prescription opioids, and long-term or short-term use of prescription opioids. As these factors are exclusively applicable only to patients who use prescription opioids and not applicable to non-opioid users, they cannot be adjusted for in the analyses as they are not present in the unexposed group (non-opioid users) of COPD patients.

A major limitation of the study is based on the lack of a method to identify adverse drug-related behaviors (ADRB) using administrative claims data. One of the rationales for the study is associated with the idea that the use of prescription opioids has an ability to induce psychological behaviors such as ADRB. ADRB may influence the patients to rely heavily on prescription opioids to provide immediate symptoms relief and possibly overlook the use of long-term maintenance medications for COPD. However, identification of ADRB is challenging with the use of administrative claims data. Although ADRB could not be identified in the study a previously published study has provided evidence that patients taking prescription opioids both on a long-term and acute basis have a statistically significantly higher likelihood of developing ADRB²⁷. Future studies may look at identifying ADRB and their effect on medication adherence and healthcare resource utilization among patients with COPD.

The study only includes information on privately insured patients in the age range of 40 to 64 years. The results of the study are only generalizable to the study population. The results of the study therefore may not applicable to patients who are not privately insured such as patients with Medicare, Medicaid, or patients without any health insurance coverage, or patients below 40 years of age or older patients 65 years of age and above. Middle-aged patients as included in the current study are more likely

to be employed than older patients. Use of prescription opioids among employed patients may limit their ability to work and therefore these patients may likely use more discretion when using prescription opioids. As older patients are more likely to be retired then middle-aged patients the use of prescription opioids among this population may be different.

Future research

Future research could benefit by improving on the limitations of the study highlighted above. Future research could develop methods to identify the presence of adverse drug related behaviors (ADRB) associated with the use of prescription opioids. ADRB could impact patients' behaviors associated with prescription opioid use and may mediate the effect of the use of prescription opioids on adherence to COPD maintenance medications and total all-cause healthcare costs.

Future studies could also benefit by identifying the reasons (diagnosis) or indications for which opioids were prescribed. For example, patients using prescription opioids for acute pain or pain associated with post-surgical procedures may exhibit different characteristics than patients who receive prescription opioids for chronic noncancer pain (CNCP) conditions. Stratified analyses in these different groups of patients may help explain whether the impact of prescription opioid use on adherence to maintenance medications and total all-cause healthcare costs persists in both the groups of patients.

Future studies could also assess characteristics associated with the use of prescription opioids such as the daily dosage of prescription opioids measured using morphine equivalent dosing, use of either long-acting or short-acting prescription

opioids, and combination or opioid only agents. Quantifying prescription opioids in these categories may help facilitate a better picture of the association of prescription opioid use and adherence to COPD maintenance medications among COPD patients.

Future research could also assess if the use of prescription opioids has an impact of healthcare resource utilization such as inpatient visits, emergency room visits, and outpatient visits associated with COPD. Such analyses could help better identify the impact of prescription opioid use on healthcare resource utilization and could facilitate in quantifying the burden of prescription opioid use among COPD patients.

Since the results of the current study are generalizable only to privately insured patients in the age range of 40 to 64 years, future studies could replicate the study among older COPD patients and also among patients belonging to other healthcare plans such as Medicare Medicaid, and also uninsured COPD patients.

As this is the first study to assess the impact of prescription opioid use on adherence to COPD maintenance medications, COPD exacerbation, and total all-cause healthcare costs among COPD patients, future studies are needed to provide evidence on the reproducibility of these results among similar or different population of COPD patients.

Study implications and conclusions

The results of the study show that the use of prescription opioids among patients with COPD is significantly associated with lower adherence to COPD maintenance medications. This finding suggests improving the management of COPD patients to address non-adherence to maintenance therapy. Although the study results did not find prescription opioid use to have an impact on moderate or severe COPD exacerbations

the impact of prescription opioid use on healthcare resource utilization such as inpatient visits, emergency room visits, and outpatient visits was not studied, and future research could help identify such impact. Also, the study results indicate higher healthcare costs for the management of COPD patients concurrently taking prescription opioids. Proper identification and management of prescription opioid therapy along with efforts to improve COPD-related adherence could potentially decrease the total healthcare costs of management of COPD patients.

Early identification of concurrent prescription opioid use and management of poor adherence to maintenance medications for COPD may lead to improved COPD symptoms and lower total healthcare costs. For COPD patients taking maintenance medications, identification of concurrent prescription opioid use might be an effective gauge of potential poor medication adherence in the future and may advocate for improved surveillance and management to attain optimum medication adherence. The results from the study could facilitate designing effective interventions that would help reduce non-adherence to maintenance medications for COPD and further help control total healthcare costs leading to better allocation of limited healthcare resources among COPD patients. The results of the current study could encourage future research to identify the effects of concurrent prescription opioid use on adherence to medications for other chronic conditions.

References

- GOLD 2017 Global Strategy for the Diagnosis, Management and Prevention of COPD [Internet]. Glob. Initiat. Chronic Obstr. Lung Dis. - GOLD. [cited 2016 Dec 20];Available from: http://goldcopd.org/gold-2017-global-strategy-diagnosismanagement-prevention-copd/
- Adeloye D, Chua S, Lee C, et al. Global and regional estimates of COPD prevalence: Systematic review and meta-analysis. J Glob Health 2015;5(2):020415.
- 3. Lopez AD, Shibuya K, Rao C, et al. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J 2006;27(2):397–412.
- World Health Organization. Projections of mortality and causes of death 2015 and 2030 [Internet]. WHO. [cited 2016 Dec 20];Available from: http://www.who.int/healthinfo/global_burden_disease/projections/en/
- GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet Lond Engl 2015;385(9963):117–71.
- American Lung Association. COPD [Internet]. Am. Lung Assoc. [cited 2017 Jan 16];Available from: http://www.lung.org/lung-health-and-diseases/lung-diseaselookup/copd/

- CDC Features Increase expected in medical care costs for COPD [Internet]. 2017
 [cited 2017 Oct 20];Available from: http://www.cdc.gov/Features/ds-copd-costs/
- Mannino DM, Higuchi K, Yu T-C, et al. Economic Burden of COPD in the Presence of Comorbidities. Chest 2015;148(1):138–50.
- Nahin RL. Estimates of pain prevalence and severity in adults: United States, 2012. J Pain 2015;16(8):769–780.
- Tsang A, Von Korff M, Lee S, et al. Common chronic pain conditions in developed and developing countries: gender and age differences and comorbidity with depression-anxiety disorders. J Pain 2008;9(10):883–891.
- Daubresse M, Chang H-Y, Yu Y, et al. Ambulatory diagnosis and treatment of nonmalignant pain in the United States, 2000–2010. Med Care [Internet] 2013 [cited 2016 Dec 19];51(10). Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3845222/
- Furlan AD, Yazdi F, Tsertsvadze A, et al. A systematic review and meta-analysis of efficacy, cost-effectiveness, and safety of selected complementary and alternative medicine for neck and low-back pain. Evid Based Complement Alternat Med [Internet] 2011 [cited 2016 Dec 19];2012. Available from: http://www.hindawi.com/journals/ecam/2012/953139/abs/
- 13. Noble M, Treadwell JR, Tregear SJ, et al. Long-term opioid management for chronic noncancer pain. Cochrane Database Syst Rev 2010;(1):CD006605.

- Ballantyne JC, Mao J. Opioid therapy for chronic pain. N Engl J Med 2003;349(20):1943–1953.
- 15. Kalso E, Edwards JE, Moore RA, McQuay HJ. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain 2004;112(3):372–380.
- 16. Fredheim OMS, Borchgrevink PC, Mahic M, Skurtveit S. A pharmacoepidemiological cohort study of subjects starting strong opioids for nonmalignant pain: a study from the Norwegian Prescription Database. PAIN® 2013;154(11):2487–2493.
- 17. Boudreau D, Von Korff M, Rutter CM, et al. Trends in long-term opioid therapy for chronic non-cancer pain. Pharmacoepidemiol Drug Saf 2009;18(12):1166–1175.
- Control C for D, (CDC P, others. Vital signs: overdoses of prescription opioid pain relievers—United States, 1999–2008. MMWR Morb Mortal Wkly Rep 2011;60(43):1487.
- International RTI, America US of, SAMHSA O of AS, America US of. Results From the 2009 National Survey on Drug Use and Health: Volume I. Summary of National Findings. 2010 [cited 2016 Dec 19];Available from: https://www.ncjrs.gov/App/Publications/abstract.aspx?ID=253943
- Factsheet on Opioids Factsheet-opioids-061516.pdf [Internet]. [cited 2016 Dec 19];Available from: https://www.hhs.gov/sites/default/files/Factsheet-opioids-061516.pdf

- 21. Inocencio TJ, Carroll NV, Read EJ, Holdford DA. The Economic Burden of Opioid-Related Poisoning in the United States. Pain Med 2013;14(10):1534–1547.
- 22. MMWR. Morbidity and mortality weekly report, Vol. 64, no. 26, July 10, 2015 32001 | Morbidity and Mortality Weekly Report (MMWR) [Internet]. [cited 2016 Dec
 19];Available from: https://stacks.cdc.gov/view/cdc/32001
- 23. Overdose Death Rates [Internet]. 2015 [cited 2016 Dec 19];Available from: https://www.drugabuse.gov/related-topics/trends-statistics/overdose-death-rates
- Manchikanti L, Fellows B, Damron KS, Pampati V, McManus CD. Prevalence of illicit drug use among individuals with chronic pain in the Commonwealth of Kentucky: an evaluation of patterns and trends. J Ky Med Assoc 2005;103(2):55– 62.
- Manchikanti L, Cash KA, Damron KS, Manchukonda R, Pampati V, McManus CD.
 Controlled substance abuse and illicit drug use in chronic pain patients: An evaluation of multiple variables. Pain Physician 2006;9(3):215–225.
- 26. Ricardo Buenaventura M, Rajive Adlaka M, Nalini Sehgal M. Opioid complications and side effects. Pain Physician 2008;11:S105–S120.
- Edlund MJ, Martin BC, Russo JE, DeVries A, Braden JB, Sullivan MD. The role of opioid prescription in incident opioid abuse and dependence among individuals with chronic non-cancer pain: the role of opioid prescription. Clin J Pain 2014;30(7):557.

- 28. Daniell HW. Opioid endocrinopathy in women consuming prescribed sustainedaction opioids for control of nonmalignant pain. J Pain 2008;9(1):28–36.
- 29. Mercadante S, Villari P, Ferrera P. Burst ketamine to reverse opioid tolerance in cancer pain. J Pain Symptom Manage 2003;25(4):302–305.
- Byas-Smith MG, Chapman SL, Reed B, Cotsonis G. The effect of opioids on driving and psychomotor performance in patients with chronic pain. Clin J Pain 2005;21(4):345–352.
- 31. Swegle JM, Logemann C. Management of common opioid-induced adverse effects. Am Fam Physician [Internet] 2006 [cited 2016 Dec 19];74(8). Available from: http://search.ebscohost.com/login.aspx?direct=true&profile=ehost&scope=site&aut htype=crawler&jrnl=0002838X&AN=23004458&h=%2BE54MgOiRV4V6QyZaVD04 0yfOy74TlkXhKSvMTxWjsUnlvUGe3xjvoNJc39KHdrWrCxNxyMOaqQZ5vBo2fHRA w%3D%3D&crl=c
- 32. White JM, Irvine RJ. Mechanisms of fatal opioid overdose. Addiction 1999;94(7):961–972.
- 33. Hess LM, Raebel MA, Conner DA, Malone DC. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother 2006;40(7–8):1280–1288.
- McDonnell PJ, Jacobs MR. Hospital admissions resulting from preventable adverse drug reactions. Ann Pharmacother 2002;36(9):1331–1336.

- 35. Schiff GD, Fung S, Speroff T, McNutt RA. Decompensated heart failure: symptoms, patterns of onset, and contributing factors. Am J Med 2003;114(8):625–630.
- 36. Senst BL, Achusim LE, Genest RP, et al. Practical approach to determining costs and frequency of adverse drug events in a health care network. Am J Health Syst Pharm 2001;58(12):1126–1132.
- Misdrahi D, Llorca PM, Lancon C, Bayle FJ. [Compliance in schizophrenia: predictive factors, therapeutical considerations and research implications].
 L'Encephale 2001;28(3 Pt 1):266–272.
- 38. Rodgers PT, Ruffin DM. Medication nonadherence: Part II–A pilot study in patients with congestive heart failure. Manag Care Interface 1998;11(9):67–9.
- Levy G, Zamacona MK, Jusko WJ. Developing compliance instructions for drug labeling. Clin Pharmacol Ther 2000;68(6):586–591.
- 40. Berg JS, Dischler J, Wagner DJ, Raia JJ, Palmer-Shevlin N. Medication compliance: a healthcare problem. Ann Pharmacother 1993;27(9 Suppl):S1–S24.
- Group CDPR, others. Influence of adherence to treatment and response of cholesterol on mortality in the Coronary Drug Project. N Engl J Med 1980;1980(303):1038–1041.
- 42. LaRosa JC. Poor compliance: the hidden risk factor. Curr Atheroscler Rep 2000;2(1):1–4.

- 43. Horwitz RI, Horwitz SM. Adherence to treatment and health outcomes. Arch Intern Med 1993;153(16):1863–1868.
- Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J 2008;32(4):962–969.
- 45. Kamour A, David Mannino MD, Kanotra S, others. Prevalence and Comorbidities of Chronic Obstructive Pulmonary Disease Among Adults in Kentucky Across Gender and Area Development Districts, 2011. Chronic Obstr Pulm Dis J COPD Found 2(4):296–312.
- 46. Haupt D, Krigsman K, Nilsson JLG. Medication persistence among patients with asthma/COPD drugs. Pharm World Sci 2008;30(5):509–514.
- 47. Restrepo RD, Alvarez MT, Wittnebel LD, et al. Medication adherence issues in patients treated for COPD. Int J Chron Obstruct Pulmon Dis 2008;3(3):371–384.
- Serra-Batlles J, Plaza V, Badiola C, Morejón E. Patient perception and acceptability of multidose dry powder inhalers: a randomized crossover comparison of Diskus/Accuhaler with Turbuhaler. J Aerosol Med 2002;15(1):59–64.
- 49. Rodríguez-Roisin R. The airway pathophysiology of COPD: implications for treatment. COPD J Chronic Obstr Pulm Dis 2005;2(2):253–262.

- van Boven JF, Chavannes NH, van der Molen T, Rutten-van Mölken MP, Postma MJ, Vegter S. Clinical and economic impact of non-adherence in COPD: a systematic review. Respir Med 2014;108(1):103–113.
- 51. Simoni-Wastila L, Wei Y-J, Qian J, et al. Association of chronic obstructive pulmonary disease maintenance medication adherence with all-cause hospitalization and spending in a Medicare population. Am J Geriatr Pharmacother 2012;10(3):201–210.
- Toy EL, Beaulieu NU, McHale JM, et al. Treatment of COPD: Relationships between daily dosing frequency, adherence, resource use, and costs. Respir Med [Internet] 2010 [cited 2010 Oct 18];Available from: http://www.ncbi.nlm.nih.gov/pubmed/20880687
- 53. Eaddy MT, Cook CL, O'Day K, Burch SP, Cantrell CR. How patient cost-sharing trends affect adherence and outcomes. Pharm Ther 2012;37(1):45–55.
- 54. Halpern R, Baker CL, Su J, et al. Outcomes associated with initiation of tiotropium or fluticasone/salmeterol in patients with chronic obstructive pulmonary disease.
 Patient Prefer Adherence 2011;5:375.
- 55. Vestbo J, Anderson JA, Calverley PM, et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax 2009;64(11):939–943.
- Jennings A-L, Davies AN, Higgins JPT, Gibbs JSR, Broadley KE. A systematic review of the use of opioids in the management of dyspnoea. Thorax 2002;57(11):939–44.

- 57. Rocker GM, Simpson AC, Horton R, et al. Opioid therapy for refractory dyspnea in patients with advanced chronic obstructive pulmonary disease: patients' experiences and outcomes. CMAJ Open 2013;1(1):E27-36.
- 58. Roberts MH, Mapel DW, Hartry A, Von Worley A, Thomson H. Chronic pain and pain medication use in chronic obstructive pulmonary disease. A cross-sectional study. Ann Am Thorac Soc 2013;10(4):290–8.
- 59. Janssen DJA, Spruit MA, Uszko-Lencer NH, Schols JMGA, Wouters EFM. Symptoms, comorbidities, and health care in advanced chronic obstructive pulmonary disease or chronic heart failure. J Palliat Med 2011;14(6):735–43.
- Woodcock AA, Gross ER, Gellert A, Shah S, Johnson M, Geddes DM. Effects of dihydrocodeine, alcohol, and caffeine on breathlessness and exercise tolerance in patients with chronic obstructive lung disease and normal blood gases. N Engl J Med 1981;305(27):1611–6.
- Stark RD, O'Neill PA. Dihydrocodeine for breathlessness in "pink puffers." Br Med J Clin Res Ed 1983;286(6373):1280–1.
- Abernethy AP, Currow DC, Frith P, Fazekas BS, McHugh A, Bui C. Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. BMJ 2003;327(7414):523–8.
- Currow DC, McDonald C, Oaten S, et al. Once-daily opioids for chronic dyspnea: a dose increment and pharmacovigilance study. J Pain Symptom Manage 2011;42(3):388–99.

- Vozoris NT, Wang X, Fischer HD, et al. Incident opioid drug use and adverse respiratory outcomes among older adults with COPD. Eur Respir J 2016;48(3):683–93.
- 65. Atreja N, Fleming M, Chen H, Johnson M, Zhivan H, Todd K. Impact of long term opioid use on oral antihyperglycemic medication adherence among individuals with type 2 diabetes mellitus: a retrospective database analysis. [Internet]. [cited 2017 Jan 16];Available from:

https://www.ispor.org/ScientificPresentationsDatabase/Presentation/64748

- Ekstrom MP, Bornefalk-Hermansson A, Abernethy AP, Currow DC. Safety of benzodiazepines and opioids in very severe respiratory disease: national prospective study. BMJ 2014;348:g445.
- Vozoris NT, Wang X, Austin PC, et al. Adverse cardiac events associated with incident opioid drug use among older adults with COPD. Eur J Clin Pharmacol 2017;
- Babitsch B, Gohl D, von Lengerke T. Re-revisiting Andersen's Behavioral Model of Health Services Use: a systematic review of studies from 1998-2011. Psycho-Soc Med 2012;9:Doc11.
- Aday LA, Andersen R. A Framework for the Study of Access to Medical Care. Health Serv Res 1974;9(3):208–20.
- Andersen RM. Revisiting the behavioral model and access to medical care: does it matter? J Health Soc Behav 1995;1–10.

- 71. Bhattacharya R, Shen C, Wachholtz AB, Dwibedi N, Sambamoorthi U. Depression treatment decreases healthcare expenditures among working age patients with comorbid conditions and type 2 diabetes mellitus along with newly-diagnosed depression. BMC Psychiatry 2016;16:247.
- Hochhausen L, Le H-N, Perry DF. Community-based mental health service utilization among low-income Latina immigrants. Community Ment Health J 2011;47(1):14–23.
- Parslow R, Jorm A, Christensen H, Jacomb P. Factors associated with young adults' obtaining general practitioner services. Aust Health Rev Publ Aust Hosp Assoc 2002;25(6):109–18.
- 74. Brown ER, Davidson PL, Yu H, et al. Effects of community factors on access to ambulatory care for lower-income adults in large urban communities. Inq J Med Care Organ Provis Financ 2004;41(1):39–56.
- 75. Chen AW, Kazanjian A, Wong H. Determinants of mental health consultations among recent Chinese immigrants in British Columbia, Canada: implications for mental health risk and access to services. J Immigr Minor Health 2008;10(6):529– 40.
- 76. Jackson H, Hubbard R. Detecting chronic obstructive pulmonary disease using peak flow rate: cross sectional survey. BMJ 2003;327(7416):653–4.

- 77. Celli BR, MacNee W, ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23(6):932–46.
- 78. National Heart, Lung, and Blood Institute. COPD, Learn More Breathe Better [Internet]. [cited 2017 Jan 16];Available from: https://www.nhlbi.nih.gov/health/educational/copd/
- 79. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010;363(12):1128–38.
- Walters JA, Smith S, Poole P, Granger RH, Wood-Baker R. Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease. Cochrane Libr [Internet] 2010 [cited 2017 Jan 16];Available from: http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001390.pub3/full
- Poole PJ, Chacko E, Wood-Baker RWB, Cates CJ. Influenza vaccine for patients with chronic obstructive pulmonary disease. Cochrane Libr [Internet] 2000 [cited 2017 Jan 16];Available from: http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD002733/full
- 82. Nici L, Lareau S, ZuWALLACK R. Pulmonary rehabilitation in the treatment of chronic obstructive pulmonary disease. Am Fam Physician 2010;82(6):655.
- 83. Guy GP. Vital Signs: Changes in Opioid Prescribing in the United States, 2006– 2015. MMWR Morb Mortal Wkly Rep [Internet] 2017 [cited 2017 Oct 18];66.
 Available from: https://www.cdc.gov/mmwr/volumes/66/wr/mm6626a4.htm

- Pain & Policy Studies Group. Global opioid consumption, 2015 [Internet]. [cited 2017 Oct 18];Available from: http://www.painpolicy.wisc.edu/global
- Centers for Disease Control and Prevention. NVSS National Vital Statistics System Homepage [Internet]. 2017 [cited 2017 Sep 25];Available from: https://www.cdc.gov/nchs/nvss/index.htm
- Birnbaum HG, White AG, Schiller M, Waldman T, Cleveland JM, Roland CL.
 Societal costs of prescription opioid abuse, dependence, and misuse in the United States. Pain Med 2011;12(4):657–667.
- Merskey HE. Classification of chronic pain: Descriptions of chronic pain syndromes and definitions of pain terms. Pain [Internet] 1986 [cited 2016 Dec 19];Available from: http://psycnet.apa.org/psycinfo/1987-31773-001
- 88. Simon LS. Relieving pain in America: A blueprint for transforming prevention, care, education, and research. J Pain Palliat Care Pharmacother 2012;26(2):197–198.
- Shah A. Characteristics of Initial Prescription Episodes and Likelihood of Long-Term Opioid Use—United States, 2006–2015. MMWR Morb Mortal Wkly Rep [Internet] 2017 [cited 2017 Sep 25];66. Available from: https://www.cdc.gov/mmwr/volumes/66/wr/mm6610a1.htm
- Deyo RA, Hallvik SE, Hildebran C, et al. Association between initial opioid prescribing patterns and subsequent long-term use among opioid-naïve patients: A statewide retrospective cohort study. J Gen Intern Med 2017;32(1):21–27.

- Paulozzi LJ, Mack KA, Hockenberry JM, others. Vital signs: variation among states in prescribing of opioid pain relievers and benzodiazepines—United States, 2012.
 MMWR Morb Mortal Wkly Rep 2014;63(26):563–8.
- Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain—United States, 2016. JAMA 2016;315(15):1624–1645.
- 93. Savage SR, Joranson DE, Covington EC, Schnoll SH, Heit HA, Gilson AM. Definitions related to the medical use of opioids: evolution towards universal agreement. J Pain Symptom Manage 2003;26(1):655–667.
- 94. Abuse NI on D. The Science of Drug Abuse and Addiction: The Basics [Internet]. [cited 2016 Dec 19];Available from: https://www.drugabuse.gov/publications/mediaguide/science-drug-abuse-addiction-basics
- 95. ASAM Definition of Addiction [Internet]. [cited 2016 Dec 19];Available from: http://www.asam.org/quality-practice/definition-of-addiction
- 96. Corsini E, Zacharoff K. Definitions related to aberrant drug-related behavior: Is there correct terminology? [Internet]. [cited 2016 Dec 19];Available from: https://www.painedu.org/articles_timely.asp?ArticleNumber=58
- 97. Jones CM. Heroin use and heroin use risk behaviors among nonmedical users of prescription opioid pain relievers–United States, 2002–2004 and 2008–2010. Drug Alcohol Depend 2013;132(1):95–100.

- Cicero TJ, Ellis MS, Surratt HL, Kurtz SP. The changing face of heroin use in the United States: a retrospective analysis of the past 50 years. JAMA Psychiatry 2014;71(7):821–826.
- 99. Uniform Controlled Substances Act (1994) [Internet]. [cited 2016 Dec
 19];Available from:
 http://www.uniformlaws.org/shared/docs/controlled%20substances/UCSA_final%20
 _94%20with%2095amends.pdf
- 100. National Institute on Drug Abuse. Misuse of prescription drugs. [Internet]. [cited 2017 Oct 18];Available from: https://www.drugabuse.gov/publications/research-reports/misuse-prescription-drugs/summary
- 101. Marschall U, L'hoest H, Radbruch L, Häuser W. Long-term opioid therapy for chronic non-cancer pain in Germany. Eur J Pain Lond Engl 2016;20(5):767–76.
- Bliesener N, Albrecht S, Schwager A, Weckbecker K, Lichtermann D, Klingmuller
 D. Plasma testosterone and sexual function in men receiving buprenorphine
 maintenance for opioid dependence. J Clin Endocrinol Metab 2005;90(1):203–206.
- Daniell HW. Hypogonadism in men consuming sustained-action oral opioids. J Pain 2002;3(5):377–384.
- 104. Ensrud KE, Blackwell T, Mangione CM, et al. Central nervous system active medications and risk for fractures in older women. Arch Intern Med 2003;163(8):949–957.

- 105. Mercadante S, Arcuri E. Hyperalgesia and opioid switching. Am J Hosp Palliat Med 2005;22(4):291–294.
- 106. Chu LF, Clark DJ, Angst MS. Opioid tolerance and hyperalgesia in chronic pain patients after one month of oral morphine therapy: a preliminary prospective study. J Pain 2006;7(1):43–48.
- 107. Dimsdale JE, Norman D, DeJardin D, Wallace MS. The effect of opioids on sleep architecture. J Clin Sleep Med 2007;3(1):33–36.
- 108. Schug SA, Garrett WR, Gillespie G. Opioid and non-opioid analgesics. Best Pract Res Clin Anaesthesiol 2003;17(1):91–110.
- 109. Pattinson KTS. Opioids and the control of respiration. Br J Anaesth 2008;100(6):747–758.
- 110. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353(5):487–497.
- De Geest S, Sabaté E. Adherence to long-term therapies: evidence for action.
 Eur J Cardiovasc Nurs 2003;2(4):323–323.
- 112. Cramer J, Rosenheck R, Kirk G, Krol W, Krystal J. Medication compliance feedback and monitoring in a clinical trial: predictors and outcomes. Value Health 2003;6(5):566–573.

- 113. Waeber B, Leonetti G, Kolloch R, McInnes GT, group H study, others. Compliance with aspirin or placebo in the Hypertension Optimal Treatment (HOT) study. J Hypertens 1999;17(7):1041–1045.
- 114. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23(8):1296–1310.
- 115. Gellad WF, Grenard JL, Marcum ZA. A systematic review of barriers to medication adherence in the elderly: looking beyond cost and regimen complexity.
 Am J Geriatr Pharmacother 2011;9(1):11–23.
- 116. Golin CE, Liu H, Hays RD, et al. A prospective study of predictors of adherence to combination antiretroviral medication. J Gen Intern Med 2002;17(10):756–765.
- 117. Elliott WJ, Maddy R, Toto R, Bakris G. Hypertension in patients with diabetes: overcoming barriers to effective control. Postgrad Med 2000;107(3):29–38.
- 118. Black HR. Will better-tolerated antihypertensive agents improve blood pressure control? JNC VI revisited. Am J Hypertens 1999;12(S9):225S–230S.
- 119. Ickovics JR, Meade CS. Adherence to HAART among patients with HIV: breakthroughs and barriers. AIDS Care 2002;14(3):309–318.
- 120. Peterson AM, Nau DP, Cramer JA, Benner J, Gwadry-Sridhar F, Nichol M. A checklist for medication compliance and persistence studies using retrospective databases. Value Health 2007;10(1):3–12.

- 121. Nau DP. Proportion of days covered (PDC) as a preferred method of measuring medication adherence. Springf VA Pharm Qual Alliance [Internet] 2012 [cited 2016 Jun 24];Available from: http://ep.yimg.com/ty/cdn/epill/pdcmpr.pdf
- 122. Owen JA. Medicare star ratings: Stakeholder proceedings on community pharmacy and managed care partnerships in quality: American Pharmacists Association and Academy of Managed Care Pharmacy. J Am Pharm Assoc 2014;54(3):228–240.
- 123. Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Longterm persistence in use of statin therapy in elderly patients. Jama 2002;288(4):455–461.
- 124. Benner JS, Pollack MF, Smith TW, Bullano MF, Willey VJ, Williams SA.
 Association between short-term effectiveness of statins and long-term adherence to lipid-lowering therapy. Am J Health Syst Pharm [Internet] 2005 [cited 2016 Jun 24];62(14). Available from:

http://search.ebscohost.com/login.aspx?direct=true&profile=ehost&scope=site&aut htype=crawler&jrnl=10792082&AN=17530677&h=4kLqY4uBugfGjL4ELZgDR6Dpc b0iB4LFpYfA0CWul9nCdr4hG7aDyZ3QveZNac6UDDXcA1CME1eHIXHaf2Jf7g%3 D%3D&crl=c

125. Chapman RH, Benner JS, Petrilla AA, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 2005;165(10):1147– 1152.

- 126. Benner JS, Tierce JC, Ballantyne CM, et al. Follow-up lipid tests and physician visits are associated with improved adherence to statin therapy. Pharmacoeconomics 2004;22(3):13–23.
- 127. Curkendall SM, Thomas N, Bell KF, Juneau PL, Weiss AJ. Predictors of medication adherence in patients with type 2 diabetes mellitus. Curr Med Res Opin 2013;29(10):1275–1286.
- 128. Klink M, Quan SF. Prevalence of reported sleep disturbances in a general adult population and their relationship to obstructive airways diseases. Chest 1987;91(4):540–6.
- 129. Edmonds P, Karlsen S, Khan S, Addington-Hall J. A comparison of the palliative care needs of patients dying from chronic respiratory diseases and lung cancer. Palliat Med 2001;15(4):287–95.
- 130. Vozoris NT, Wang X, Fischer HD, et al. Incident opioid drug use among older adults with chronic obstructive pulmonary disease: a population-based cohort study. Br J Clin Pharmacol 2016;81(1):161–70.
- 131. Cicero TJ, Wong G, Tian Y, Lynskey M, Todorov A, Isenberg K. Co-morbidity and utilization of medical services by pain patients receiving opioid medications: data from an insurance claims database. Pain 2009;144(1–2):20–7.
- Aday LA, Awe WC. Health services utilization models. Handb Health Behav Res Pers Soc Determinants 1997;153–172.


- 133. Hansen LG, Chang S. Health research data for the real world: the MarketScan databases. Ann Arbor Truven Health Anal Inc 2012;
- 134. Wurst KE, St Laurent S, Mullerova H, Davis KJ. Characteristics of patients with COPD newly prescribed a long-acting bronchodilator: a retrospective cohort study. Int J Chron Obstruct Pulmon Dis 2014;9:1021–31.
- 135. Albrecht JS, Park Y, Hur P, et al. Adherence to Maintenance Medications among Older Adults with Chronic Obstructive Pulmonary Disease. The Role of Depression. Ann Am Thorac Soc 2016;13(9):1497–504.
- 136. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45(6):613–9.
- 137. Choudhry NK, Shrank WH, Levin RL, et al. Measuring concurrent adherence to multiple related medications. Am J Manag Care 2009;15(7):457.
- 138. Rupali N. Impact of the Medicare Part D coverage gap on prescription drug utilization and medication adherence [Internet]. 2011 [cited 2017 Feb 6];Available from: https://repository.unm.edu/handle/1928/12101
- 139. FitzGerald JM, Haddon JM, Bradley-Kennedy C, Kuramoto L, Ford GT, Group RS. Resource use study in COPD (RUSIC): a prospective study to quantify the effects of COPD exacerbations on health care resource use among COPD patients. Can Respir J 2007;14(3):145–152.

- 140. Stanford RH, Nag A, Mapel DW, et al. Validation of a new risk measure for chronic obstructive pulmonary disease exacerbation using health insurance claims data. Ann Am Thorac Soc 2016;13(7):1067–1075.
- 141. Roberts M. Comparative effectiveness of triple therapy compared to combination or mono long-acting pharmacotherapy for COPD. 2013;
- 142. Rosenbaum PR. Optimal matching for observational studies. J Am Stat Assoc1989;84(408):1024–1032.
- 143. Krigsman K, Nilsson JLG, Ring L. Refill adherence for patients with asthma and COPD: comparison of a pharmacy record database with manually collected repeat prescriptions. Pharmacoepidemiol Drug Saf 2007;16(4):441–8.
- 144. Krigsman K, Nilsson JLG, Ring L. Adherence to multiple drug therapies: refill adherence to concomitant use of diabetes and asthma/COPD medication. Pharmacoepidemiol Drug Saf 2007;16(10):1120–8.
- 145. Scherrer JF, Salas J, Sullivan MD, et al. The influence of prescription opioid use duration and dose on development of treatment resistant depression. Prev Med 2016;91:110–116.
- 146. Medicare Payment Advisory Commission. Report to the congress. Medicare and the health care delivery system [Internet]. [cited 2018 Sep 20];Available from: http://medpac.gov/docs/default-source/reports/june-2015-report-to-the-congressmedicare-and-the-health-care-delivery-system.pdf

- 147. Rose AJ, Hermos JA, Frayne SM, Pogach LM, Berlowitz DR, Miller DR. Does opioid therapy affect quality of care for diabetes mellitus? Am J Manag Care 2009;15(4):217–24.
- 148. Krein SL, Heisler M, Piette JD, Makki F, Kerr EA. The effect of chronic pain on diabetes patients' self-management. Diabetes Care 2005;28(1):65–70.
- 149. Jeevanjee S, Penko J, Guzman D, Miaskowski C, Bangsberg DR, Kushel MB. Opioid analgesic misuse is associated with incomplete antiretroviral adherence in a cohort of HIV-infected indigent adults in San Francisco. AIDS Behav 2014;18(7):1352–8.
- 150. Wedzicha JA, Donaldson GC. Exacerbations of chronic obstructive pulmonary disease. Respir Care 2003;48(12):1204–1215.
- 151. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157(5):1418–1422.
- 152. Okubadejo AA, Jones PW, Wedzicha JA. Quality of life in patients with chronic obstructive pulmonary disease and severe hypoxaemia. Thorax 1996;51(1):44–47.
- 153. Okubadejo AA, O'shea L, Jones PW, Wedzicha JA. Home assessment of activities of daily living in patients with severe chronic obstructive pulmonary disease on long-term oxygen therapy. Eur Respir J 1997;10(7):1572–1575.

- 154. Dang-Tan T, Zhang S, Tavares RV, et al. The Burden of Illness Related to Chronic Obstructive Pulmonary Disease Exacerbations in Québec, Canada. Can Respir J 2017;2017.
- 155. Seemungal TA, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161(5):1608–1613.
- 156. Miravitlles M, Ferrer M, Pont A, et al. Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study. Thorax 2004;59(5):387–395.
- 157. Motheral BR, Fairman KA. The use of claims databases for outcomes research: rationale, challenges, and strategies. Clin Ther 1997;19(2):346–366.
- 158. Peyrot M, McMurry Jr JF, Kruger DF. A biopsychosocial model of glycemic control in diabetes: stress, coping and regimen adherence. J Health Soc Behav 1999;141–158.
- 159. Nurymberg K, Kreitler S, Weissler K. The cognitive orientation of compliance in short-and long-term type 2 diabetic patients. Patient Educ Couns 1996;29(1):25–39.

Appendix A: UNM Human Research Review Committee approval



Because it has been granted exemption, this research is not subject to continuing review.

This determination applies only to the activities described in this submission and does not apply should you make any changes to these documents. If changes are being considered and there are

The University of New Mexico + MSC08 4560 + 1 University of New Mexico + Albuquerque, NM 87131-0001 + Phone 505 272 1129 + Fax 505 272 0803 + hsc.uum.edu/som/research/lurre + BMSB 871

Page 1 of 2

questions about whether HRRC review is needed, please submit a study modification to the HRRC for a determination. A change in the research may disqualify this research from the current review category. You can create a modification by clicking Create Modification / CR within the study.

In conducting this study, you are required to follow the Investigator Manual dated April 1, 2015 (HRP-103), which can be found by navigating to the IRB Library.

Sincerely,

Thom & Myden

Thomas F. Byrd, MD HRRC Chair

The University of New Mexico + MSC08 4560 + 1 University of New Mexico + Albuquerque, NM 87131-0001 + Phone 505 272.1129 + Fax 505.272.0803 + bsc.anm.edu/som/research/hrrc + BMSB 871 Page 2 of 2